CRISPR-associated transposases and uses thereof

ABSTRACT

Provided herein are systems, methods, and compositions for the modification of target DNA sequences. More particularly, systems, methods, and compositions for editing genomic DNA in eukaryotic cells with a CRISPR-associated transposase are provided. Also provided are vectors and vector systems which encode one or more CRISPR-associated transposases, as well as methods for the design and use of such vectors. Also provided are methods for identifying and validating novel CRISPR-associated transposases.

CROSS-REFERENCE TO RELATED APPLICATIONS AND INCORPORATION OF SEQUENCE LISTING

This application is a U.S. National Stage of International Application No. PCT/US2016/069221, filed Dec. 29, 2016, which claims priority to U.S. Provisional Application No. 62/272,441, filed Dec. 29, 2015, both of which are incorporated by reference in their entirety herein. The sequence listing is contained in the file “P34377US01_SEQ.txt”, which is 4,394,282 bytes in size (measured in operating system MS Windows) and created on Jun. 28, 2018.

BACKGROUND

CRISPRs (Clustered Regularly Interspaced Short Palindromic Repeats) are loci found in the genomes of bacteria and archaea that contain multiple short direct repeats. CRISPR RNAs (crRNAs) associate with CRISPR-associated (Cas) effector proteins to form CRISPR-Cas systems that recognize foreign nucleic acids. CRISPRs systems are part of the adaptive immune system of bacteria and archaea, protecting them against invading nucleic acids, such as viruses, by cleaving the foreign DNA in a sequence-dependent manner. Immunity is acquired by integrating of short fragments of the invading DNA, known as spacers, between two adjacent repeats at the proximal end of a CRISPR locus. The CRISPR arrays are transcribed during subsequent encounters with invasive nucleic acids and are processed into small interfering CRISPR RNAs (crRNAs) of approximately 40 nt in length, which associate with the trans-activating CRISPR RNA (tracrRNA) to guide the CRISPR associated nuclease to the invasive nucleic acid. The CRISPR/Cas9 effector complex cleaves homologous double-stranded DNA sequences known as protospacers in the invading DNA. A prerequisite for cleavage is the presence of a conserved protospacer-adjacent motif (PAM) downstream of the target DNA, which, for Cas9, usually has the sequence 5′-NGG-3′ but less frequently NAG. Specificity is provided by a “seed sequence” in the crRNA which is located approximately 12 bases upstream of the PAM, which must be capable of hybridizing with the target sequence. Cpf1, a type V Cas effector protein, acts in a similar manner to Cas9, but Cpf1 does not require a tracrRNA.

CRISPR-Cas systems are dived into two classes: Class 1 CRISPR systems, subdivided into types I, III, and IV, and Class 1 systems utilize multiple Cas proteins with a crRNA to form a complex; and Class 2 CRISPR systems, subdivided into types II and V, utilize a single Cas protein with a crRNA to form a complex capable of sequence specific genome modification.

SUMMARY

Several embodiments relate to a recombinant nucleic acid comprising a heterologous promoter operably linked to a polynucleotide encoding a CRISPR-associated transposase, wherein the CRISPR-associated transposase comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 124-246 and 275-287 or a fragment thereof. Several embodiments relate to a recombinant nucleic acid comprising a heterologous promoter operably linked to a polynucleotide encoding a CRISPR-associated transposase, wherein the CRISPR-associated transposase has a sequence homology or identity of at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% with a CRISPR-associated transposase comprising an amino acid sequence selected from SEQ ID NOs: 124-246 and 275-287. In some embodiments, a vector comprising a recombinant nucleic acid comprising a heterologous promoter operably linked to a polynucleotide encoding CRISPR-associated transposase with an amino acid sequence selected from the group consisting of SEQ ID NOs: 124-246 and 275-286 are provided. In some embodiments, a vector comprising a recombinant nucleic acid comprising a heterologous promoter operably linked to a polynucleotide encoding CRISPR-associated transposase, wherein the CRISPR-associated transposase has a sequence homology or identity of at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% with a CRISPR-associated transposase comprising an amino acid sequence selected from SEQ ID NOs: 124-246 and 275-287 are provided.

Several embodiments relate to a recombinant nucleic acid comprising a heterologous promoter operably linked to a polynucleotide encoding a CRISPR-associated transposase, wherein the polynucleotide comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-123 and 604-627 or a fragment thereof. Several embodiments relate to a recombinant nucleic acid comprising a heterologous promoter operably linked to a polynucleotide encoding a CRISPR-associated transposase, wherein the polynucleotide comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 2020-2699 or a fragment thereof. Several embodiments relate to a recombinant nucleic acid comprising a heterologous promoter operably linked to a polynucleotide encoding a CRISPR-associated transposase, wherein the polynucleotide comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 2700-3379 or a fragment thereof. Several embodiments relate to a recombinant nucleic acid comprising a heterologous promoter operably linked to a polynucleotide encoding a CRISPR-associated transposase, wherein the polynucleotide comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from SEQ ID NOs: 1-123, 604-627 and 2020-3379. Several embodiments relate to a vector comprising a recombinant nucleic acid comprising a heterologous promoter operably linked to a polynucleotide encoding CRISPR-associated transposase wherein the polynucleotide comprises a sequence selected from SEQ ID NOs: 1-123, 604-627 and 2020-3379. In some embodiments, the vector comprises a recombinant nucleic acid comprising a heterologous promoter operably linked to a polynucleotide encoding CRISPR-associated transposase, wherein the polynucleotide comprises a sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to a sequence selected from SEQ ID NOs: 1-123, 604-627 and 2020-3379.

Several embodiments relate to a cell comprising a recombinant nucleic acid comprising a heterologous promoter operably linked to a polynucleotide encoding a CRISPR-associated transposase, wherein the CRISPR-associated transposase comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 124-246 and 275-287 or a fragment thereof. Several embodiments relate to a cell comprising a recombinant nucleic acid comprising a heterologous promoter operably linked to a polynucleotide encoding a CRISPR-associated transposase, wherein the CRISPR-associated transposase has a sequence homology or identity of at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% with a CRISPR-associated transposase comprising an amino acid sequence selected from SEQ ID NOs: 124-246 and 275-287. In some embodiments, the recombinant nucleic acid comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% homology to a nucleic acid sequence selected from SEQ ID NOs: 1-123, 604-627 and 2020-3379. In some embodiments, the recombinant nucleic acid is expressed transiently in the cell. In some embodiments, the recombinant nucleic acid is integrated into a genome of the cell. In some embodiments, the recombinant nucleic acid is integrated into a B chromosome of the cell. In some embodiments, the cell is a prokaryotic cell. In some embodiments, the cell is a eukaryotic cell. In some embodiments, the eukaryotic cell is a plant cell. In some embodiments, the eukaryotic cell is an algal cell. In some embodiments, the eukaryotic cell is a mammalian cell.

In one aspect, the present disclosure provides a system for sequence-specific modification of a target nucleic acid sequence comprising (a) a guide RNA or a DNA molecule encoding a guide RNA, where the guide RNA is specific for a target nucleic acid sequence, and (b) a polynucleotide encoding an CRISPR-associated transposase comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% homology to a sequence selected from the group consisting of SEQ ID NOs: 124-246, and 275-287.

In one aspect, the present disclosure provides a method for modification of a target nucleic acid sequence in a cell comprising providing to the cell a CRISPR-associated transposase comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% homology to a sequence selected from the group consisting of SEQ ID NOs: 124-246 and 275-287 or a polynucleotide encoding the CRISPR-associated transposase. In some embodiments the CRISPR-associated transposase is encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% homology to a nucleic acid sequence selected from SEQ ID NOs: 1-123, 604-627 and 2020-3379.

In one aspect, the present disclosure provides a method for sequence-specific modification of a target nucleic acid sequence in a cell comprising providing to a cell (a) a guide RNA specific for a target nucleic acid sequence in a cell, and (b) an a CRISPR-associated transposase comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% homology to a sequence selected from the group consisting of SEQ ID NOs: 124-246 and 275-287 or polynucleotide encoding the CRISPR-associated transposase, wherein the target nucleic acid sequence is modified. In some embodiments the polynucleotide encoding the CRISPR-associated transposase comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% homology to a nucleic acid sequence selected from SEQ ID NOs: 1-123, 604-627 and 2020-3379.

In an aspect, the present disclosure provides a eukaryotic cell containing a target nucleic acid sequence that has been modified with sequence specificity by a method for sequence-specific modification of a target nucleic acid sequence in a cell comprising providing to a cell (a) a guide RNA specific for a target nucleic acid sequence in a cell, and (b) an a CRISPR-associated transposase comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% homology to a sequence selected from the group consisting of SEQ ID NOs: 124-246 and 275-287 or polynucleotide encoding the CRISPR-associated transposase, where the target nucleic acid sequence is modified. In some embodiments the polynucleotide encoding the CRISPR-associated transposase comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% homology to a nucleic acid sequence selected from SEQ ID NOs: 1-123, 604-627 and 2020-3379.

In an aspect, the present disclosure provides a method of selectively modulating transcription of at least one target DNA in a eukaryotic cell comprising contacting the eukaryotic cell with: (a) a guide RNA or a DNA encoding a guide RNA where the guide RNA further comprises: (i) a first segment comprising a nucleotide sequence that is complementary to the target DNA; and (ii) a second segment that interacts with a CRISPR-associated transposase; and (b) an polynucleotide encoding the CRISPR-associated transposase, wherein the CRISPR-associated transposase comprises an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% homology to a sequence selected from the group consisting of SEQ ID NOs: 124-246 and 275-287, where components (a) and (b) are located on same or different vectors, where the guide RNA and the CRISPR-associated transposase form a complex in the eukaryotic cell, and where the complex selectively modulates transcription of the target DNA. In some embodiments the polynucleotide encoding the CRISPR-associated transposase comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% homology to a nucleic acid sequence selected from SEQ ID NOs: 1-123, 604-627 and 2020-3379.

Several embodiments relate to a method of identifying a CRISPR-associated transposase from a bacterial genome. In some embodiments, a polynucleotide encoding a CRISPR-associated transposase is identified based on its association within the bacterial genome with a CRISPR locus. In certain aspects, the polynucleotide encoding the CRISPR-associated transposase is further identified by association within the bacterial genome with a Cas1, a Cas2, or a Cas1 and a Cas2 but not Cas5 or Cas3. In some embodiments, the polynucleotide encoding the CRISPR-associated transposase is located in the same operon as the CRISPR locus. In other embodiments, the polynucleotide encoding the CRISPR-associated transposase is located within 2.5 kilobases of the CRISPR loci. In some embodiments, a polynucleotide encoding the CRISPR-associated transposase is identified by having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to CRISPR-associated transposases comprising a sequence cluster identified in Table 1. In some embodiments, the bacterial genome is selected from the group consisting of: Lysinibacillus sp., Brevibacillus sp., Sphingobium sp., Undibacterium sp., Bacillus sp., Chryseobacterium sp., Sphingomonas sp., Paenibacillus sp., Streptomyces sp., Stenotrophomonas sp., and Labrys sp. In some embodiments, the bacterial genome is selected from the group consisting of: Brevibacillus laterosporus; Bacillus thuringiensis; Bacillus weihenstephanensis, Bacillus megaterium, Enterococcus faecalis; Brevibacillus brevis; Undibacterium pigrum; Novosphingobium rosa; Labrys methylaminiphilus; Brevibacillus parabrevis; Paenibacillus thiaminolyticus; Paenibacillus lentimorbus; and Paenibacillus terrae.

Several embodiments relate to a nucleic acid-targeting system comprising a CRISPR-associated transposase comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% homology to a sequence selected from the group consisting of SEQ ID NOs: 124-246 and 275-287. In some embodiments, the nucleic acid-targeting system further comprises a guide RNA capable of hybridizing with a target sequence. In some embodiments, the nucleic acid-targeting system further comprises a tracrRNA. In some embodiments, the nucleic acid-targeting system further comprises a divalent cation. In some embodiments, the nucleic acid-targeting system further comprises Mg2+. In some embodiments, the nuclease activity of the CRISPR-associated transposase is inactivated. In some embodiments, the nucleic acid-targeting system comprises a CRISPR-associated transposase with a heterologous functional domain.

Several embodiments relate to a method of enhancing recombination at selected genomic loci, comprising providing to a plant cell at least one nucleic acid-targeting system that introduces genome modification in a first genomic locus, thereby inducing recombination between the first genomic locus and a second genomic locus, wherein the at least one nucleic acid-targeting system does not introduce a genome modification at the second genomic locus, and selecting at least one plant cell comprising a recombination event between the first genomic locus and the second genomic locus. Several embodiments relate to a method of enhancing recombination at selected genomic loci, comprising providing to a plant cell at least one nucleic acid-targeting system that introduces genome modification at a first genomic locus and a second genomic locus, thereby inducing recombination between the first genomic locus and the second genomic locus, and selecting at least one plant cell comprising a recombination event between the first genomic locus and the second genomic locus. Several embodiments relate to a method of enhancing recombination at selected genomic loci, comprising providing to a cell a first nucleic acid-targeting system that introduces a genome modification at a first genomic locus and a second nucleic acid-targeting system that introduces a genome modification at a second genomic locus, thereby inducing recombination between the first genomic locus and the second genomic locus, and selecting at least one progeny comprising a recombination event between the first genomic locus and the second genomic locus. In some embodiments the first and second genomic loci are in cis. In some embodiments, the first and second genomic loci are in trans. In some embodiments, the first and second genomic loci are homologs. In some embodiments, the first and second genomic loci are paralogs. In some embodiments, the first and second genomic loci are homeologs. In some embodiments, the first and second genomic loci are identical. In some embodiments, the first genomic locus and the second genomic locus are on homologous chromosomes. In some embodiments, the first genomic locus and the second genomic locus are on non-homologous chromosomes. In some embodiments, the first genomic locus and the second genomic locus are on homoeologous chromosomes. In some embodiments, the first and second genomic loci share at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity. In some embodiments, the first genomic locus and the second genomic locus are located on homologous chromosomes. In some embodiments, the first genomic locus and the second genomic locus are located on non-homologous chromosomes. In some embodiments, the genome modification is a double strand break (DSB). In some embodiments, the genome modification is a single strand break. In some embodiments, the genome modification occurs at the beginning of meiosis. In some embodiments, the recombination is asymmetric. In some embodiments, the recombination is symmetric. In some embodiments, the first target sequence and/or the second target sequence is genic. In some embodiments, the first target sequence and/or the second target sequence is within an intergenic region. In some embodiments, the first target sequence is in a genomic locus that is homologous to at least about 100 bp, at least about 150 bp, at least about 200 bp, at least about 250 bp, at least about 300 bp, at least about 350 bp, at least about 400 bp, at least about 450 bp, at least about 500 bp, at least about 600 bp, at least about 700 bp, at least about 800 bp, at least about 900 bp, or at least about 1000 bp of a genomic locus containing the second target sequence. In some embodiments, the first target sequence is in a genomic locus that is homologous to at least about 100 bp, at least about 150 bp, at least about 200 bp, at least about 250 bp, at least about 300 bp, at least about 350 bp, at least about 400 bp, at least about 450 bp, at least about 500 bp, at least about 600 bp, at least about 700 bp, at least about 800 bp, at least about 900 bp, or at least about 1000 bp of a genomic locus containing the second target sequence, wherein the genomic locus containing the first target sequence and the genomic locus containing the second target sequence are in corresponding positions in the genome. In some embodiments, the first target sequence is in a genomic locus that is homologous to at least about 100 bp, at least about 150 bp, at least about 200 bp, at least about 250 bp, at least about 300 bp, at least about 350 bp, at least about 400 bp, at least about 450 bp, at least about 500 bp, at least about 600 bp, at least about 700 bp, at least about 800 bp, at least about 900 bp, or at least about 1000 bp of a genomic locus containing the second target sequence, wherein the genomic locus containing the first target sequence and the genomic locus containing the second target sequence are not in corresponding positions in the genome. In some embodiments, the first target sequence has at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the second target sequence. In some embodiments, one or more of the first genomic locus and the second genomic locus comprise one or more genomic regions selected independently from the group consisting of a gene, an array of tandemly duplicated genes, an enhancer, a suppressor, a promoter, a termination sequence, a splice acceptor sequence, a splice donor sequence, an intron, an exon, an siRNA, and a quantitative trait locus (QTL). In some embodiments, progeny of the one plant cell comprising the recombination event between the first genomic locus and the second genomic locus exhibit resistance to one or more diseases selected from Anthracnose Stalk Rot (Colletotrichum graminicola), Fusarium Ear Rot (Fusarium verticillioides), Fusarium Stalk Rot (Fusarium spp.), Gibberella Ear Rot (Gibberella moniliformis), Gibberella Stalk Rot (Gibberella zeae), Goss's Wilt and Leaf Blight (Clavibacter michiganensis), Gray Leaf Spot (Cercospora zeae-maydis, C. zeina), Northern Corn Leaf Blight (Exserohilum turcicum), Sudden death syndrome (Fusarium solani f. sp. glycines), Asian soybean rust (Phakopsora pachyrhizi), Phytophthora root and stem rot (Phytophthora sojae), Root-knot Nematode (Meloidogyne spp.), Soybean Cyst Nematode (Heterodera glycines), Reniform nematode (Rotylenchulus reniformis), Root-knot nematode (Meloidogyne incognita), Fusarium wilt (Fusarium oxysporurn f sp. vasinfectum), Verticillium wilt (Verticillium dahlia), Fusarium head blight (Fusarium graminearum), Fusarium seedling blight (Fusarium spp., Septoria nodorum), Fusarium Leaf Blotch (Monographella nivalis), and Stem Rust (Puccinia graminis). In some embodiments, the plant is a maize plant. In some embodiments, the plant is a soybean plant. In some embodiments, the plant is a cotton plant. In some embodiments, the plant is a wheat plant. In some embodiments, the plant is a sorghum plant. In some embodiments, the plant is a canola plant. In some embodiments, the nucleic acid-targeting system comprises a CRISPR-associated transposase comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% homology to a sequence selected from the group consisting of SEQ ID NOs: 124-246 and 275-287. In some embodiments, the nucleic acid-targeting system further comprises a guide RNA capable of hybridizing with a target sequence. In some embodiments, the nucleic acid-targeting system further comprises a tracrRNA. In some embodiments, the nucleic acid-targeting system further comprises a divalent cation. In some embodiments, the nucleic acid-targeting system further comprises Mg2+. In some embodiments, the nuclease activity of the CRISPR-associated transposase is inactivated. In some embodiments, the nucleic acid-targeting system comprises a CRISPR-associated transposase with a heterologous functional domain. Several embodiments relate to a plant, plant cell or a seed of a plant produced by according to the aforementioned methods.

Several embodiments relate to a method of introgressing a genomic locus of interest into a selected germplasm, comprising generating a plant cell comprising a first parental genome comprising the genomic locus of interest and a second parental genome comprising the selected germplasm, providing to the plant cell a first nucleic acid-targeting system that introduces genome modification in the first parental genome at a target sequence adjacent to the genomic locus of interest, thereby inducing recombination between the first parental genome and the second parental genome, and selecting at least one progeny comprising at least one recombinant chromosome comprising the selected germplasm and the genomic locus of interest. Several embodiments relate to a method of introgressing a genomic locus of interest into a selected germplasm, comprising generating a plant cell comprising a first parental genome comprising the genomic locus of interest and a second parental genome comprising the selected germplasm, providing to the plant cell a first nucleic acid-targeting system that introduces genome modification in the first parental genome at a target sequence adjacent to the genomic locus of interest and a genome modification at a target site in the second parental genome, thereby inducing recombination between the first parental genome and the second parental genome, and selecting at least one progeny comprising at least one recombinant chromosome comprising the selected germplasm and the genomic locus of interest. Several embodiments relate to a method of introgressing a genomic locus of interest into a selected germplasm, comprising generating a plant cell comprising a first parental genome comprising the genomic locus of interest and a second parental genome comprising the selected germplasm, providing to the plant cell a first nucleic acid-targeting system that introduces genome modification in the first parental genome at a target sequence adjacent to the genomic locus of interest and a second nucleic acid-targeting system that introduces a genome modification in the first parental genome at a second target sequence adjacent to the genomic locus, wherein the second target sequence is on opposite side of the genome genomic locus of interest from the target sequence of the first nucleic acid-targeting system, thereby inducing recombination between the first parental genome and the second parental genome, and selecting at least one plant cell comprising at least one recombinant chromosome comprising the selected germplasm and the genomic locus of interest. Several embodiments relate to a method of introgressing a genomic locus of interest into a selected germplasm, comprising generating a plant cell comprising a first parental genome comprising the genomic locus of interest and a second parental genome comprising the selected germplasm, providing to the plant cell a first nucleic acid-targeting system that introduces genome modification in the first parental genome at a target sequence adjacent to the genomic locus of interest and a genome modification at a target site in the second parental genome and further introducing into the plant cell a second nucleic acid-targeting system that introduces a genome modification in the first parental genome at a second target sequence adjacent to the genomic locus, wherein the second target sequence is on opposite side of the genome genomic locus of interest from the target sequence of the first nucleic acid-targeting system, thereby inducing recombination between the first parental genome and the second parental genome, and selecting at least one plant cell comprising at least one recombinant chromosome comprising the selected germplasm and the genomic locus of interest. In some embodiments, the second nucleic acid-targeting system introduces a genome modification at a target sequence in the second parental genome. In some embodiments, the recombination is asymmetric. In some embodiments, the recombination is symmetric. In some embodiments, the genomic locus of interest comprises one or more genomic regions selected independently from the group consisting of a gene, an array of tandemly duplicated genes, a multigene family, an enhancer, a suppressor, a promoter, a termination sequence, a splice acceptor sequence, a splice donor sequence, an intron, an exon, an siRNA, a sequence encoding a non-coding RNA, a microRNA, a transgene, and a quantitative trait locus (QTL). In some embodiments, the genome modification is a double strand break (DSB). In some embodiments, the genome modification is a single strand break. In some embodiments, the genome modification is a recombinase-mediated DNA exchange reaction. In some embodiments, the genome modification is a transposase-mediated DNA exchange reaction. In some embodiments, the genome modification occurs at the beginning of meiosis. In some embodiments, the target sequence is genic. In some embodiments, the target sequence is within an intergenic region. In some embodiments, the target sequence is in a genomic locus of the first parental genome that is homologous to at least about 100 bp, at least about 150 bp, at least about 200 bp, at least about 250 bp, at least about 300 bp, at least about 350 bp, at least about 400 bp, at least about 450 bp, at least about 500 bp, at least about 600 bp, at least about 700 bp, at least about 800 bp, at least about 900 bp, or at least about 1000 bp of a genomic locus of the second parental genome. In some embodiments, the target sequence is in a genomic locus of the first parental genome that is homologous to at least about 100 bp, at least about 150 bp, at least about 200 bp, at least about 250 bp, at least about 300 bp, at least about 350 bp, at least about 400 bp, at least about 450 bp, at least about 500 bp, at least about 600 bp, at least about 700 bp, at least about 800 bp, at least about 900 bp, or at least about 1000 bp of a genomic locus of the second parental genome, wherein the genomic locus of the first parental genome and the genomic locus of the second parental genome are located in corresponding positions. In some embodiments, the target sequence is in a genomic locus of the first parental genome that is homologous to at least about 100 bp, at least about 150 bp, at least about 200 bp, at least about 250 bp, at least about 300 bp, at least about 350 bp, at least about 400 bp, at least about 450 bp, at least about 500 bp, at least about 600 bp, at least about 700 bp, at least about 800 bp, at least about 900 bp, or at least about 1000 bp of a genomic locus of the second parental genome, wherein the genomic locus of the first parental genome and the genomic locus of the second parental genome are not located in corresponding positions, leading to asymmetric recombination. In some embodiments, the first parental genome and the second parental genome are not sexually compatible. In some embodiments, the first parental genome and the second parental genome are different species. In some embodiments, the first parental genome is Triticum aestivum (wheat) and the second parental genome is selected from Aegilops ovate, Ae. biuncialis, Ae. triuncialis, Ae. quarrosa, Secale cereal, Triticum dicoccoides, Triticum dicoccum and Triticum durum. In some embodiments, the first parental genome is selected from Aegilops ovate, Ae. biuncialis, Ae. triuncialis, Ae. quarrosa, Secale cereal, Triticum dicoccoides, Triticum dicoccum and Triticum durum and the second parental genome is Triticum aestivum (wheat). In some embodiments, the first parental genome is Gossypium hirsutum (cotton) and the second parental genome is selected from G. sturtii, G. davidsonii, G. arboretum and G. raimondii. In some embodiments, the first parental genome is selected from G. sturtii, G. davidsonii, G. arboretum and G. raimondii and the second parental genome is Gossypium hirsutum (cotton). In some embodiments, the first parental genome and/or the second parental genome are haploid. In some embodiments, the first parental genome and/or the second parental genome are diploid. In some embodiments, the genomic locus of interest is Rp1 disease resistance locus. In some embodiments, the genomic locus of interest is Rpp1 disease resistance locus. In some embodiments, the genomic locus of interest is Rps1 disease resistance locus. In some embodiments, the genomic locus of interest is Rhg1 disease resistance locus. In some embodiments, the genomic locus of interest is Rgh4 disease resistance locus. In some embodiments, the plant is a maize plant. In some embodiments, the plant is a soybean plant. In some embodiments, the plant is a cotton plant. In some embodiments, the plant is a wheat plant. In some embodiments, the plant is a sorghum plant. In some embodiments, the plant is a canola plant. In some embodiments, the nucleic acid-targeting system comprises a CRISPR-associated transposase comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% homology to a sequence selected from the group consisting of SEQ ID NOs: 124-246 and 275-287. In some embodiments, the nucleic acid-targeting system further comprises a guide RNA capable of hybridizing with a target sequence. In some embodiments, the nucleic acid-targeting system further comprises a tracrRNA. In some embodiments, the nucleic acid-targeting system further comprises a divalent cation. In some embodiments, the nucleic acid-targeting system further comprises Mg2+. In some embodiments, the nuclease activity of the CRISPR-associated transposase is inactivated. In some embodiments, the nucleic acid-targeting system comprises a CRISPR-associated transposase with a heterologous functional domain. Several embodiments relate to a plant, plant cell or a seed of a plant produced by according to the aforementioned methods.

Several embodiments relate to a method of removing linkage drag, comprising generating a plant cell comprising a first parental genome and a second parental genome, wherein the first parental genome comprises a genomic locus of interest linked in cis to a undesirable genomic locus, providing to the cell a first nucleic acid-targeting system that introduces a genome modification between the genomic locus of interest and the undesirable genomic locus, thereby inducing recombination between the first parental genome and the second parental genome and unlinking the genomic locus of interest and the undesirable locus, and selecting at least one progeny comprising the genomic locus of interest. Several embodiments relate to a method of removing linkage drag, comprising generating a plant cell comprising a first parental genome and a second parental genome, wherein the first parental genome comprises a genomic locus of interest linked in cis to an undesirable genomic locus, providing to the cell a first nucleic acid-targeting system that introduces a first genome modification between the genomic locus of interest and the undesirable genomic locus and a second genome modification on the opposite side of the undesirable genomic locus from the first genome modification, thereby inducing recombination between the first parental genome and the second parental genome and removing the undesirable locus while maintaining the germplasm of the first parental genome distal to the second genome modification, and selecting at least one progeny comprising the genomic locus of interest. In some embodiments, the second nucleic acid-targeting system introduces a genome modification at a target sequence in the second parental genome. In some embodiments, the recombination is asymmetric. In some embodiments, the recombination is symmetric. In some embodiments, the genomic locus of interest comprises one or more genomic regions selected independently from the group consisting of a gene, an array of tandemly duplicated genes, a multigene family, an enhancer, a suppressor, a promoter, a termination sequence, a splice acceptor sequence, a splice donor sequence, an intron, an exon, an siRNA, a sequence encoding a non-coding RNA, a microRNA, a transgene, and a quantitative trait locus (QTL). In some embodiments, the genome modification is a double strand break (DSB). In some embodiments, the genome modification is a single strand break. In some embodiments, the genome modification is a recombinase-mediated DNA exchange reaction. In some embodiments, the genome modification is a transposase-mediated DNA exchange reaction. In some embodiments, the genome modification occurs at the beginning of meiosis. In some embodiments, the first parental genome and the second parental genome are not sexually compatible. In some embodiments, the first parental genome and the second parental genome are different species. In some embodiments, the first parental genome is Triticum aestivum (wheat) and the second parental genome is selected from Aegilops ovate, Ae. biuncialis, Ae. triuncialis, Ae. quarrosa, Secale cereal, Triticum dicoccoides, Triticum dicoccum and Triticum durum. In some embodiments, the first parental genome is selected from Aegilops ovate, Ae. biuncialis, Ae. triuncialis, Ae. quarrosa, Secale cereal, Triticum dicoccoides, Triticum dicoccum and Triticum durum and the second parental genome is Triticum aestivum (wheat). In some embodiments, the first parental genome is Gossypium hirsutum (cotton) and the second parental genome is selected from G. sturtii, G. davidsonii, G. arboretum and G. raimondii. In some embodiments, the first parental genome is selected from G. sturtii, G. davidsonii, G. arboretum and G. raimondii and the second parental genome is Gossypium hirsutum (cotton). In some embodiments, the first parental genome and/or the second parental genome are haploid. In some embodiments, the first parental genome and/or the second parental genome are diploid. In some embodiments, the genomic locus of interest is Rp1 disease resistance locus. In some embodiments, the genomic locus of interest is Rpp1 disease resistance locus. In some embodiments, the genomic locus of interest is Rps1 disease resistance locus. In some embodiments, the genomic locus of interest is Rhg1 disease resistance locus. In some embodiments, the genomic locus of interest is Rhg4 disease resistance locus. In some embodiments, the plant is a maize plant. In some embodiments, the plant is a soybean plant. In some embodiments, the plant is a cotton plant. In some embodiments, the plant is a wheat plant. In some embodiments, the plant is a sorghum plant. In some embodiments, the plant is a canola plant. In some embodiments, the nucleic acid-targeting system comprises a CRISPR-associated transposase comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% homology to a sequence selected from the group consisting of SEQ ID NOs: 124-246 and 275-287. In some embodiments, the nucleic acid-targeting system further comprises a guide RNA capable of hybridizing with a target sequence. In some embodiments, the nucleic acid-targeting system further comprises a tracrRNA. In some embodiments, the nucleic acid-targeting system further comprises a divalent cation. In some embodiments, the nucleic acid-targeting system further comprises Mg2+. In some embodiments, the nuclease activity of the CRISPR-associated transposase is inactivated. In some embodiments, the nucleic acid-targeting system comprises a CRISPR-associated transposase with a heterologous functional domain. Several embodiments relate to a plant, plant cell or a seed of a plant produced by according to the aforementioned methods.

Several embodiments relate to a method of coupling genomic loci in repulsion, comprising generating a plant cell comprising a first parental genome comprising a first genomic locus and a second parental genome comprising a second genomic locus, wherein the first genomic locus and the second genetic locus are in repulsion, providing to the cell a first nucleic acid-targeting system that introduces a genome modification adjacent to the first genomic locus, thereby inducing recombination between the first parental genome and the second parental genome, and selecting at least one plant cell comprising the first genomic locus and the second genomic locus on the same chromosome. In some embodiments, the first genomic locus and the second genomic locus are located on homologous chromosomes. In some embodiments, the first parental genome and the second parental genome are not sexually compatible. In some embodiments, the first parental genome and the second parental genome are different species. In some embodiments, the first genomic locus of interest and/or the second genomic locus of interest comprises one or more genomic regions selected independently from the group consisting of a gene, an array of tandemly duplicated genes, an enhancer, a suppressor, a promoter, a termination sequence, a splice acceptor sequence, a splice donor sequence, an intron, an exon, an siRNA, and a quantitative trait locus (QTL). In some embodiments, the first parental genome and/or the second parental genome are haploid. In some embodiments, the first parental genome and/or the second parental genome are diploid. In some embodiments, the first parental genome is Triticum aestivum (wheat) and the second parental genome is selected from Aegilops ovate, Ae. biuncialis, Ae. triuncialis, Ae. quarrosa, Secale cereal, Triticum dicoccoides, Triticum dicoccum and Triticum durum. In some embodiments, the first parental genome is selected from Aegilops ovate, Ae. biuncialis, Ae. triuncialis, Ae. quarrosa, Secale cereal, Triticum dicoccoides, Triticum dicoccum and Triticum durum and the second parental genome is Triticum aestivum (wheat). In some embodiments, the first parental genome is Gossypium hirsutum (cotton) and the second parental genome is selected from G. sturtii, G. davidsonii, G. arboretum and G. raimondii. In some embodiments, the first parental genome is selected from G. sturtii, G. davidsonii, G. arboretum and G. raimondii and the second parental genome is Gossypium hirsutum (cotton). In some embodiments, the genomic locus of interest is Rp1 disease resistance locus. In some embodiments, the first genomic locus of interest and/or the second genomic locus of interest is Rpp1 disease resistance locus. In some embodiments, the first genomic locus of interest and/or the second genomic locus of interest is Rps1 disease resistance locus. In some embodiments, the first genomic locus of interest and/or the second genomic locus of interest Rhg1 disease resistance locus. In some embodiments, the first genomic locus of interest and/or the second genomic locus of interest Rhg4 disease resistance locus. In some embodiments, the first genomic locus of interest is Rhg1 and the second genomic locus of interest Rhg4. In some embodiments, the plant is a maize plant. In some embodiments, the plant is a soybean plant. In some embodiments, the plant is a cotton plant. In some embodiments, the plant is a wheat plant. In some embodiments, the plant is a sorghum plant. In some embodiments, the plant is a canola plant. In some embodiments, the nucleic acid-targeting system comprises a CRISPR-associated transposase comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% homology to a sequence selected from the group consisting of SEQ ID NOs: 124-246 and 275-287. In some embodiments, the nucleic acid-targeting system further comprises a guide RNA capable of hybridizing with a target sequence. In some embodiments, the nucleic acid-targeting system further comprises a tracrRNA. In some embodiments, the nucleic acid-targeting system further comprises a divalent cation. In some embodiments, the nucleic acid-targeting system further comprises Mg2+. In some embodiments, the nuclease activity of the CRISPR-associated transposase is inactivated. In some embodiments, the nucleic acid-targeting system comprises a CRISPR-associated transposase with a heterologous functional domain. Several embodiments relate to a plant, plant cell or a seed of a plant produced by according to the aforementioned methods.

Several embodiments relate to a method of generating a new array of tandemly duplicated genes, comprising contacting a cell with a nucleic acid-targeting system that cleaves at least one target sequence in a first array of tandemly duplicated genes thereby inducing asymmetric recombination with a homologous sequence of a second array of tandemly duplicated genes and selecting at least one progeny comprising a new array of tandemly duplicated genes. In some embodiments, the first and second arrays of tandemly duplicated genes are identical. In other embodiments, the first and second arrays of tandemly duplicated genes are different. In some embodiments, the asymmetric recombination generates two new arrays of tandemly duplicated genes, depending on the recombination site. In some embodiments, the asymmetric recombination results in a deletion in at least one of the tandemly duplicated genes. In some embodiments, the cell is a plant cell. In a further embodiment, the plant cell is obtained from a plant selected from an inbred plant or a hybrid plant. In other embodiments, the cell is a mammalian cell. In some embodiments, the nucleic acid-targeting system comprises a CRISPR-associated transposase comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% homology to a sequence selected from the group consisting of SEQ ID NOs: 124-246 and 275-287. In some embodiments, the nucleic acid-targeting system further comprises a guide RNA capable of hybridizing with a target sequence. In some embodiments, the nucleic acid-targeting system further comprises a tracrRNA. In some embodiments, the nucleic acid-targeting system further comprises a divalent cation. In some embodiments, the nucleic acid-targeting system further comprises Mg2+. In some embodiments, the nuclease activity of the CRISPR-associated transposase is inactivated. In some embodiments, the nucleic acid-targeting system comprises a CRISPR-associated transposase with a heterologous functional domain. Several embodiments relate to a plant, plant cell or a seed of a plant produced by according to the aforementioned methods.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shows a multiple sequence alignment of CRISPR-associated transposase protein sequences SEQ ID NOs: 228-232.

FIG. 2 shows the multiple sequence alignment of three CRISPR spacer sequences and five bacterial phage sequences. The three spacers (spacer-1: SEQ ID NO: 2004, spacer-2: SEQ ID NO: 2005, spacer-3: SEQ ID NO: 2006) are from CRISPR regions associated with transposases in protein cluster 1. The five phage sequences (KJ920400.1: SEQ ID NO: 2007, HE614281.1: SEQ ID NO: 2008, HE614282.1: SEQ ID NO: 2009, KJ024807.1: SEQ ID NO: 2010, NC 029008.1: SEQ ID NO: 2011) are blast search hits of spacer sequences against datasets of phage and viral genomic sequences. The conserved “TCA” motif in the rectangle box is a putative 5′-PAM for the transposases.

FIG. 3 shows the predicted stem-loop secondary structure for the CRISPR repeat sequence 1 (SEQ ID NO: 2012) and the CRISPR repeat sequence 2 (SEQ ID NO: 2013) from the transposase-associated CRISPR region (SEQ ID NO: 662). The structure of the repeat sequences suggests that the repeat sequence alone is sufficient to form an effective guide RNA.

FIG. 4 shows a diagram of the predicted protein domain structure of the CRISPR-associated transposase of SEQ ID NO: 136 (DNA: SEQ ID NO: 304). Seven Puf (Pumilio-family RNA binding repeat) domains are predicted and labeled as Puf-1 to Puf-7. The protein is also predicted to contain an IS605_ORFB domain (amino acids 221-336), and a Zn_Ribbon domain (amino acids 350-416). The conserved RuvC catalytic sites in the split RuvC I, II, and III regions are indicated by D233, E354, and D408, respectively.

FIG. 5 shows the amino acid sequence of the CRISPR-associated transposase of SEQ ID NO: 136 with domain annotations: seven Puf domains Puf-1 to Puf-7 are underlined and labeled; two pfam domains, IS605_ORFB and Zn_Ribbon region, are enclosed by brackets [ ] and [[ ]] respectively; and the conserved RuvC catalytic sites D233, E354, and D408 are pointed out by arrows.

FIG. 6 shows a multiple sequence alignment of five CRISPR repeat sequences (SEQ ID NOs: 2012-2016) from the CRISPR region (SEQ ID NO: 662) associated with the CRISPR-associated transposase of SEQ ID NO: 136 (DNA: SEQ ID NO: 304). The conserved nucleotides that are consistent with the consensus Puf binding motif (5′-UGUANAUA-3′) are underlined and shown in bold.

FIG. 7 shows a diagram of an Escherichia coli based blue-white selection assay to screen for nuclease activity. A bacterial expression plasmid generated using a pUC19 (pUC) vector with a kanamycin (kan) selection marker was used to clone a region of interest (ROI) encoding a putative transposase and associated guide-RNA. A reporter plasmid was also generated that contained a target sequence encoding a spacer from the CRISPR region, which is flanked by variable sequence (indicated by NNNspacerNNN), a lacZ reporter gene, a chloramphenicol selection cassette (chlor), and a low-copy number bacterial promoter (p15a). The two plasmids were co-transformed into E. coli, and the presence of white colonies indicates cutting by the transposase. Sequence analysis of plasmid recovered from white colonies is used to confirm the nuclease activity.

FIG. 8 shows a diagram of Mycobacterium cutting assay to validate nuclease activity of CRISPR-associated transposases. The same expression and reporter plasmids used for the E. coli blue-white selection of FIG. 7 are used to co-transform Mycobacterium. Due to endogenous plasmid repair in Mycobacterium, repair of double-strand breaks in the LacZ reporter plasmid results in insertions and deletions indels at the repair site. The presence of indels in the LacZ vector is indicative of nuclease activity. PCR and/or sequencing primers designed to the spacer cassette are used to detect indels in recovered reporter plasmids.

FIG. 9 shows a diagram of an in vitro cutting assay. The region comprising the CRISPR-associated transposase is cloned into an expression vector and the transposase is expressed in E. coli and the purified protein is incubated in vitro with the DNA target for cutting (NNNspacerNNN). The resulting DNA is (a) analyzed for fragment length by gel electrophoresis, and (b) by sequence analysis.

FIG. 10 shows a diagram of a cutting assay for eukaryotic cells. The CRISPR-associated transposase and associated guide RNA are cloned into a vector to facilitate expression in a eukaryotic cell. The expression vectors, double strand oligo (ds oligo), and (optionally) plasmid DNA containing target sequence are co-transformed into a eukaryotic cell. The nuclease activity on either (a) chromosomal DNA, or (b) introduced plasmid template is evaluated with standard molecular biology assays (PCR (Taqman® (TM)), restriction fragment size analysis, or sequencing).

FIG. 11 shows a diagram of prokaryotic blue-white selection assay design for the validation of CRISPR-associated transposase activity. The top row shows diagrams of the vectors used for CRISPR-associated transposase (RGEN) expression. The bottom row shows diagrams of the vectors containing the putative target sequence (NNNspacerNNNspacerNNN) and the LacZ marker. The left top and bottom pair are the control lacking the target sequence. The middle top and bottom pair are the control lacking the CRISPR-associated transposase (RGEN). The right top and bottom pair are the test assay with the respective vectors containing the CRISPR-associated transposase (RGEN) and the target sequence.

FIG. 12 shows a diagram of the Guide RNA binding assay using Alpha Screen (Perkin Elmer) technology. This assay system uses a donor and acceptor bead that when brought into close proximity emits a detectable fluorescent signal. The putative guide RNAs (gRNA) are made using in vitro transcription. These guide RNA sequences are linked to the flank sequences (Flank1: SEQ ID NO: 3380; Flank2: SEQ ID NO: 3381) via the linker sequence (SEQ ID NO: 3382). The nucleotide sequence (Flank2) binds to an oligo with an Alpha Streptavidin donor bead attached. A CRISPR-associated transposase is expressed in E. coli with a His-tag. This His-tag (represented in the figure as 6-His_tag) serves as the binding site for the Alpha acceptor bead. When CRISPR-associated transposase binds to the putative guide RNA a detectable fluorescent signal is produced.

DETAILED DESCRIPTION

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Where a term is provided in the singular, the inventors also contemplate aspects of the disclosure described by the plural of that term. Where there are discrepancies in terms and definitions used in references that are incorporated by reference, the terms used in this application shall have the definitions given herein. Other technical terms used have their ordinary meaning in the art in which they are used, as exemplified by various art-specific dictionaries, for example, “The American Heritage® Science Dictionary” (Editors of the American Heritage Dictionaries, 2011, Houghton Mifflin Harcourt, Boston and New York), the “McGraw-Hill Dictionary of Scientific and Technical Terms” (6th edition, 2002, McGraw-Hill, New York), or the “Oxford Dictionary of Biology” (6th edition, 2008, Oxford University Press, Oxford and New York). The inventors do not intend to be limited to a mechanism or mode of action. Reference thereto is provided for illustrative purposes only.

The practice of the present disclosure employs, unless otherwise indicated, conventional techniques of biochemistry, chemistry, molecular biology, microbiology, cell biology, genomics, plant breeding, and biotechnology, which are within the skill of the art. See Green and Sambrook, MOLECULAR CLONING: A LABORATORY MANUAL, 4th edition (2012); CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (F. M. Ausubel, et al. eds., (1987)); the series METHODS IN ENZYMOLOGY (Academic Press, Inc.): PCR 2: A PRACTICAL APPROACH (M. J. MacPherson, B. D. Hames and G. R. Taylor eds. (1995)); Harlow and Lane, eds. (1988) ANTIBODIES, A LABORATORY MANUAL; ANIMAL CELL CULTURE (R. I. Freshney, ed. (1987)); RECOMBINANT PROTEIN PURIFICATION: PRINCIPLES AND METHODS, 18-1142-75, GE Healthcare Life Sciences; C. N. Stewart, A. Touraev, V. Citovsky, T. Tzfira eds. (2011) PLANT TRANSFORMATION TECHNOLOGIES (Wiley-Blackwell); and R. H. Smith (2013) PLANT TISSUE CULTURE. TECHNIQUES AND EXPERIMENTS (Academic Press, Inc.).

Any references cited herein are incorporated by reference in their entireties.

As used herein, the singular form “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise. For example, the term “a compound” or “at least one compound” may include a plurality of compounds, including mixtures thereof. Thus, for example, reference to “plant,” “the plant,” or “a plant” also includes a plurality of plants; also, depending on the context, use of the term “plant” can also include genetically similar or identical progeny of that plant; use of the term “a nucleic acid” optionally includes, as a practical matter, many copies of that nucleic acid molecule.

As used herein, the term “about” indicates that a value includes the inherent variation of error for the method being employed to determine a value, or the variation that exists among experiments.

As used herein, the terms “CRISPR-associated enzyme” refers to genome modification enzymes that associated in its native context (e.g., in a bacterial genome) with a CRISPR locus. In some embodiments, the CRISPR-associated enzymes are CRISPR-associated transposases.

As used herein, “encoding” refers either to a polynucleotide (DNA or RNA) encoding for the amino acids of a polypeptide or a DNA encoding for the nucleotides of an RNA. As used herein, “coding sequence” and “coding region” are used interchangeably and refer to a polynucleotide that encodes a polypeptide. The boundaries of a coding region are generally determined by a translation start codon at its 5′ end and a translation stop codon at its 3′ end.

As used herein, an “endogenous” molecule is one that is normally present in a particular cell at a particular developmental stage under particular environmental conditions.

As used herein, an “expression cassette” refers to a polynucleotide sequence which may or may not be operably linked to one or more expression elements such as an enhancer, a promoter, a leader, an intron, a 5′ untranslated region (UTR), a 3′ UTR, or a transcription termination sequence. In some embodiments, an expression cassette comprises at least a first polynucleotide sequence capable of initiating transcription of an operably linked second polynucleotide sequence and optionally a transcription termination sequence operably linked to the second polynucleotide sequence.

As used herein, the term “gene” or “genic” means a locatable region of genomic sequence corresponding to a unit of inheritance. A gene may include regulatory regions, such as promoters, enhancers, 5′-untranslated regions, intron regions, exon regions, 3′-untranslated regions, transcribed regions, and other functional sequence regions that may exist as native genes or transgenes in a plant or a mammalian genome. Depending upon the circumstances, the term “target gene” can refer to the full-length nucleotide sequence of a gene targeted for binding and/or cleavage or the nucleotide sequence of a portion of a gene targeted for binding and/or cleavage. A target gene can be an endogenous gene or a transgene.

As used herein, the term “genomic locus” refers to a specific location on a chromosome. A genomic locus may comprise a single nucleotide, a few nucleotides, a large number of nucleotides, a gene, a portion of a gene, a gene cluster, a multigene family or array of genes in a genomic region.

As used herein, the term “homologous recombination” refers to the exchange of nucleotide sequences at a conserved region shared by two genomic loci or by a donor DNA and a target site. Homologous recombination includes symmetric homologous recombination and asymmetric homologous recombination. Asymmetric homologous recombination may also be referred to as unequal recombination.

As used herein, the term “identity” when used in relation to nucleic acids, describes the degree of similarity between two or more nucleotide sequences. The percentage of “sequence identity” between two sequences can be determined by comparing two optimally aligned sequences over a comparison window, such that the portion of the sequence in the comparison window may comprise additions or deletions (gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison, and multiplying the result by 100 to yield the percentage of sequence identity. A sequence that is identical at every position in comparison to a reference sequence is said to be identical to the reference sequence and vice-versa. An alignment of two or more sequences may be performed using any suitable computer program. For example, a widely used and accepted computer program for performing sequence alignments is CLUSTALW v1.6 (Thompson, et al. (1994) Nucl. Acids Res., 22: 4673-4680).

As used herein, a “non-coding sequence” can encode a functional RNA (e.g. transfer RNA, ribosomal RNA, microRNA, Piwi-interacting RNA), a promoter, an intron, an untranslated region of an mRNA (e.g., a 5′ untranslated region or a 3′ untranslated region), a pseudogene, a repeat sequence, or a transposable element. Non-coding sequences do not encode functional polypeptides.

As used herein, the terms “nucleic acid,” “polynucleotide,” and “oligonucleotide are used interchangeably and refer to deoxyribonuclotides (DNA), ribonucleotides (RNA), and functional analogues thereof, such as complementary DNA (cDNA) in linear or circular conformation. Nucleic acid molecules provided herein can be single stranded or double stranded. Nucleic acid molecules comprise the nucleotide bases adenine (A), guanine (G), thymine (T), cytosine (C). Uracil (U) replaces thymine in RNA molecules. Analogues of the natural nucleotide bases, as well as nucleotide bases that are modified in the base, sugar, and/or phosphate moieties are also provided herein. The symbol “N” can be used to represent any nucleotide base (e.g., A, G, C, T, or U). As used herein, “complementary” in reference to a nucleic acid molecule or nucleotide bases refers to A being complementary to T (or U), and G being complementary to C. Two complementary nucleic acid molecules are capable of hybridizing with each other under appropriate conditions. In an aspect of the present disclosure, two nucleic acid sequences are homologous if they have at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity with each other.

As used herein, “operably linked” means that the operably linked nucleic acid sequences exhibit their desired function. For example, in an aspect of this disclosure, a provided DNA promoter sequence can initiate transcription of an operably linked DNA sequence into RNA. A nucleic acid sequence provided herein can be upstream or downstream of a physically or operably linked nucleic acid sequence. In an aspect, a first nucleic acid molecule provided herein is both physically linked and operably linked to a second nucleic acid molecule provided herein. In another aspect, a first nucleic acid molecule provided herein is neither physically linked nor operably linked to a second nucleic acid molecule provided herein. As used herein, “upstream” means the nucleic acid sequence is positioned before the 5′ end of a linked nucleic acid sequence. As used herein, “downstream” means the nucleic acid sequence is positioned after the 3′ end of a linked nucleic acid sequence.

As used herein, the term “plant” refers to any photosynthetic, eukaryotic, unicellular or multicellular organism of the kingdom Plantae and includes a whole plant or a cell or tissue culture derived from a plant, comprising any of: whole plants, plant components or organs (e.g., leaves, stems, roots, etc.), plant tissues, seeds, plant cells, protoplasts and/or progeny of the same. A progeny plant can be from any filial generation, e.g., F1, F2, F3, F4, F5, F6, F7, etc. A “plant cell” is a biological cell of a plant, taken from a plant or derived through culture from a cell taken from a plant. The term plant encompasses monocotyledonous and dicotyledonous plants. The methods, systems, and compositions described herein are useful across a broad range of plants. Suitable plants in which the methods, systems, and compositions disclosed herein can be used include, but are not limited to, cereals and forage grasses (e.g., alfalfa, rice, maize, wheat, barley, oat, sorghum, pearl millet, finger millet, cool-season forage grasses, and bahiagrass), oilseed crops (e.g., soybean, oilseed brassicas including canola and oilseed rape, sunflower, peanut, flax, sesame, and safflower), legume grains and forages (e.g., common bean, cowpea, pea, fava bean, lentil, tepary bean, Asiatic beans, pigeonpea, vetch, chickpea, lupine, alfalfa, and clovers), temperate fruits and nuts (e.g., apple, pear, peach, plums, berry crops, cherries, grapes, olive, almond, and Persian walnut), tropical and subtropical fruits and nuts (e.g., citrus including limes, oranges, and grapefruit; banana and plantain, pineapple, papaya, mango, avocado, kiwifruit, passionfruit, and persimmon), vegetable crops (e.g., solanaceous plants including tomato, eggplant, and peppers; vegetable brassicas; radish, carrot, cucurbits, alliums, asparagus, and leafy vegetables), sugar cane, tubers (e.g., beets, parsnips, potatoes, turnips, sweet potatoes), and fiber crops (sugarcane, sugar beet, stevia, potato, sweet potato, cassava, and cotton), plantation crops, ornamentals, and turf grasses (tobacco, coffee, cocoa, tea, rubber tree, medicinal plants, ornamentals, and turf grasses), and forest tree species.

As used herein, “plant genome” refers to a nuclear genome, a mitochondrial genome, or a plastid (e.g., chloroplast) genome of a plant cell. In some embodiments, a plant genome may comprise a parental genome contributed by the male and a parental genome contributed by the female. In some embodiments, a plant genome may comprise only one parental genome.

As used herein, “polynucleotide” refers to a nucleic acid molecule containing multiple nucleotides and generally refers both to “oligonucleotides” (a polynucleotide molecule of 18-25 nucleotides in length) and polynucleotides of 26 or more nucleotides. Aspects of this disclosure include compositions including oligonucleotides having a length of 18-25 nucleotides (e. g., 18-mers, 19-mers, 20-mers, 21-mers, 22-mers, 23-mers, 24-mers, or 25-mers), or medium-length polynucleotides having a length of 26 or more nucleotides (e. g., polynucleotides of 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, about 65, about 70, about 75, about 80, about 85, about 90, about 95, about 100, about 110, about 120, about 130, about 140, about 150, about 160, about 170, about 180, about 190, about 200, about 210, about 220, about 230, about 240, about 250, about 260, about 270, about 280, about 290, or about 300 nucleotides), or long polynucleotides having a length greater than about 300 nucleotides (e. g., polynucleotides of between about 300 to about 400 nucleotides, between about 400 to about 500 nucleotides, between about 500 to about 600 nucleotides, between about 600 to about 700 nucleotides, between about 700 to about 800 nucleotides, between about 800 to about 900 nucleotides, between about 900 to about 1000 nucleotides, between about 300 to about 500 nucleotides, between about 300 to about 600 nucleotides, between about 300 to about 700 nucleotides, between about 300 to about 800 nucleotides, between about 300 to about 900 nucleotides, or about 1000 nucleotides in length, or even greater than about 1000 nucleotides in length, for example up to the entire length of a target gene including coding or non-coding or both coding and non-coding portions of the target gene). Where a polynucleotide is double-stranded, its length can be similarly described in terms of base pairs.

As used herein, terms “polypeptide”, “peptide” and “protein” are used interchangeably to refer to a polymer of amino acid residues. The term also applies to amino acid polymers in which one or more amino acids are chemical analogues or modified derivatives of a corresponding naturally-occurring amino acids.

As used herein, “protoplast” refers to a plant cell that has had its protective cell wall completely or partially removed using, for example, mechanical or enzymatic means resulting in an intact biochemical competent unit of living plant that can reform their cell wall, proliferate and regenerate grow into a whole plant under proper growing conditions.

As used herein, “promoter” refers to a nucleic acid sequence located upstream or 5′ to a translational start codon of an open reading frame (or protein-coding region) of a gene and that is involved in recognition and binding of RNA polymerase I, II, or III and other proteins (trans-acting transcription factors) to initiate transcription. In some embodiments described herein, the promoter is a plant promoter. A “plant promoter” is a native or non-native promoter that is functional in plant cells. Constitutive promoters are functional in most or all tissues of a plant throughout plant development. Tissue-, organ- or cell-specific promoters are expressed only or predominantly in a particular tissue, organ, or cell type, respectively. Rather than being expressed “specifically” in a given tissue, plant part, or cell type, a promoter may display “enhanced” expression, i.e., a higher level of expression, in one cell type, tissue, or plant part of the plant compared to other parts of the plant. Temporally regulated promoters are functional only or predominantly during certain periods of plant development or at certain times of day, as in the case of genes associated with circadian rhythm, for example. Inducible promoters selectively express an operably linked DNA sequence in response to the presence of an endogenous or exogenous stimulus, for example by chemical compounds (chemical inducers) or in response to environmental, hormonal, chemical, and/or developmental signals. Inducible or regulated promoters include, for example, promoters regulated by light, heat, stress, flooding or drought, phytohormones, wounding, or chemicals such as ethanol, jasmonate, salicylic acid, or safeners. In an aspect, a promotor provided herein is a constitutive promoter. In another aspect, a promoter provided herein is a regulatable promoter. In an aspect, a promoter provided herein is located within a sequence of interest. In another aspect, a promoter provided herein is not located within a sequence of interest. A number of promoters that are active in plant cells have been described in the literature. Such promoters would include but are not limited to the nopaline synthase (NOS) (Ebert et al., 1987) and octopine synthase (OCS) promoters that are carried on Ti plasmids of Agrobacterium tumefaciens, the caulimovirus promoters such as the cauliflower mosaic virus (CaMV) 19S (Lawton et al., Plant Molecular Biology (1987) 9: 315-324) and 35S promoters (Odell et al., Nature (1985) 313: 810-812), the Figwort mosaic virus (FMV) 35S promoter (U.S. Pat. Nos. 6,051,753; 5,378,619), and the enhanced CaMV35S promoter (e35S). Additional promoters that can find use are the sucrose synthase promoter (Yang and Russell, Proceedings of the National Academy of Sciences, USA (1990) 87: 4144-4148), the R gene complex promoter (Chandler et al., Plant Cell (1989) 1: 1175-1183), and the chlorophyll a/b binding protein gene promoter, PC1SV (U.S. Pat. No. 5,850,019), and AGRtu.nos (GenBank Accession V00087; Depicker et al., Journal of Molecular and Applied Genetics (1982) 1: 561-573; Bevan et al., 1983) promoters. A variety of other plant gene promoters that are regulated in response to environmental, hormonal, chemical, and/or developmental signals, also can be used for expression of heterologous genes in plant cells, including, for instance, promoters regulated by (1) heat (Callis et al., Plant Physiology, (1988) 88: 965-968), (2) light (e.g., pea RbcS-3A promoter, Kuhlemeier et al., Plant Cell, (1989) 1: 471-478; maize RbcS promoter, Schaffner et al., Plant Cell (1991) 3: 997-1012); (3) hormones, such as abscisic acid (Marcotte et al., Plant Cell, (1989) 1: 969-976), (4) wounding (e.g., Siebertz et al., Plant Cell, (1989) 961-968); or other signals or chemicals. Tissue specific promoters are also known. In some embodiments, a promoter is capable of causing sufficient expression to result in the production of an effective amount of the gene product of interest. Examples describing such promoters include without limitation U.S. Pat. No. 6,437,217 (maize RS81 promoter), U.S. Pat. No. 5,641,876 (rice actin promoter), U.S. Pat. No. 6,426,446 (maize RS324 promoter), U.S. Pat. No. 6,429,362 (maize PR-1 promoter), U.S. Pat. No. 6,232,526 (maize A3 promoter), U.S. Pat. No. 6,177,611 (constitutive maize promoters), U.S. Pat. Nos. 5,322,938, 5,352,605, 5,359,142 and 5,530,196 (35S promoter), U.S. Pat. No. 6,433,252 (maize L3 oleosin promoter), U.S. Pat. No. 6,429,357 (rice actin 2 promoter as well as a rice actin 2 intron), U.S. Pat. No. 5,837,848 (root specific promoter), U.S. Pat. No. 6,294,714 (light inducible promoters), U.S. Pat. No. 6,140,078 (salt inducible promoters), U.S. Pat. No. 6,252,138 (pathogen inducible promoters), U.S. Pat. No. 6,175,060 (phosphorus deficiency inducible promoters), U.S. Pat. No. 6,635,806 (gamma-coixin promoter), and U.S. patent application Ser. No. 09/757,089 (maize chloroplast aldolase promoter). In some embodiments, promoter hybrids can be constructed to enhance transcriptional activity (U.S. Pat. No. 5,106,739). In some embodiments, promoter hybrids can be constructed to combine a desired transcriptional activity, transcriptional inducibility, transcriptional tissue specificity, and/or transcriptional developmental specificity. Promoters that function in plants include but are not limited to promoters that are inducible, viral, synthetic, constitutive, temporally regulated, spatially regulated, and spatio-temporally regulated. Other promoters that are tissue-enhanced, tissue-specific, or developmentally regulated are also known in the art and envisioned to have utility in the practice of this disclosure. Promoters used in the provided nucleic acid molecules and transformation vectors of the present disclosure can be modified, if desired, to affect their control characteristics. Promoters can be derived by means of ligation with operator regions, random or controlled mutagenesis, etc. Furthermore, the promoters can be altered to contain multiple “enhancer sequences” to assist in elevating gene expression.

As used herein, a “recombinant nucleic acid” refers to a nucleic acid molecule (DNA or RNA) having a coding and/or non-coding sequence distinguishable from endogenous nucleic acids found in natural systems. In some aspects, a recombinant nucleic acid provided herein is used in any composition, system or method provided herein. In some aspects, a recombinant nucleic acid may any CRISPR-associated transposase provided herein. In some aspects, a recombinant nucleic acid may comprise or encode any guide RNA provided herein can be used in any composition, system or method provided herein. In some aspects, a recombinant nucleic acid can comprise any donor polynucleotide provided herein can be used in any composition, system or method provided herein. In an aspect, a vector provided herein comprises any recombinant nucleic acid provided herein. In another aspect, a cell provided herein comprises a recombinant nucleic acid provided herein. In another aspect, a cell provided herein comprises a vector provided herein.

As used herein, the term “recombination” refers to the process by which two DNA molecules exchange nucleotide sequences. In some aspects, the compositions, systems or methods provided herein promote recombination between two DNA molecules. In some embodiments, recombination occurs between two sets of parental chromosomes. In some embodiments, recombination occurs between two homologous chromosomes. In some embodiments, recombination occurs between non-homologous chromosomes. In some embodiments, recombination occurs between homoeologous chromosomes. In some embodiments, recombination results in the production of a new gene sequence, number of genes, arrangement of genes, allele or combination of alleles. Many methods for detecting recombination are know in the art and include, but are not limited to, 1) phenotypic screening, 2) molecular marker technologies such as single nucleotide polymorphism—SNP analysis by TaqMan® or Illumina/Infinium technology, 3) Southern blot, and 4) sequencing.

As used herein, the term “recombination event” refers to an instance of recombination between two DNA molecules.

As used herein, the term “recombination rate” refers to the probability that a recombination event will occur between two genomic loci. The recombination rate may be influenced by a number of factors, including, but not limited to, the distance between two genomic loci, the chromosomal region (e.g., centromereic, telomereic) in which the loci occur, transcriptional activity, the presence of chromosomal inversions and other factors. Methods for measuring recombination include, but are not limited to, linkage analysis in mapping populations, and quantitative technologies such as quantitative PCR (qPCR) or droplet digital PCR (ddPCR), as described in the present disclosure. In some aspects, the compositions, systems or methods provided herein increase the recombination rate. As used herein, the term “regulatory element” is intended to include promoters, enhancers, internal ribosomal entry sites (IRES), and other expression control elements (e.g., transcription termination signals, such as polyadenylation signals and poly-U sequences). Such regulatory elements are described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory elements include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). A tissue-specific promoter may direct expression primarily in a desired tissue of interest, such as meristem, or particular cell types (e.g., pollen). Regulatory elements may also direct expression in a temporal-dependent manner, such as in a cell-cycle dependent or developmental stage-dependent manner, which may or may not also be tissue or cell-type specific. Also encompassed by the term “regulatory element” are enhancer elements, such as WPRE; CMV enhancers; the R-U5′ segment in LTR of HTLV-I (Mol. Cell. Biol., Vol. 8(1), p. 466-472, 1988); and SV40 enhancer.

As used herein, the terms “target sequence” or “target site” refer to a nucleotide sequence modified by a CRISPR-associated transposase as described herein. A target sequence may be genic or non-genic. In some aspects, a target sequence provided herein comprises a genic region. In other aspects, a target sequence provided herein comprises an intergenic region. In yet another aspect, a target sequence provided herein comprises both a genic region and an intergenic region. In an aspect, a target sequence provided herein comprises a coding nucleic acid sequence. In another aspect, a target sequence provided herein comprises a non-coding nucleic acid sequence. In an aspect, a target sequence provided herein is located in a promoter. In another aspect, a target sequence provided herein comprises an enhancer sequence. In yet another aspect, a target sequence provided herein comprises both a coding nucleic acid sequence and a non-coding nucleic acid sequence. In one aspect, a target sequence provided herein is cleaved by a double-strand break inducing agent, such as a CRISPR-associated transposase as described herein.

Novel CRISPR-Associated Transposases

The present disclosure provides polynucleotide sequences and amino acid sequences of novel CRISPR-associated transposases identified from various bacterial genomes. In some embodiments, the CRISPR-associated transposases provided herein comprise an amino acid sequence selected from SEQ ID NOs: 124-246 and 275-287, fragments thereof, homologs thereof and orthologs thereof. The terms “ortholog” and “homolog” are well known in the art. A “homologue” of a CRISPR-associated transposase as described herein is a protein isolated from the same species which performs the same or a similar function as the protein it is a homolog of Homologous proteins may, but need not, be structurally related, or are only partially structurally related. An “ortholog” of a CRISPR-associated transposase as described herein is a protein isolated from a different species which performs the same or a similar function as the protein it is an ortholog of. Orthologous proteins may but need not be structurally related, or are only partially structurally related. Homologs and orthologs may be identified by homology modeling or structural BLAST (Dey F, Cliff Zhang Q, Petrey D, Honig B. Toward a “structural BLAST”: using structural relationships to infer function. Protein Sci. 2013 April; 22(4):359-66. doi: 10.1002/pro.2225.). In some embodiments, the homolog or ortholog of a novel CRISPR-associated transposase as described herein has a sequence homology or identity of at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% with a CRISPR-associated transposase comprising an amino acid sequence selected from SEQ ID NOs: 124-246 and 275-287.

In some embodiments, the CRISPR-associated transposase provided herein form a complex with a guide RNA that directs the CRISPR-associated transposase to a target site where the CRISPR-associated transposase introduces a single-strand break or a double-strand break (DSB) in a nucleic acid sequence. The targeted nucleic acid sequence can be DNA, RNA, or a DNA/RNA hybrid. The introduced DSB can be repaired by non-homologous end joining (NHEJ) creating high likelihood of introducing small insertions or deletions (Indels) leading to frame shift mutations. Alternatively, a DNA sequence with desired mutation can be substituted at the region of DSB when homology dependent repair (HDR) pathway is applied. In some embodiments a recombinant nucleic acid comprising a one or more transgenes is integrated at the target site.

The instant disclosure also provides a recombinant nucleic acid comprising a heterologous promoter operably linked to a polynucleotide encoding a CRISPR-associated transposase as described herein. In some embodiments, the CRISPR-associated transposases provided herein are encoded by a polynucleotide sequence comprising a sequence selected from SEQ ID NOs: 1-123, 604-627 and 2020-3379, or a fragment thereof. In some embodiments, the CRISPR-associated transposases provided herein are encoded by a polynucleotide sequence comprising a sequence having at least 80% identity, at least 81% identity, at least 82% identity, at least 83% identity, at least 84% identity, at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity to a sequence selected from SEQ ID NOs: 1-123, 604-627 and 2020-3379, or a fragment thereof. In one aspect, a recombinant nucleic acid provided herein comprises one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more heterologous promoters operably linked to one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more polynucleotides encoding a CRISPR-associated transposase. In some embodiments, a recombinant nucleic acid provided herein encodes one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more guide RNAs. As used herein, the term “guide RNA” refers to an RNA molecule comprising a nucleotide sequence that can guide CRISPR enzyme to a target DNA molecule by hybridizing to a target sequence. In one aspect, a guide RNA provided herein comprises a CRISPR RNA (crRNA). In one aspect, a guide RNA provided herein comprises a CRISPR RNA (crRNA) complexed with a trans-activating CRISPR RNA (tracrRNA). In another aspect, a guide RNA provided herein comprises a single-chain guide RNA. In an aspect, a single-chain guide RNA provided herein comprises both a crRNA and a tracrRNA.

In some embodiments, a recombinant nucleic acid provided herein comprises a polynucleotide encoding a guide RNA. In an aspect, a recombinant nucleic acid provided herein comprises one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more polynucleotides encoding one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more guide RNAs. In one aspect, a polynucleotide encoding a guide RNA provided herein is operably linked to a second promoter. In one aspect, a polynucleotide encoding a guide RNA provided herein is operably linked to a U6 snRNA promoter. In one aspect, a polynucleotide encoding a guide RNA provided herein is operably linked to a U6 snRNA promoter as described in WO20150131101, incorporated by reference herein. In another aspect, a guide RNA provided herein is an isolated RNA. In an aspect, a guide RNA provided herein is encoded in a viral vector, a plasmid vector, or an Agrobacterium vector. In an aspect, a guide RNA provided herein comprises a crRNA. In an aspect, a guide RNA provided herein comprises a tracrRNA. In another aspect, a guide RNA provided herein comprises a single-chain guide RNA. In an aspect, a single-chain guide RNA provided herein comprises both a crRNA and a tracrRNA.

In some embodiments, a recombinant nucleic acid provided herein comprises one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more donor polynucleotides. As used herein, a “donor polynucleotide” is a polynucleotide molecule capable of being inserted into a genome of a recipient cell using a CRISPR-associated transposase or method as described herein. In another aspect, a donor polynucleotide provided herein is operably linked to a second promoter. In yet another aspect, a donor polynucleotide provided herein comprises at least one promoter. In an aspect, a donor polynucleotide provided herein comprises one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more transgenes. In an aspect, a donor polynucleotide provided herein comprises one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more coding nucleic acid sequences, one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more non-coding nucleic acid sequences, or a combination of one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more coding nucleic acid sequences and one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more non-coding nucleic acid sequences. In an aspect, a donor polynucleotide provided herein comprises one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more nucleic acid sequences for templated editing. In some embodiments, a recombinant nucleic acid comprising a donor polynucleotide is provided to a cell in the same vector as a CRISPR-associated transposase. In some embodiments, a recombinant nucleic acid comprising a donor polynucleotide is provided to a cell independently of a CRISPR-associated transposase. In an aspect, a donor polynucleotide provided herein is encoded in a viral vector, a plasmid vector, or an Agrobacterium vector.

In some embodiments, a polynucleotide encoding the CRISPR-associated transposase is from the genome of a bacterium selected from the group consisting of: Lysinibacillus sp., Brevibacillus sp., Sphingobium sp., Undibacterium sp., Bacillus sp., Chryseobacterium sp., Sphingomonas sp., Paenibacillus sp., Streptomyces sp., Stenotrophomonas sp., and Labrys sp. In other embodiments, a polynucleotide encoding the CRISPR-associated transposase is from the genome of a bacterium selected from the group consisting of: Brevibacillus laterosporus; Bacillus thuringiensis; Bacillus weihenstephanensis; Bacillus megaterium; Enterococcus faecalis; Brevibacillus brevis; Undibacterium pigrum; Novosphingobium rosa; Labrys methylaminiphilus; Brevibacillus parabrevis; Paenibacillus thiaminolyticus; Paenibacillus lentimorbus; and Paenibacillus terrae. In certain aspects, a polynucleotide encoding the CRISPR-associated transposase is associated within the bacterial genome with a CRISPR repeat locus. In certain aspects, a polynucleotide encoding the CRISPR-associated transposase is further identified in the bacterial genome by associated with a Cas1, a Cas2, or a Cas1 and a Cas2 but not Cas5 or Cas3. In some embodiments, the polynucleotide encoding the CRISPR-associated transposase is located in the same operon as the CRISPR locus. In other embodiments, the polynucleotide encoding the CRISPR-associated transposase is located within 2.5 kilobases of the CRISPR loci. In another embodiment, the polynucleotide encoding the CRISPR-associated transposase is further identified by the presence of one or more pfam domains identified in Table 5. In an aspect, a polynucleotide encoding a CRISPR-associated transposase provided herein is characterized by: being from a genome of a Lysinibacillus sp., a Brevibacillus sp., a Sphingobium sp., a Undibacterium sp., a Bacillus sp., a Chryseobacterium sp., a Sphingomonas sp., a Paenibacillus sp., a Streptomyces sp., a Stenotrophomonas sp., or a Labrys sp.; being from a genome of Bacillus thuringiensis, Brevibacillus brevis, Brevibacillus laterosporus, Brevibacillus parabrevis, Bacillus weihenstephanensis, Bacillus megaterium, Enterococcus faecalis, Labrys methylaminiphilus, Novosphingobium rosa, Paenibacillus thiaminolyticus, Paenibacillus lentimorbus, Paenibacillus terrae or Undibacterium pigrum; being associated with a bacterial genome by association with a CRISPR repeat locus; being identified in a bacterial genome by association with a Cas1 protein, a Cas2 protein, or a Cas1 protein and a Cas2 protein, but not a Cas3 protein or Cas5 protein; being located in the same operon as a CRISPR loci; being located within 10, 25, 50, 75, 100, 150, 200, 250, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1250, 1500, 1750, 2000, 2500, 3000, 4000, 5000, 7500, or 10,000 nucleotides of a CRISPR loci; being a polynucleotide comprising a sequence encoding a protein having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to a sequence selected from SEQ ID NOs: 124-246 and 275-287; and any combination thereof.

Several embodiments described herein relate to targeted genome modification in eukaryotic cells, for example, plant cells. Some embodiments relate to a composition for cleaving a target DNA comprising a CRISPR-associated transposase as described herein, and the use thereof. In some embodiments, the CRISPR-associated transposase is selected from the group consisting of SEQ ID NOs:124-246 and 275-287, homologs thereof and orthologs thereof. In some embodiments, a complex comprising CRISPR-associated transposase and a guide RNA specific for a target DNA is described. In some embodiments, the complex further comprises a divalent cation. In some embodiments the CRISPR-associated transposase, when complexed with a guide RNA, effects cleavage of the target DNA thereby modifying the target DNA. In some embodiments, cleavage comprises cleaving one or two strands at the location of the target DNA by the CRISPR-associated transposase. In some embodiments, formation of a complex comprising a CRISPR-associated transposase and a guide RNA results in cleavage of one or both strands in or near (e.g. within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, or more base pairs from) the target sequence. In some embodiments, cleavage results in decreased transcription of a target gene. In some embodiments, cleavage results in an increase recombination rate between two genomic loci. In some embodiments, cleavage results in integration of one ore more transgenes. In some embodiments, cleavage results in integration of a cis-genic sequence. In some embodiments, cleavage results in an insertion or deletion of nucleotides at or near the target sequence. In some embodiments, the cleaved target DNA is repaired by homologous recombination with an exogenous template polynucleotide. In some embodiments, the template polynucleotide comprises one or more exogenous transgenes. In some embodiments, the one or more exogenous transgenes are flanked by sequence homologous to the cleavage site. In some embodiments, the template polynucleotide comprises a sequence that has at least at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity, or 100% identity, to at least 50 bp, at least 100 bp, at least 150 bp, at least 200 bp, at least 250 bp, at least 300 bp, at least 350 bp, at least 400 bp, at least 450 bp, at least 500 bp, at least 550 bp, at least 600 bp, at least 650 bp, at least 700 bp, at least 750 bp, at least 800 bp, at least 850 bp, at least 900 bp, at least 950 bp, or at least 1,000 bp of a nucleic acid sequence comprising the target sequence. In some embodiments, the template polynucleotide comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more nucleotide mutations compared to the target sequence. In some embodiments, the cleaved target DNA is repaired by non-homologous end joining (NHEJ) wherein said repair results in a mutation comprising an insertion, deletion, or substitution of one or more nucleotides of said target DNA.

Several embodiments relate to a method of modifying a targeted DNA sequence in a eukaryotic cell. In some embodiments, the method comprises allowing a CRISPR-associated transposase comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% homology to a sequence selected from the group consisting of SEQ ID NOs: 124-246 and 275-287 cleave the targeted DNA sequence. In some embodiments, the CRISPR-associated transposase complexed with a guide RNA cleaves a targeted DNA sequence. In some embodiments, the method comprises delivering one or more vectors to said eukaryotic cells, wherein the one or more vectors drive expression of one or more of: the CRISPR-associated transposase, a guide RNA, and a donor polynucleotide.

In an aspect, the disclosure provides methods of identifying putative CRISPR-associated transposases from bacterial genomes. In some embodiments, the method comprises: (a) identification of large protein sequences (approximately 1,000 amino acids); (b) that these protein sequences were located in the same operon with a Cas1 and a Cas2, but not a Cas5 or a Cas3; and (c) that the proteins were in the same operon within <2.5 kb of a CRISPR loci. In some embodiments, the method comprises: (a) identification of large protein sequences (approximately 1,000 amino acids); (b) that these protein sequences comprise one or more pfam domains as described in Table 5; and (c) that the proteins were in the same operon within <2.5 kb of a CRISPR loci.

Nucleic Acid-Targeting Systems and Components Thereof

The present disclosure provides a nucleic acid-targeting system for sequence-specific modification of a target nucleic acid sequence. As used herein, the terms “nucleic acid-targeting system” refers to transcripts and other elements involved in the expression of or directing the activity of CRISPR-associated transposases, which may include sequences encoding a CRISPR-associated transposase. In some embodiments, the CRISPR-associated transposase comprises an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% homology to a sequence selected from the group consisting of SEQ ID NOs: 124-246 and 275-287. In some embodiments, the nucleic acid-targeting system comprises a CRISPR RNA (crRNA) sequence that acts as a nucleic acid-targeting guide RNA. In some embodiments, the crRNA sequence comprises a CRISPR repeat sequence as described in Table 9, or a portion thereof. In some embodiments, the nucleic acid-targeting system comprises (in some systems, but not all systems) a trans-activating CRISPR RNA (tracrRNA) sequence, or other sequences and transcripts from a CRISPR locus. In some systems, a tracrRNA sequence is not required. In other systems, a tracrRNA sequence is required. In some embodiments, the targeted nucleic acid is DNA or RNA. In other embodiments, the targeted nucleic acid is a DNA-RNA hybrid or derivatives thereof. In some embodiments, a targeted nucleic acid is located in the nucleus or cytoplasm of a cell. In some embodiments, the nucleic acid-targeting system further comprises a divalent cation. In some embodiments, the nucleic acid-targeting system further comprises Mg2+. In some embodiments, the nuclease activity of the CRISPR-associated transposase is inactivated. In some embodiments, the nucleic acid-targeting system further comprises a CRISPR-associated transposase with a heterologous functional domain. In some embodiments, the nucleic acid-targeting system is functional in a eukaryotic cell. In some embodiments, the nucleic acid-targeting system is functional in a plant cell.

In an embodiment, the nucleic acid-targeting system comprises a polynucleotide encoding a CRISPR-associated transposase. In a further embodiment, the CRISPR-associated transposase comprises an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to a sequence selected from the group consisting of SEQ ID NOs: 124-246 and 275-287. In another embodiment, the polynucleotide encoding the CRISPR-associated transposase comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-123, 604-627 and 2020-3379. In some embodiments, the nucleic acid-targeting system further comprises a guide RNA or a DNA molecule encoding a guide RNA, wherein the guide RNA is comprises a sequence that is complementary to a target nucleic acid sequence. In some embodiments, the guide RNA or a DNA molecule encoding a guide RNA is provided on a first nucleic acid molecule and the polynucleotide encoding the CRISPR-associated transposase is provided on a second nucleic acid molecule. In other embodiments, the guide RNA or a DNA molecule encoding a guide RNA and the polynucleotide encoding a CRISPR-associated transposase is are provided on a single nucleic acid molecule. In some embodiments, the guide RNA comprises a portion of one or more crRNA sequences provided in Tables 8, 9 and 10. In some embodiments, the guide RNA comprises a CRISPR repeat sequence of one or more crRNA sequences provided in Table 8. In some embodiments, the guide RNA comprises a CRISPR repeat sequence as described in Table 9. In some embodiments, the guide RNA comprises a CRISPR repeat sequence as described in Table 10.

In some embodiments, the target nucleic acid sequence comprises coding sequence, non-coding sequence, or a combination of coding and non-coding sequence. In some embodiments, the target nucleic acid sequence comprises an endogenous gene or a transgene.

In some embodiments, the guide RNA comprises a crRNA and a tracrRNA. In some embodiments, the guide RNA comprises a single-chain guide RNA. In some embodiments, the guide RNA comprises a single-chain guide RNA comprising a crRNA. In some embodiments, the crRNA comprises a portion of a crRNA sequence provided in Tables 9 and 10.

In some embodiments, the nucleic acid-targeting system disclosed herein further comprises a donor polynucleotide. In some embodiments, the donor polynucleotide comprises a coding sequence, a non-coding sequence, or a combination of coding and non-coding sequence. In some embodiments, the donor polynucleotide comprises a promoter. In some embodiments, the donor polynucleotide comprises a regulatory element. In some embodiments, the donor polynucleotide comprises one or more transgenes.

As used herein, the term “guide RNA” refers to any polynucleotide sequence having sufficient complementarity with a target nucleic acid sequence to hybridize with the target nucleic acid sequence and direct sequence-specific binding of a CRISPR-associated transposase to the target nucleic acid sequence. In some embodiments, the degree of complementarity, when optimally aligned using a suitable alignment algorithm, is about or more than about 50%, 60%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more. Optimal alignment may be determined with the use of any suitable algorithm for aligning sequences.

In some embodiments, the guide RNA comprises a mature crRNA. In certain embodiments, the mature crRNA comprises, consists essentially of, or consists of a direct repeat sequence and a guide sequence or spacer sequence. Examples of direct repeat sequences and spacer sequences may be found in Tables 9 and 10. Examples of crRNA sequences may be found in Tables 8, 9 and 10. In certain embodiments, the guide RNA comprises, consists essentially of, or consists of a direct repeat sequence linked to a guide sequence or spacer sequence. In some embodiments, a guide RNA sequence is about or more than about 5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 75, or more nucleotides in length. In some embodiments, a guide RNA sequence is less than about 75, 50, 45, 40, 35, 30, 25, 20, 15, 12, or fewer nucleotides in length. In some embodiments, the guide RNA sequence is 10-30 nucleotides long. In some embodiments, the guide RNA sequence is 10-20 nucleotides long. A guide RNA sequence may be selected to target any target sequence. In some embodiments, the target sequence is a sequence within a genome of a cell. In some embodiments, the target sequence is unique in the target genome.

In some embodiments, the mature crRNA comprises a stem loop or an optimized stem loop structure or an optimized secondary structure. In some embodiments the mature crRNA comprises a stem loop or an optimized stem loop structure in the direct repeat sequence, wherein the stem loop or optimized stem loop structure is important for cleavage activity. In certain embodiments, the mature crRNA comprises a single stem loop. In certain embodiments, the direct repeat sequence comprises a single stem loop. In certain embodiments, the cleavage activity of the nucleic acid-targeting system is modified by introducing mutations that affect the stem loop RNA duplex structure. In some embodiments, mutations which maintain the RNA duplex of the stem loop may be introduced, whereby the cleavage activity of the nucleic acid-targeting system is maintained. In other embodiments, mutations which disrupt the RNA duplex structure of the stem loop may be introduced, whereby the cleavage activity of the nucleic acid-targeting system is completely abolished.

The ability of a guide RNA sequence to direct sequence-specific binding of a nucleic acid-targeting system to a target nucleic acid sequence may be assessed by any suitable assay. For example, the components of a nucleic acid-targeting system sufficient to form a nucleic acid-targeting complex, including the CRISPR-associated transposase and guide sequence to be tested, may be provided to a host cell having the corresponding target nucleic acid sequence, such as by transfection with vectors encoding the components of the nucleic acid-targeting complex, followed by an assessment of preferential targeting (e.g., cleavage) within the target nucleic acid sequence. Similarly, cleavage of a target nucleic acid sequence may be evaluated in vitro by providing the target nucleic acid sequence, components of a nucleic acid-targeting system, including the CRISPR-associated transposase and/or guide sequence to be tested and a control guide sequence different from the test guide sequence, and comparing binding or rate of cleavage at the target sequence between the test and control guide sequence reactions. Other assays are possible, and will occur to those skilled in the art. A guide sequence, and hence a nucleic acid-targeting guide RNA may be selected to target any target nucleic acid sequence. The target sequence may be DNA. The target sequence may be any RNA sequence. In some embodiments, the target sequence may be a sequence within a RNA molecule selected from the group consisting of messenger RNA (mRNA), pre-mRNA, ribosomal RNA (rRNA), transfer RNA (tRNA), micro-RNA (miRNA), small interfering RNA (siRNA), small nuclear RNA (snRNA), small nucleolar RNA (snoRNA), double stranded RNA (dsRNA), non coding RNA (ncRNA), long non-coding RNA (lncRNA), and small cytoplasmatic RNA (scRNA). In some embodiments, the target sequence may be a sequence within a RNA molecule selected from the group consisting of mRNA, pre-mRNA, and rRNA. In some embodiments, the target sequence may be a sequence within a RNA molecule selected from the group consisting of ncRNA, and lncRNA. In some embodiments, the target sequence may be a sequence within an mRNA molecule or a pre-mRNA molecule.

As used herein, the term “tracrRNA” includes any polynucleotide sequence that has sufficient complementarity with a crRNA sequence to hybridize. In some embodiments, the tracrRNA is not required for cleavage activity of a nucleic acid-targeting system. In other embodiments, the tracrRNA is required for cleavage activity of a nucleic acid-targeting system.

In some embodiments, one of more components of a nucleic acid-targeting system disclosed herein are expressed or delivered in a vector. As used herein, the term “vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. Vectors include, but are not limited to, nucleic acid molecules that are single-stranded, double-stranded, or partially double-stranded; nucleic acid molecules that comprise one or more free ends, no free ends (e.g., circular); nucleic acid molecules that comprise DNA, RNA, or both; and other varieties of polynucleotides known in the art. One type of vector is a “plasmid”, which refers to a circular double stranded DNA loop into which additional DNA segments can be inserted, such as by standard molecular cloning techniques. Another type of vector is an Agrobacterium. Another type of vector is a viral vector, wherein virally-derived DNA or RNA sequences are present in the vector for packaging into a virus (e.g., retroviruses, replication defective retroviruses, Tobacco mosaic virus (TMV), Potato virus X (PVX) and Cowpea mosaic virus (CPMV), tobamovirus, Gemini viruses, adenoviruses, replication defective adenoviruses, and adeno-associated viruses). Viral vectors also include polynucleotides carried by a virus for transfection into a host cell. In some embodiments, a viral vector may be delivered to a plant using Agrobacterium. Certain vectors are capable of autonomous replication in a host cell into which they are introduced. Other vectors are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively-linked. Such vectors are referred to herein as “expression vectors”. Vectors for and that result in expression in a eukaryotic cell can be referred to herein as “eukaryotic expression vectors.” Common expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression desired, etc. A vector can be introduced into host cells to thereby produce transcripts, proteins, or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., clustered regularly interspersed short palindromic repeats (CRISPR) transcripts, proteins, enzymes, mutant forms thereof, fusion proteins thereof, etc.).

Recombinant expression vectors can comprise a nucleic acid of the disclosure in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory elements, which may be selected on the basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed.

As used herein, the terms “template nucleic acid” or “donor polynucleotide” may be used interchangeably and refer to a nucleic acid sequence which can be used in conjunction with a CRISPR-associated transposase comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% homology to a sequence selected from the group consisting of SEQ ID NOs: 124-246 and 275-287 or an ortholog or homolog thereof to alter the structure of a target sequence. In some embodiments, the template nucleic acid or donor polynucleotide comprises one or more, two or more, three or more, four or more, five or more transgenes. In an embodiment, the target sequence is modified to have some or all of the sequence of the template nucleic acid, typically at or near cleavage site(s). In an embodiment, the template nucleic acid is single stranded. In an alternate embodiment, the template nucleic acid is double stranded. In an embodiment, the template nucleic acid is DNA, e.g., double stranded DNA. In an alternate embodiment, the template nucleic acid is single stranded DNA.

In an embodiment, the template nucleic acid alters the structure of the target sequence by participating in homologous recombination. In an embodiment, the template nucleic acid alters the sequence of the target position. In an embodiment, the template nucleic acid results in the incorporation of a modified, or non-naturally occurring base into the target nucleic acid.

The template sequence may undergo a breakage mediated or catalyzed recombination with the target sequence. In an embodiment, the template nucleic acid may include sequence that corresponds to a site on the target sequence that is cleaved by a nucleic acid-targeting system mediated cleavage event. In an embodiment, the template nucleic acid may include sequence that corresponds to both, a first site on the target sequence that is cleaved in a first nucleic acid-targeting system mediated event, and a second site on the target sequence that is cleaved in a second nucleic acid-targeting system mediated event.

In certain embodiments, the template nucleic acid can include sequence which results in an alteration in the coding sequence of a translated sequence, e.g., one which results in the substitution of one amino acid for another in a protein product, e.g., transforming a mutant allele into a wild type allele, transforming a wild type allele into a mutant allele, and/or introducing a stop codon, insertion of an amino acid residue, deletion of an amino acid residue, or a nonsense mutation. In certain embodiments, the template nucleic acid can include sequence which results in an alteration in a non-coding sequence, e.g., an alteration in an exon or in a 5′ or 3′ non-translated or non-transcribed region. Such alterations include an alteration in a regulatory element, e.g., a promoter, enhancer, and an alteration in a cis-acting or trans-acting control element.

A template nucleic acid having homology with a target sequence in a target gene may be used to alter the structure of a target gene. The template sequence may be used to alter an unwanted structure, e.g., an unwanted or mutant nucleotide. The template nucleic acid may include sequence which, when integrated, results in: decreasing the activity of a positive regulatory element; increasing the activity of a positive regulatory element; decreasing the activity of a negative regulatory element; increasing the activity of a negative regulatory element; decreasing the expression of a gene; increasing the expression of a gene; increasing resistance to a herbicide; increasing resistance to a disease; increasing resistance to a insect or nematode pest; increasing resistance to an abiotic stress (e.g., drought, nitrogen deficiency); increasing resistance to viral entry; correcting a mutation or altering an unwanted amino acid residue conferring, increasing, abolishing or decreasing a biological property of a gene product, e.g., increasing the enzymatic activity of an enzyme, or increasing the ability of a gene product to interact with another molecule.

In some embodiments, a template nucleic acid may include sequence which results in: a change in sequence of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more nucleotides of the target sequence. In an embodiment, the template nucleic acid may be 20+/−10, 30+/−10, 40+/−10, 50+/−10, 60+/−10, 70+/−10, 80+/−10, 90+/−10, 100+/−10, 110+/−10, 120+/−10, 130+/−10, 140+/−10, 150+/−10, 160+/−10, 170+/−10, 180+/−10, 190+/−10, 200+/−10, 210+/−10, of 220+/−10 nucleotides in length. In an embodiment, the template nucleic acid may be 30+/−20, 40+/−20, 50+/−20, 60+/−20, 70+/−20, 80+/−20, 90+/−20, 100+/−20, 110+/−20, 120+/−20, 130+/−20, 140+/−20, I 50+/−20, 160+/−20, 170+/−20, 180+/−20, 190+/−20, 200+/−20, 210+/−20, of 220+/−20 nucleotides in length. In an embodiment, the template nucleic acid is 10 to 1,000, 20 to 900, 30 to 800, 40 to 700, 50 to 600, 50 to 500, 50 to 400, 50 to 300, 50 to 200, or 50 to 100 nucleotides in length.

In some embodiments, a donor nucleic acid comprises the following components: [5′ homology arm]-[sequence of interest]-[3′ homology arm]. The homology arms provide for recombination into the chromosome. In some embodiments, the sequence of interest replaces an undesired element, e.g., a mutation or signature, with the sequence of interest. In some embodiments, the sequence of interest comprises one or more, two or more, three or more, four or more, or five or more transgenes. In an embodiment, the homology arms flank the most distal cleavage sites. In an embodiment, the 3′ end of the 5′ homology arm is the position next to the 5′ end of the sequence of interest. In an embodiment, the 5′ homology arm can extend at least 10, 20, 30, 40, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1500, or 2000 nucleotides 5′ from the 5′ end of the sequence of interest. In an embodiment, the 5′ end of the 3′ homology arm is the position next to the 3′ end of the sequence of interest. In an embodiment, the 3′ homology arm can extend at least 10, 20, 30, 40, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1500, or 2000 nucleotides 3′ from the 3′ end of the sequence of interest.

In certain embodiments, one or both homology arms may be shortened to avoid including certain sequence repeat elements. For example, a 5′ homology arm may be shortened to avoid a sequence repeat element. In other embodiments, a 3′ homology arm may be shortened to avoid a sequence repeat element. In some embodiments, both the 5′ and the 3′ homology arms may be shortened to avoid including certain sequence repeat elements.

In certain embodiments, a donor nucleic acid may designed for use as a single-stranded oligonucleotide. When using a single-stranded oligonucleotide, 5′ and 3′ homology arms may range up to about 200 bases in length, e.g., at least 25, 50, 75, 100, 125, 150, 175, or 200 bases in length.

In certain embodiments, the components of the nucleic acid-targeting system may further comprise at least one or more nuclear localization signal (NLS), nuclear export signal (NES), functional domain, flexible linker, mutation, deletion, alteration or truncation. The one or more of the NLS, the NES or the functional domain may be conditionally activated or inactivated.

In some embodiments, the nucleic acid-targeting system as described herein is functional at 20° C., 21° C., 22° C., 23° C., 24° C., 24° C., 25° C., 26° C., 27° C., 28° C., 29° C., 30° C., 31° C., 32° C., 33° C., 34° C., 35° C., 36° C., 37° C., 38° C., 39° C., 40° C., 41° C., 42° C., 43° C., 44° C., 45° C., 46° C., 47° C., 48° C., 49° C., or 50° C.

In certain embodiments, one or more components of a nucleic acid-targeting system are comprised on one or more vectors for delivery to a eukaryotic cell. In some embodiments, one or more vector(s) encode(s): one or more of (i) one or more CRISPR-associated transposases, more particularly, one or more CRISPR-associated transposases comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% homology to a sequence selected from the group consisting of SEQ ID NOs: 124-246 and 275-287; (ii) a first guide RNA capable of hybridizing to a first target sequence in a cell; and (iii) a second guide RNA capable of hybridizing to a second target sequence in the cell. Not wishes to be bound by a particular theory, the first guide RNA directs a first CRISPR-associated transposase to the first target sequence in the cell; the second guide RNA directs a second CRISPR-associated transposase to the second target sequence in the celle. The various coding sequences (CRISPR-associated transposase, guide RNAs) can be included on a single vector or on multiple vectors. For instance, it is possible to encode the CRISPR-associated transposase on one vector and the various RNA sequences on another vector, or to encode the CRISPR-associated transposase and various guide RNAs on one vector, and donor nucleic acids on additional vectors, or any other permutation. In an aspect, a system uses a total of one, two, three, four, five or more different vectors. Where multiple vectors are used, it is possible to deliver them in unequal numbers.

In certain embodiments, recombinant nucleic acids encoding guide RNAs may be designed in an array format such that multiple guide RNA sequences can be simultaneously released. In some embodiments, expression of one or more guide RNAs is U6-driven. In some embodiments, CRISPR-associated transposases complex with multiple guide RNAs to mediate genome editing and at multiple target sequences. Some embodiments relate to expression of singly or in tandem array format from 1 up to 4 or more different guide sequences; e.g. up to about 20 or about 30 guides sequences. Each individual guide sequence may target a different target sequence. Such may be processed from, e.g. one chimeric pol3 transcript. Pol3 promoters such as U6 or H1 promoters may be used. Pol2 promoters such as those mentioned throughout herein. Inverted terminal repeat (iTR) sequences may flank the Pol3 promoter-gRNA(s)-Pol2 promoter-Cas.

In another embodiment, a construct that will transiently express a gRNA and/or CRISPR-associated transposase is created and introduced into a cell. In yet another embodiment, the vector will produce sufficient quantities of the gRNAs and/or CRISPR-associated transposase in order for the desired episomal or genomic target site or sites to be effectively modified by a nucleic acid-targeting system as described herein. For instance, the disclosure contemplates preparation of a vector that can be bombarded, electroporated, chemically transfected or transported by some other means across the plant cell membrane. Such a vector could have several useful properties. For instance, in one embodiment, the vector can replicate in a bacterial host such that the vector can be produced and purified in sufficient quantities for transient expression. In another embodiment, the vector can encode a drug resistance gene to allow selection for the vector in a host, or the vector can also comprise an expression cassette to provide for the expression of the gRNA and/or CRISPR-associated transposase in a plant. In a further embodiment, the expression cassette could contain a promoter region, a 5′ untranslated region, an optional intron to aid expression, a multiple cloning site to allow facile introduction of a sequence encoding gRNAs and/or CRISPR-associated transposases, and a 3′ UTR. In particular embodiments, the promoters in the expression cassette would be U6 promoters from Zea maize. In yet other embodiments, the promoters would be chimeric U6 promoters from Zea maize. In some embodiments, it can be beneficial to include unique restriction sites at one or at each end of the expression cassette to allow the production and isolation of a linear expression cassette, which can then be free of other vector elements. The untranslated leader regions, in certain embodiments, can be plant-derived untranslated regions. Use of an intron, which can be plant-derived, is contemplated when the expression cassette is being transformed or transfected into a monocot cell.

In some embodiments, a recombinant nucleic acid as described herein may comprise multiple U6 promoters with differing sequences. A utility of having multiple U6 promoters with differing sequence is to minimize problems in vector stability, which is typically associated with sequence repeats. Further, highly repetitive regions in chromosomes may lead to genetic instability and silencing. Therefore, another utility of using multiple U6 promoters in the nucleic acid-targeting system is to facilitate vector stacking of multiple gRNA cassettes in the same transformation construct, where the differing gRNA transcript levels are to be maximized for efficient targeting of a single target site. Chimeric U6 promoters can result in new, functional versions with improved or otherwise modified expression levels.

In several embodiments, an expression vector comprises at least one expression cassette encoding one or more components of a nucleic acid-targeting system as described herein may comprise a promoter. In certain embodiments, the promoter is a constitutive promoter, a tissue specific promoter, a developmentally regulated promoter, or a cell cycle regulated promoter. Certain contemplated promoters include ones that only express in the germline or reproductive cells, among others. Such developmentally regulated promoters have the advantage of limiting the expression of the nucleic acid-targeting system to only those cells in which DNA is inherited in subsequent generations. Therefore, a nucleic acid-targeting system mediated genetic modification (i.e., chromosomal or episomal dsDNA cleavage) is limited only to cells that are involved in transmitting their genome from one generation to the next. This might be useful if broader expression of the nucleic acid-targeting system were genotoxic or had other unwanted effects. Examples of such promoters include the promoters of genes encoding DNA ligases, recombinases, replicases, and so on.

In some embodiments, the recombinant nucleic acid molecules described herein can be incorporated into any suitable plant transformation plasmid or vector. In some embodiments, the plant transformation plasmid or vector contains a selectable or screenable marker and associated regulatory elements as described, along with one or more nucleic acids encoded by a structural gene.

Inducible Nucleic Acid-Targeting System

In one aspect, the disclosure provides a non-naturally occurring or engineered nucleic acid-targeting system which may comprise at least one switch wherein the activity of the nucleic acid-targeting system is controlled by contact with at least one inducer energy source as to the switch. In an embodiment of the disclosure, the control as to the at least one switch or the activity of the nucleic acid-targeting system may be activated, enhanced, terminated or repressed. The contact with the at least one inducer energy source may result in a first effect and a second effect. The first effect may be one or more of nuclear import, nuclear export, recruitment of a secondary component (such as an effector molecule), conformational change (of protein, DNA or RNA), cleavage, release of cargo (such as a caged molecule or a cofactor), association or dissociation. The second effect may be one or more of activation, enhancement, termination or repression of the control as to the at least one switch or the activity of the nucleic acid-targeting system. In one embodiment the first effect and the second effect may occur in a cascade.

Aspects of control as detailed in this application relate to at least one or more switch(es). The term “switch” as used herein refers to a system or a set of components that act in a coordinated manner to affect a change, encompassing all aspects of biological function such as activation, repression, enhancement or termination of that function. In one aspect the term switch encompasses genetic switches which comprise the basic components of gene regulatory proteins and the specific DNA sequences that these proteins recognize. In one aspect, switches relate to inducible and repressible systems used in gene regulation. In general, an inducible system may be off unless there is the presence of some molecule (called an inducer) that allows for gene expression. The molecule is said to “induce expression”. The manner by which this happens is dependent on the control mechanisms as well as differences in cell type. A repressible system is on except in the presence of some molecule (called a corepressor) that suppresses gene expression. The molecule is said to “repress expression”. The manner by which this happens is dependent on the control mechanisms as well as differences in cell type. The term “inducible” as used herein may encompass all aspects of a switch irrespective of the molecular mechanism involved.

In another aspect of the disclosure the nucleic acid-targeting system may further comprise at least one or more nuclear localization signal (NLS), nuclear export signal (NES), functional domain, flexible linker, mutation, deletion, alteration or truncation. The one or more of the NLS, the NES or the functional domain may be conditionally activated or inactivated. In another embodiment, the mutation may be one or more of a mutation in a transcription factor homology region, a mutation in a DNA binding domain (such as mutating basic residues of a basic helix loop helix), a mutation in an endogenous NLS or a mutation in an endogenous NES. The disclosure comprehends that the inducer energy source may be heat, ultrasound, electromagnetic energy or chemical.

In some embodiments, the inducer energy source may be an antibiotic, a small molecule, a hormone, a hormone derivative, a steroid or a steroid derivative. In some embodiments, the inducer energy source may be abscisic acid (ABA), salicylic acid, doxycycline (DOX), cumate, rapamycin, 4-hydroxytamoxifen (4OHT), estrogen or ecdysone. The disclosure provides that the at least one switch may be selected from the group consisting of antibiotic based inducible systems, electromagnetic energy based inducible systems, small molecule based inducible systems, nuclear receptor based inducible systems and hormone based inducible systems.

The present nucleic acid-targeting system may be designed to modulate or alter expression of individual endogenous genes in a temporally and spatially precise manner. The nucleic acid-targeting system may be designed to bind to the promoter sequence of the gene of interest to change gene expression.

Another system contemplated by the present disclosure is a chemical inducible system based on change in sub-cellular localization. An inducible nucleic acid-targeting system may be engineered to target a genomic locus of interest where the CRISPR-associated transposase is split into two fusion constructs that are further linked to different parts of a chemical or energy sensitive protein. This chemical or energy sensitive protein will lead to a change in the sub-cellular localization of either half of the CRISPR-associated transposase upon the binding of a chemical or energy transfer to the chemical or energy sensitive protein. This transportation of fusion constructs from one sub-cellular compartments or organelles, in which its activity is sequestered due to lack of substrate for the reconstituted nucleic acid-targeting system, into another one in which the substrate is present would allow the components to come together and reconstitute functional activity and to then come in contact with its desired substrate (i.e. genomic DNA in the mammalian nucleus) and result in activation or repression of target gene expression.

Other inducible systems are contemplated such as, but not limited to, regulation by heavy-metals, steroid hormones, heat shock and other reagents have been developed.

In particular embodiments, the nucleic acid-targeting systems described herein are placed under the control of a passcode kill switch, which is a mechanisms which efficiently kills the host cell when the conditions of the cell are altered. In some embodiments, this is ensured by introducing hybrid Lacl-GalR family transcription factors, which require the presence of IPTG to be switched on (Chan et al. 2015 Nature Nature Chemical Biology doi:10.1038/nchembio.1979) which can be used to drive a gene encoding an enzyme critical for cell-survival. By combining different transcription factors sensitive to different chemicals, a “code” can be generated, This system can be used to spatially and temporally control the extent of nucleic acid-targeting system-induced genetic modifications, which can be of interest in different fields including therapeutic applications and may also be of interest to avoid the “escape” of transgene containing organisms from their intended environment.

Self-Inactivating Systems

In some embodiments, once all copies of a gene in the genome of a cell have been edited, continued nucleic acid-targeting system expression in that cell is no longer necessary. In some embodiments, sustained expression would be undesirable in case of off-target effects at unintended genomic sites, etc. In some embodiments, time-limited expression of components of the nucleic acid-targeting system would be useful. Inducible expression offers one approach, another approach may be a self-inactivating nucleic acid-targeting system that relies on the use of a non-coding guide target sequence within the vector itself. Thus, after expression begins, the nucleic acid-targeting system will lead to its own destruction, but before destruction is complete it will have time to edit the genomic copies of the target gene. In some embodiments, self inactivating nucleic acid-targeting system includes additional RNA (i.e., guide RNA) that targets the coding sequence for the CRISPR-associated transposase or that targets one or more non-coding guide target sequences complementary to unique sequences present in one or more of the following: (a) within the promoter driving expression of the non-coding RNA elements, (b) within the promoter driving expression of the CRISPR-associated transposase, (c) within 100 bp of the ATG translational start codon in the CRISPR-associated transposase coding sequence, (d) within the inverted terminal repeat (iTR) of a viral delivery vector.

In some embodiments, one or more guide RNAs can be delivered via a vector, e.g., a separate vector or the same vector that is encoding the CRISPR-associated transposase. When provided by a separate vector, a guide RNA that targets CRISPR-associated transposase expression can be administered sequentially or simultaneously. When administered sequentially, the guide RNA that targets CRISPR-associated transposase expression may be delivered after the guide RNA that is intended for gene editing or genome engineering. This period may be a period of minutes (e.g. 5 minutes, 10 minutes, 20 minutes, 30 minutes, 45 minutes, 60 minutes). This period may be a period of hours (e.g. 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours). This period may be a period of days (e.g. 2 days, 3 days, 4 days, 7 days). This period may be a period of weeks (e.g. 2 weeks, 3 weeks, 4 weeks). This period may be a period of months (e.g. 2 months, 4 months, 8 months, 12 months). This period may be a period of years (2 years, 3 years, 4 years). In some embodiments, the CRISPR-associated transposase associates with a first guide RNA capable of hybridizing to a first target, such as a genomic locus or loci of interest and undertakes the function(s) desired of the nucleic acid-targeting system (e.g., gene engineering); and subsequently the CRISPR-associated transposase may then associate with the second guide RNA capable of hybridizing to the sequence encoding at least part of the CRISPR-associated transposase. Where the guide RNA targets the sequences encoding expression of the CRISPR-associated transposase, the transposase becomes impeded and the system becomes self inactivating. In some embodiments, guide RNA that targets CRISPR-associated transposase expression applied via, for example particle bombardment, lipofection, nanoparticles, microvesicles, may be administered sequentially or simultaneously. Similarly, self-inactivation may be used for inactivation of one or more guide RNA used to target one or more targets.

In some aspects, a single guide RNA is provided that is capable of hybridizing to a sequence downstream of a start codon, thereby after a period of time there is a loss of CRISPR-associated transposase expression. In some aspects, one or more guide RNA(s) are provided that are capable of hybridizing to one or more coding or non-coding regions of the polynucleotide encoding one or more components the nucleic acid-targeting system, whereby after a period of time there is a inactivation of one or more, or in some cases all, of the components of the nucleic acid-targeting system. In some aspects, and not to be limited, a cell may comprise a plurality of CRISPR-associated enzymes, where a first CRISPR-associated enzyme targets a genomic locus or loci to be edited, and a second CRISPR-associated enzyme targets the polynucleotide encoding one or more components of the nucleic acid-targeting system. In some embodiments, the first and second CRISPR-associated enzymes are independently selected from the group consisting of Cas9, Cpf1, Ncc1 and CRISPR-associated transposase.

Modification of CRISPR-Associated Transposases

In an embodiment, nucleic acid molecule(s) encoding the CRISPR-associated transposases disclosed herein, or an ortholog or homolog thereof, may be codon-optimized for expression in an eukaryotic cell. In some embodiments, nucleic acid molecule(s) encoding the CRISPR-associated transposases disclosed herein, or an ortholog or homolog thereof, may be codon-optimized for expression in a plant cell. Examples of codon-optimized nucleic acid molecule(s) encoding the CRISPR-associated transposases are provided in Table 12. In some embodiments, a nucleic acid molecule may comprise one or more sequences selected from SEQ ID NOs: 2020-2699. In some embodiments, a nucleic acid molecule may comprise one or more sequences selected from SEQ ID NOs: 2700-3379. Nucleic acid molecule(s) can be engineered or non-naturally occurring. The terms “non-naturally occurring” or “engineered” are used interchangeably and indicate the involvement of the hand of man. The terms, when referring to nucleic acid molecules or polypeptides mean that the nucleic acid molecule or the polypeptide is at least substantially free from at least one other component with which they are naturally associated in nature and as found in nature. The nucleic acid-targeting systems described herein are non-naturally occurring.

In some embodiments, the CRISPR-associated transposases disclosed herein, or an ortholog or homolog thereof, may comprise one or more mutations (and hence nucleic acid molecule(s) coding for same may have mutation(s)). The mutations may be artificially introduced mutations and may include but are not limited to one or more mutations in a catalytic domain. Examples of catalytic domains with reference to a CRISPR-associated transposases may include but are not limited to RuvC I, RuvC II, RuvC III and IS605_ORFB domains.

In some embodiments, the CRISPR-associated transposases disclosed herein, or an ortholog or homolog thereof, may be used as a generic nucleic acid binding protein with fusion to or being operably linked to a functional domain. Examples of functional domains may include but are not limited to PvuII, MutH, TevI, FokI, AlwI, MlyI, SbfI, SdaI, StsI, CleDORF, Clo051, Pept071, recombinanse, transposase, methylase, translational initiator, translational activator, translational repressor, nucleases, in particular ribonucleases, a spliceosome, beads, a light inducible/controllable domain or a chemically inducible/controllable domain. The FokI nuclease domain requires dimerization to cleave DNA and therefore CRISPR-associated transposases with Fok1 functional domains are needed to bind opposite DNA strands of the cleavage site.

In some embodiments, the unmodified CRISPR-associated transposases may have cleavage activity. In some embodiments, the CRISPR-associated transposase directs cleavage of one or both nucleic acid (DNA or RNA) strands at the location of or near a target sequence, such as within the target sequence and/or within the complement of the target sequence or at sequences associated with the target sequence. In some embodiments, the CRISPR-associated transposase may direct cleavage of one or both DNA or RNA strands within about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 50, 100, 200, 500, or more base pairs from the first or last nucleotide of a target sequence. In some embodiments, the cleavage may be staggered, i.e. generating sticky ends. In some embodiments, the cleavage is a staggered cut with a 5′ overhang. In some embodiments, the cleavage is a staggered cut with a 5′ overhang of 1 to 5 nucleotides, 4 or 5 nucleotides. In some embodiments, a vector encodes a CRISPR-associated transposase that may be mutated with respect to a corresponding wild-type enzyme such that the mutated CRISPR-associated transposase lacks the ability to cleave one or both DNA or RNA strands of a target polynucleotide containing a target sequence. As a further example, two or more catalytic domains of a CRISPR-associated transposase (e.g. RuvC I, RuvC II, RuvC III or IS605 ORFB domain) may be mutated to produce a mutated CRISPR-associated transposases substantially lacking all DNA cleavage activity. In some embodiments, a CRISPR-associated transposases may be considered to substantially lack all cleavage activity when the cleavage activity of the mutated CRISPR-associated transposase is about no more than 25%, 10%, 5%, 1%, 0.1%, 0.01%, or less of the nucleic acid cleavage activity of the non-mutated form of the enzyme; an example can be when the nucleic acid cleavage activity of the mutated CRISPR-associated transposases is negligible as compared with the non-mutated CRISPR-associated transposase.

Target Sequences

As used herein, the term “target polynucleotide” or “target sequence” refers to a nucleotide sequence that occurs in a polynucleotide against which a CRISPR-associated transposase is directed. In some embodiments, the target polynucleotide or target sequence is in a gene. In this context, the term “gene” means a locatable region of genomic sequence, corresponding to a unit of inheritance, which includes regulatory regions, such as promoters, enhancers, 5′ untranslated regions, intron regions, 3′ untranslated regions, transcribed regions, and other functional sequence regions that may exist as native genes or transgenes in a plant genome. Depending upon the circumstances, the term target sequence or target gene can refer to the full-length nucleotide sequence of the gene or gene product targeted for suppression or the nucleotide sequence of a portion of the gene or gene product targeted for suppression.

The target polynucleotide of a nucleic acid-targeting system as described herein can be any polynucleotide endogenous or exogenous to a prokaryotic or a eukaryotic cell. For example, the target polynucleotide can be a polynucleotide residing in the nucleus of the eukaryotic cell. The target polynucleotide can be a sequence coding a gene product (e.g., a protein) or a non-coding sequence (e.g., a regulatory polynucleotide or a junk DNA), or a combination of both.

Examples of target polynucleotides include a sequence associated with a signaling biochemical pathway, e.g., a signaling biochemical pathway-associated gene or polynucleotide. Examples of target polynucleotides include genes that encode proteins that provide tolerance to herbicides, such as 5-enolpyruvylshikimate-3-phosphate synthase (EPSPS), glyphosate oxidoreductase (GOX), glyphosate decarboxylase, glyphosate-N-acetyl transferase (GAT), dicamba monooxygenase, phosphinothricin acetyltransferase, 2,2-dichloropropionic acid dehalogenase, acetohydroxyacid synthase, acetolactate synthase (ALS), haloarylnitrilase, acetyl-coenzyme A carboxylase, dihydropteroate synthase, phytoene desaturase, Protoporphyrinogen oxidase (PPO), protoporphyrin IX oxygenase, hydroxyphenylpyruvate dioxygenase, para-aminobenzoate synthase, glutamine synthase, cellulose synthase, beta-tubulin, 4-Hydroxyphenylpyruvate dioxygenase (HPPD) and serine hydroxymethyltransferase. Examples of target polynucleotides include polynucleotides associated with a disease resistance locus. As used herein, the term “disease resistance locus” refers to a genomic region associated with disease or pathogen resistance in a plant. A disease resistance locus may comprise one or more genes, gene families, arrays of genes or QTLs encoding a protein or proteins that confer to a plant resistance to at least one disease or pathogen. In one embodiment, the disease resistance locus comprises one or more NBS-LRR disease resistance genes, also referred to as NB-LRR genes, R genes, LRR genes. In another embodiment, the disease resistance locus comprises one or more PRR disease resistance genes. The disease resistance locus may encompass a specific gene, cluster of genes, array of genes and/or gene family known to confer pathogen resistance, for example Rp1, or Rpp1, or Rps1. In another embodiment, the disease resistance locus comprises the Rgh1 locus. In another embodiment, the disease resistance locus comprises the Rgh4 locus. Alternatively, the disease resistance locus may encompass a genomic region but the actual gene/element composition conferring disease resistance is unknown. Examples of target polynucleotides include polynucleotides that encode quality traits, such as brown midrib (bmr), waxy, white, Fad2, Fad3.

Without wishing to be bound by theory, it is believed that the target sequence should be associated with a PAM (protospacer adjacent motif); that is, a short sequence recognized by the CRISPR-associated transposase. The precise sequence and length requirements for the PAM differ depending on the CRISPR-associated transposase used, but PAMs are typically 2-5 base pairs adjacent the target sequence. In some embodiments, the PAM is 5′ to the target sequence. In some embodiments, the PAM is 3′ to the target sequence. Examples of PAM sequences are given in Example 2 below, and the skilled person will be able to identify further PAM sequences for use with a given CRISPR-associated transposase. Further, engineering of the PAM Interacting (PI) domain may allow programming of PAM specificity, improve target site recognition fidelity, and increase the versatility of the CRISPR-associated transposase.

Uses of the CRISPR-Associated Transposases

In an aspect, the disclosure provides a method for sequence-specific modification of a target nucleic acid sequence in a cell, comprising providing to a cell one or more CRISPR-associated transposases. In some embodiments, the one or more CRISPR-associated transposases are provided by expressing in the cell a recombinant DNA molecule encoding the one or more CRISPR-associated transposases. In some embodiments, the one or more CRISPR-associated transposases are provided by contacting the cell with a composition comprising one or more CRISPR-associated transposases or a recombinant DNA molecule encoding the one or more CRISPR-associated transposases. In some embodiments, the one or more CRISPR-associated transposases are provided by contacting the cell with a composition comprising one or more RNA molecules encoding the one or more CRISPR-associated transposases. In some embodiments, the method further comprises providing a guide RNA capable of hybridizing to the target nucleic acid sequence to the cell. In some embodiments, the guide RNA is provided by expressing in the cell a recombinant DNA molecule encoding the guide RNA. In some embodiments, the guide RNA is provided by contacting the cell with a composition comprising the guide RNA or a recombinant DNA molecule encoding the guide RNA. In some embodiments, the guide RNA is complexed with the CRISPR-associated transposase and provided to the cell. Methods and compositions for providing RNAs to plant cells are known in the art. See, e.g., PCTUS2016035500, PCTUS2016035435, and WO2011112570, incorporated by reference herein.

In an aspect, the disclosure provides a method as herein discussed wherein the cell is a eukaryotic cell. In an aspect, the disclosure provides a method as herein discussed wherein the cell is a mammalian cell. In an aspect, the disclosure provides a method as herein discussed, wherein the cell is a non-human eukaryote cell. In an aspect, the disclosure provides a method as herein discussed, wherein the non-human eukaryote cell is a non-human mammalian cell. In an aspect, the disclosure provides a method as herein discussed, wherein the non-human mammalian cell may be a primate, bovine, ovine, procine, canine, rodent, Leporidae such as monkey, cow, sheep, pig, dog, rabbit, rat or mouse cell. In an aspect, the disclosure provides a method as herein discussed, wherein the cell may be a non-mammalian eukaryotic cell such as poultry bird (e.g., chicken), vertebrate fish (e.g., salmon, tilapia) or shellfish (e.g., oyster, claim, lobster, shrimp) cell.

In an aspect, the disclosure provides a method as herein discussed, wherein the eukaryotic cell is a plant cell. The plant cell may be of a monocot or dicot or of a crop or grain plant such as cassava, corn, sorghum, alfalfa, cotton, soybean, canola, wheat, oat or rice. The plant cell may also be of an algae, tree or production plant, fruit or vegetable (e.g., trees such as citrus trees, e.g., orange, grapefruit or lemon trees; peach or nectarine trees; apple or pear trees; nut trees such as almond or walnut or pistachio trees; nightshade plants; plants of the genus Brassica; plants of the genus Lactuca; plants of the genus Spinacia; plants of the genus Capsicum; cotton, tobacco, asparagus, avocado, papaya, cassava, carrot, cabbage, broccoli, cauliflower, tomato, eggplant, pepper, lettuce, spinach, strawberry, potato, squash, melon, blueberry, raspberry, blackberry, grape, coffee, cocoa, etc).

In another aspect, the present disclosure provides for a method of functional screening of genes in a genome in a pool of cells ex vivo or in vivo comprising the administration or expression of a library comprising a plurality of guide RNAs and wherein the screening further comprises use of a CRISPR-associated transposase as described herein. In some embodiments, the CRISPR-associated transposase is modified to comprise a heterologous functional domain. In an aspect the disclosure provides a method for screening a genome comprising the administration to a cell or expression in a cell in vivo of a library. In an aspect, the disclosure provides a method as herein discussed further comprising an activator administered to the cell or expressed in the cell. In an aspect, the disclosure provides a method as herein discussed wherein the activator is attached to a CRISPR-associated transposase as described herein. In an aspect, the disclosure provides a method as herein discussed wherein the activator is attached to the N terminus or the C terminus of the CRISPR-associated transposase. In an aspect, the disclosure provides a method as herein discussed wherein the activator is attached to a gRNA loop. In an aspect the disclosure provides a method as herein discussed further comprising a repressor administered to the cell or expressed in the cell. In an aspect, the disclosure provides a method as herein discussed wherein the screening comprises affecting and detecting gene activation, gene inhibition, or cleavage in the targeted locus.

In an aspect, the disclosure provides efficient on-target activity and minimizes off target activity. In an aspect, the disclosure provides efficient on-target cleavage by a CRISPR-associated transposase as described herein and minimizes off-target cleavage by the CRISPR-associated transposase. In an aspect, the disclosure provides guide RNA specific binding of a CRISPR-associated transposase at a gene locus without DNA cleavage. In an aspect, the disclosure provides efficient guide RNA directed on-target binding of a CRISPR-associated transposase at a genomic locus and minimizes off-target binding of the CRISPR-associated transposase. Accordingly, in an aspect, the disclosure provides target-specific gene regulation. In an aspect, the disclosure provides orthogonal activation and/or inhibition and/or cleavage of multiple targets using one or more CRISPR-associated transposases.

In an aspect, the disclosure provides a method as herein discussed comprising the delivery of one or more CRISPR-associated transposases or nucleic acid molecule(s) encoding one or more CRISPR-associated transposases, wherein said nucleic acid molecule(s) are operatively linked to regulatory sequence(s) and expressed in vivo. In an aspect, the disclosure provides a method as herein discussed wherein the expression of one ore more CRISPR-associated transposases in a cell is via a lentivirus, an adenovirus, an AAV, a geminivirus, a Tobacco Rattle Virus (TRV), Potato virus X (PVX), Tomato yellow leaf curl China virus (TYLCCV), a Begomovirus, Barley stripe mosaic virus (BSMV), Cymbidium mosaic virus (CymMV), Rice tungro bacilliform virus (RTBV), Cauliflower mosaic virus (CaMV), Turnip yellow mosaic virus (TYMV), Cabbage leaf curl virus (CbLCV), Apple latent spherical virus (ALSV), Cucumber mosaic virus (CMV), Cotton leaf crumple virus (CLCrV), African cassava mosaic virus (ACMV), Pea early browning virus (PEBV), Beet curly top virus (BCTV) or an Agrobacterium. In an aspect, the disclosure provides a method as herein discussed wherein the delivery of one or more CRISPR-associated transposases is via a particle, a nanoparticle, a lipid or a cell penetrating peptide (CPP).

In an aspect, the disclosure provides a nucleic acid-targeting system comprising a CRISPR-associated transposase and a guide RNA (gRNA) comprising a guide sequence capable of hybridizing to a target sequence in a genomic locus of interest in a cell, wherein the gRNA binds to the CRISPR-associated transposase.

In one aspect, the disclosure provides a method for altering or modifying expression of a gene product. The method may comprise introducing into a cell and expressing a DNA molecule encoding a CRISPR-associated transposase, whereby the CRISPR-associated transposase cleaves product target sequence in the genome of the cell, whereby expression of the gene product is altered. The disclosure further comprehends the CRISPR-associated transposase being codon optimized for expression in a Eukaryotic cell. In an embodiment the eukaryotic cell is a plant cell. In a further embodiment of the disclosure, the expression of the gene product is decreased.

In an aspect, the disclosure provides altered cells and progeny of those cells, as well as products made by the cells. CRISPR-associated transposases and nucleic acid-targeting systems of the disclosure are used to produce cells comprising a modified target locus. In some embodiments, the method may comprise allowing a nucleic acid-targeting complex to bind to the target DNA or RNA to effect cleavage of said target DNA or RNA thereby modifying the target DNA or RNA, wherein the nucleic acid-targeting complex comprises a CRISPR-associated transposase. In one aspect, the disclosure provides a method of repairing a genetic locus in a cell. In another aspect, the disclosure provides a method of modifying expression of DNA or RNA in a eukaryotic cell. In some embodiments, the method comprises allowing a nucleic acid-targeting complex to bind to the DNA or RNA such that said binding results in increased or decreased expression of said DNA or RNA; wherein the nucleic acid-targeting complex comprises a CRISPR-associated transposase. Similar considerations and conditions apply as above for methods of modifying a target DNA or RNA. In fact, these sampling, culturing and re-introduction options apply across the aspects of the present disclosure. In an aspect, the disclosure provides for methods of modifying a target DNA or RNA in a eukaryotic cell, which may be in vivo, ex vivo or in vitro. In some embodiments, the method comprises sampling a cell or population of cells from a plant, and modifying the cell or cells. Culturing may occur at any stage ex vivo. Such cells can be, without limitation, plant cells, animal cells, yeast cells, particular cell types of any organism, including protoplasts, somatic cells, germ cells, haploid cells, stem cells, immune cells, T cell, B cells, dendritic cells, cardiovascular cells, epithelial cells, stem cells and the like. The cells can be modified according to the disclosure to produce gene products, for example in controlled amounts, which may be increased or decreased, depending on use, and/or mutated. In certain embodiments, a genetic locus of the cell is repaired. The cell or cells may even be re-introduced into the non-human animal or plant. For re-introduced cells it may be preferred that the cells are stem cells.

In an aspect, the instant disclosure provides cells which transiently comprise the nucleic acid-targeting systems, or components thereof. For example, CRISPR-associated transposases and, optionally, guide RNAs are transiently provided to a cell and a genetic locus is altered, followed by a decline in the amount of one or more components of the nucleic acid-targeting system. Subsequently, the cells, progeny of the cells, and organisms which comprise the cells, having acquired a CRISPR-associated transposase-mediated genetic alteration, comprise a diminished amount of one or more nucleic acid-targeting system components, or no longer contain the comprise one or more nucleic acid-targeting system components.

Gene Editing or Altering Target Loci

In some embodiments, a double strand break or single strand break in one of the strands is sufficiently close to a target sequence such that template repair occurs. In an embodiment, the distance is not more than 10, 20, 50, 100, 150, 200, 250, 300, 350 or 400 nucleotides. While not wishing to be bound by a particular theory, it is believed that the break should be sufficiently close to a target sequence such that the break is within the region that is subject to exonuclease-mediated removal during end resection.

In an embodiment, a CRISPR-associated transposase comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% homology to a sequence selected from the group consisting of SEQ ID NOs: 124-246 and 275-287 or an ortholog or homolog thereof, induces a double strand break for the purpose of inducing HDR-mediated repair, where the cleavage site is between 0-200 bp (e.g., 0 to 175, 0 to 150, 0 to 125, 0 to 100, 0 to 75, 0 to 50, 0 to 25, 25 to 200, 25 to 175, 25 to 150, 25 to 125, 25 to 100, 25 to 75, 25 to 50, 50 to 200, 50 to 175, 50 to 150, 50 to 125, 50 to 100, 50 to 75, 75 to 200, 75 to 175, 75 to 150, 75 to 125, 75 to 100 bp) away from the target sequence. In an embodiment, the cleavage site is between 0-100 bp (e.g., 0 to 75, 0 to 50, 0 to 25, 25 to 100, 25 to 75, 25 to 50, 50 to 100, 50 to 75 or 75 to 100 bp) away from the target sequence.

In some embodiments, homology arms extend at least as far as the region in which end resection may occur, e.g., in order to allow the resected single stranded overhang to find a complementary region within the donor template. In some embodiments, the overall length is limited by parameters such as plasmid size or viral packaging limits. Examples of homology arm lengths include a least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950 or 1000 nucleotides.

Target sequence, as used herein, refers to a nucleic acid sequence that is modified by a CRISPR-associated transposase comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% homology to a sequence selected from the group consisting of SEQ ID NOs: 124-246 and 275-287 or an ortholog or homolog thereof. In some embodiments, the CRISPR-associated transposase is directed to the target sequence by a guide RNA. A target sequence can be modified by cleavage by a CRISPR-associated transposase and repair of the target sequence. In an embodiment, repair of a target sequence can result in addition or deletion of one or more nucleotides. In some embodiments, the target sequence may comprise one or more nucleotides that are altered by incorporation of a template nucleic acid.

In certain embodiments, CRISPR-associated transposase-induced non-homologous end-joining (NHEJ) can be used to target gene-specific knockouts. CRISPR-associated transposase-induced NHEJ can also be used to remove (e.g., delete) sequence in a gene of interest. Generally, NHEJ repairs a double-strand break in the DNA by joining together the two ends; however, generally, the original sequence is restored only if two compatible ends, exactly as they were formed by the double-strand break, are perfectly ligated. The DNA ends of the double-strand break are frequently the subject of enzymatic processing, resulting in the addition or removal of nucleotides, at one or both strands, prior to rejoining of the ends. This results in the presence of insertion and/or deletion (indel) mutations in the DNA sequence at the site of the NHEJ repair. Two-thirds of these mutations typically alter the reading frame and, therefore, produce a non-functional protein. Additionally, mutations that maintain the reading frame, but which insert or delete a significant amount of sequence, can destroy functionality of the protein. This is locus dependent as mutations in critical functional domains are likely less tolerable than mutations in non-critical regions of the protein. The indel mutations generated by NHEJ are unpredictable in nature; however, at a given break site certain indel sequences are favored and are over represented in the population, likely due to small regions of microhomology. The lengths of deletions can vary widely; most commonly in the 1-50 bp range, but they can easily be greater than 50 bp, e.g., they can easily reach greater than about 100-200 bp. Insertions tend to be shorter and often include short duplications of the sequence immediately surrounding the break site. However, it is possible to obtain large insertions, and in these cases, the inserted sequence has often been traced to other regions of the genome or to plasmid DNA present in the cells.

Because NHEJ is a mutagenic process, it may also be used to delete small sequence motifs as long as the generation of a specific final sequence is not required. If a double-strand break is targeted near to a short target sequence, the deletion mutations caused by the NHEJ repair often span, and therefore remove, the unwanted nucleotides. For the deletion of larger DNA segments, introducing two double-strand breaks, one on each side of the sequence, can result in NHEJ between the ends with removal of the entire intervening sequence. Both of these approaches can be used to delete specific DNA sequences; however, the error-prone nature of NHEJ may still produce indel mutations at the site of repair.

Both double strand cleaving and single strand cleaving CRISPR-associated transposases, or an ortholog or homolog thereof, can be used in the methods and compositions described herein to generate NHEJ-mediated indels. NHEJ-mediated indels targeted to a gene, e.g., a coding region, e.g., an early coding region of a gene of interest can be used to knockout (i.e., eliminate expression of) a gene of interest. For example, early coding region of a gene of interest includes sequence immediately following a transcription start site, within a first exon of the coding sequence, or within 500 bp of the transcription start site (e.g., less than 500, 450, 400, 350, 300, 250, 200, 150, 100 or 50 bp).

Genome Wide Knock-Out Screening

The CRISPR-associated transposases and nucleic acid-targeting systems described herein can be used to perform functional genomic screens. In some embodiments, genomic screens can utilize guide RNA based genome wide libraries. Such screens and libraries can provide for determining the function of genes, cellular pathways genes are involved in, and how any alteration in gene expression can result in a particular biological process. In some embodiments, the CRISPR-associated transposase comprises an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% homology to a sequence selected from the group consisting of SEQ ID NOs: 124-246 and 275-287 or an ortholog or homolog thereof.

In some embodiments, a genome wide library may comprise a plurality of guide RNAs, as described herein, comprising guide sequences that are capable of targeting a plurality of target sequences in a plurality of genomic loci in a population of eukaryotic cells. The population of cells may be a population of plant cells. The target sequence in the genomic locus may be a non-coding sequence. The non-coding sequence may be an intron, regulatory sequence, splice site, 3′ UTR, 5′ UTR, or polyadenylation signal. Gene function of one or more gene products may be altered by said targeting. The targeting may result in a knockout of gene function. The targeting of a gene product may comprise more than one guide RNA. A gene product may be targeted by 2, 3, 4, 5, 6, 7, 8, 9, or 10 guide RNAs. The targeting may be of about 100 or more sequences. The targeting may be of about 1000 or more sequences. The targeting may be of about 20,000 or more sequences. The targeting may be of the entire genome. The targeting may be of a panel of target sequences focused on a relevant or desirable pathway. The pathway may be an immune pathway. The pathway may be a cell division pathway.

One aspect of the disclosure comprehends a genome wide library that may comprise a plurality of guide RNAs that may comprise guide sequences that are capable of targeting a plurality of target sequences in a plurality of genomic loci, wherein said targeting results in a knockout of gene function. This library may potentially comprise guide RNAs that target each and every gene in the genome of an organism. In some embodiments, the organism is a plant.

In some embodiments of the disclosure the organism is a eukaryote (including mammal including human) or a non-human eukaryote or a non-human animal or a non-human mammal. In some embodiments, the organism is a non-human animal, and may be an arthropod, for example, an insect, or may be a nematode. In some methods of the disclosure the organism is a plant. In some methods of the disclosure the organism or subject is algae, including microalgae, or is a fungus.

Functional Alteration and Screening

In another aspect, the present disclosure provides for a method of functional evaluation and screening of genes. Several embodiments relate to the use of the CRISPR-associated transposases of the present disclosure to precisely deliver functional domains, to activate or repress genes or to alter epigenetic state by precisely altering the methylation site on a specific locus of interest, by providing a CRISPR-associated transposase comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% homology to a sequence selected from the group consisting of SEQ ID NOs: 124-246 and 275-297, wherein the CRISPR-associated transposase is modified to comprise a heterologous functional domain. In an aspect, the disclosure provides a method as herein discussed further comprising an activator administered to the host or expressed in the host. In an aspect, the disclosure provides a method as herein discussed wherein the activator is attached to a CRISPR-associated transposase. In an aspect, the disclosure provides a method as herein discussed wherein the activator is attached to the N terminus or the C terminus of the CRISPR-associated transposase. In an aspect the disclosure provides a method as herein discussed, wherein the screening comprises affecting and detecting gene activation, gene inhibition, or cleavage in the locus.

In an aspect the disclosure provides a method as herein discussed, wherein the host is a eukaryotic cell. In an aspect the disclosure provides a method as herein discussed, wherein the host is a mammalian cell. In an aspect the disclosure provides a method as herein discussed, wherein the host is a non-human eukaryote. In an aspect the disclosure provides a method as herein discussed, wherein the non-human eukaryote is a plant.

Method of Using Nucleic Acid Targeting Systems to Modify a Cell or Organism

The disclosure in some embodiments comprehends a method of modifying an cell or organism. The cell may be a prokaryotic cell or a eukaryotic cell. The cell may be a mammalian cell. The mammalian cell many be a non-human primate, bovine, porcine, rodent or mouse cell. The cell may be a non-mammalian eukaryotic cell such as poultry, fish or shrimp. The cell may also be a plant cell. The plant cell may be of a crop plant such as cassava, soybean, corn, cotton, alfalfa, canola, sorghum, wheat, or rice. The plant cell may also be of an algae, tree or vegetable. The modification introduced to the cell by the present disclosure may be such that the cell and progeny of the cell are altered for improved production of biologic products such as an antibody, oil, fiber, starch, alcohol or other desired cellular output. The modification introduced to the cell by the present disclosure may be such that the cell and progeny of the cell include an alteration that changes the biologic product produced.

The nucleic acid-targeting system may comprise one or more different vectors. In an aspect of the disclosure, the CRISPR-associated transposase is codon optimized for expression the desired cell type, preferentially a eukaryotic cell, preferably a plant cell.

Delivery of the Nucleic Acid-Targeting Systems and Components Thereof

Through this disclosure and the knowledge in the art, nucleic acid-targeting system, specifically the novel systems described herein, or components thereof or nucleic acid molecules thereof (including, for instance HDR template) or nucleic acid molecules encoding or providing components thereof may be delivered by a delivery system herein described both generally and in detail.

The CRISPR-associated transposases, for instance those encoded by a polynucleotide sequence selected from SEQ ID NOs: 1-123, 604-627 and 2020-3379, and/or any of the present RNAs, for instance a guide RNA, can be delivered using any suitable vector, e.g., plasmid or viral vectors, such as Ti plasmids of Agrobacterium tumefaciens, geminivirus, Tobacco Rattle Virus (TRV), Potato virus X (PVX), Tomato yellow leaf curl China virus (TYLCCV), Begomovirus, Barley stripe mosaic virus (BSMV), Cymbidium mosaic virus (CymMV), Rice tungro bacilliform virus (RTBV), Cauliflower mosaic virus (CaMV), Turnip yellow mosaic virus (TYMV), Cabbage leaf curl virus (CbLCV), Apple latent spherical virus (ALSV), Cucumber mosaic virus (CMV), Cotton leaf crumple virus (CLCrV), African cassava mosaic virus (ACMV), Pea early browning virus (PEBV), Beet curly top virus (BCTV), adeno associated virus (AAV), lentivirus, adenovirus or other viral vector types, or combinations thereof. Polynucleotides encoding CRISPR-associated transposases can be packaged into one or more vectors, e.g., plasmid or viral vectors. In some embodiments, the vector, e.g., plasmid or viral vector, is delivered to the tissue of interest by, for example, particle bombardment, Agrobacterium infection, or other delivery methods. Such delivery may be either via a single dose, or multiple doses. One skilled in the art understands that the actual dosage to be delivered herein may vary greatly depending upon a variety of factors, such as the vector choice, the target cell, organism, or tissue, the general condition of the subject to be treated, the degree of transformation/modification sought, the administration route, the administration mode, the type of transformation/modification sought, etc.

Such a dosage may further contain, for example, a carrier (water, saline, ethanol, glycerol, lactose, sucrose, calcium phosphate, gelatin, dextran, agar, pectin, peanut oil, sesame oil, etc.), a diluent, a pharmaceutically-acceptable carrier (e.g., phosphate-buffered saline), a pharmaceutically-acceptable excipient, and/or other compounds known in the art. The dosage may further contain one or more pharmaceutically acceptable salts such as, for example, a mineral acid salt such as a hydrochloride, a hydrobromide, a phosphate, a sulfate, etc.; and the salts of organic acids such as acetates, propionates, malonates, benzoates, etc. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, gels or gelling materials, flavorings, colorants, microspheres, polymers, suspension agents, etc. may also be present herein. In addition, one or more other conventional pharmaceutical ingredients, such as preservatives, humectants, suspending agents, surfactants, antioxidants, anticaking agents, fillers, chelating agents, coating agents, chemical stabilizers, etc. may also be present, especially if the dosage form is a reconstitutable form. Suitable ingredients include microcrystalline cellulose, carboxymethylcellulose sodium, polysorbate 80, phenylethyl alcohol, chlorobutanol, potassium sorbate, sorbic acid, sulfur dioxide, propyl gallate, the parabens, ethyl vanillin, glycerin, phenol, parachlorophenol, gelatin, albumin and a combination thereof. A thorough discussion of pharmaceutically acceptable excipients is available in REMINGTON'S PHARMACEUTICAL SCIENCES (Mack Pub. Co., N.J. 1991) which is incorporated by reference herein.

In an embodiment herein the delivery is via a plasmid. In such plasmid compositions, the dosage should be a sufficient amount of plasmid to elicit a response. For instance, suitable quantities of plasmid DNA in plasmid compositions can be from about 0.1 to about 2 mg, or from about 1 μg to about 10 μg. Plasmids of the disclosure will generally comprise one or more of (i) a promoter; (ii) a sequence encoding CRISPR-associated transposase, operably linked to said promoter; (iii) a selectable marker; (iv) an origin of replication; and (v) a transcription terminator downstream of and operably linked to (ii). The plasmid can also encode a guide RNA and/or a tracrRNA, but one or more of these may instead be encoded on a different vector.

In some embodiments the RNA molecules of the disclosure are delivered in liposome or lipofectin formulations and the like and can be prepared by methods well known to those skilled in the art. Such methods are described, for example, in U.S. Pat. Nos. 5,593,972, 5,589,466, 5,580,859, and 9,121,022 which are herein incorporated by reference. Delivery systems aimed specifically at the enhanced and improved delivery of siRNA into mammalian cells have been developed, (see, for example, Shen et al FEBS Let. 2003, 539:111-114; Xia et al., Nat. Biotech. 2002, 20:1006-1010; Reich et al., Mol. Vision. 2003, 9: 210-216; Sorensen et al., J. Mol. Biol. 2003, 327: 761-766; Lewis et al., Nat. Gen. 2002, 32: 107-108 and Simeoni et al., NAR 2003, 31, 11: 2717-2724) and may be applied to the present disclosure.

In some embodiments, RNA delivery is in vivo delivery. It is possible to deliver RNA molecules encoding CRISPR-associated transposases and guide RNAs into cells using liposomes or nanoparticles. Thus delivery of the CRISPR-associated transposases and/or delivery of the RNAs of the disclosure may be in RNA form and via microvesicles, liposomes or particle or particles. For example, mRNA encoding a CRISPR-associated transposase can be packaged into liposomal particles for delivery in vivo. Liposomal transfection reagents such as lipofectamine from Life Technologies and other reagents on the market can effectively deliver RNA molecules into the liver.

Means of delivery of RNA also include delivery of RNA via particles (Cho, S., Goldberg, M., Son, S., Xu, Q., Yang, F., Mei, Y., Bogatyrev, S., Langer, R. and Anderson, D., Lipid-like nanoparticles for small interfering RNA delivery to endothelial cells, Advanced Functional Materials, 19: 3112-3118, 2010) or exosomes (Schroeder, A., Levins, C., Cortez, C., Langer, R., and Anderson, D., Lipid-based nanotherapeutics for siRNA delivery, Journal of Internal Medicine, 267: 9-21, 2010, PMID: 20059641). Indeed, exosomes have been shown to be particularly useful in delivery siRNA, a system with some parallels to the CRISPR system. For instance, El-Andaloussi S, et al. (“Exosome-mediated delivery of siRNA in vitro and in vivo.” Nat Protoc. 2012 December; 7(12):2112-26. doi: 10.1038/nprot.2012.131. Epub 2012 Nov. 15.) describe how exosomes are promising tools for drug delivery across different biological barriers and can be harnessed for delivery of siRNA in vitro and in vivo.

Several embodiments relate to enhancing NHEJ or HR efficiency. NHEJ efficiency can be enhanced by co-expressing end-processing enzymes such as Trex2 (Dumitrache et al. Genetics. 2011 August; 188(4): 787-797). It is preferred that HR efficiency is increased by transiently inhibiting NHEJ machineries such as Ku70 and Ku86. HR efficiency can also be increased by co-expressing prokaryotic or eukaryotic homologous recombination enzymes such as RecBCD, RecA.

Particle Delivery Systems and/or Formulations

Several types of particle delivery systems and/or formulations are known to be useful in a diverse spectrum of applications. In general, a particle is defined as a small object that behaves as a whole unit with respect to its transport and properties. Particles are further classified according to diameter. Coarse particles cover a range between 2,500 and 10,000 nanometers. Fine particles are sized between 100 and 2,500 nanometers. Ultrafine particles, or nanoparticles, are generally between 1 and 100 nanometers in size. The basis of the 100-nm limit is the fact that novel properties that differentiate particles from the bulk material typically develop at a critical length scale of under 100 nm.

As used herein, a particle delivery system/formulation is defined as any biological delivery system/formulation which includes a particle in accordance with the present disclosure. A particle in accordance with the present disclosure is any entity having a greatest dimension (e.g. diameter) of less than 100 microns (μm). In some embodiments, inventive particles have a greatest dimension of less than 10 μm. In some embodiments, inventive particles have a greatest dimension of less than 2000 nanometers (nm). In some embodiments, inventive particles have a greatest dimension of less than 1000 nanometers (nm). In some embodiments, inventive particles have a greatest dimension of less than 900 nm, 800 nm, 700 nm, 600 nm, 500 nm, 400 nm, 300 nm, 200 nm, or 100 nm. Typically, inventive particles have a greatest dimension (e.g., diameter) of 500 nm or less. In some embodiments, inventive particles have a greatest dimension (e.g., diameter) of 250 nm or less. In some embodiments, inventive particles have a greatest dimension (e.g., diameter) of 200 nm or less. In some embodiments, inventive particles have a greatest dimension (e.g., diameter) of 150 nm or less. In some embodiments, inventive particles have a greatest dimension (e.g., diameter) of 100 nm or less. Smaller particles, e.g., having a greatest dimension of 50 nm or less are used in some embodiments of the disclosure. In some embodiments, inventive particles have a greatest dimension ranging between 25 nm and 200 nm.

Particles delivery systems within the scope of the present disclosure may be provided in any form, including but not limited to solid, semi-solid, emulsion, or colloidal particles. As such any of the delivery systems described herein, including but not limited to, e.g., lipid-based systems, liposomes, micelles, microvesicles, exosomes, or gene gun may be provided as particle delivery systems within the scope of the present disclosure.

The disclosure involves at least one component of the nucleic acid-targeting system, e.g., CRISPR-associated transposase, gRNA, delivered via at least one nanoparticle complex. In some aspects, the disclosure provides methods comprising delivering one or more polynucleotides, such as or one or more vectors as described herein, one or more transcripts thereof, and/or one or proteins transcribed therefrom, to a host cell. In some aspects, the disclosure further provides cells produced by such methods, and plants comprising or produced from such cells. In some embodiments, a CRISPR-associated transposase in combination with (and optionally complexed with) a guide RNA is delivered to a cell. Conventional viral and non-viral based gene transfer methods can be used to introduce nucleic acids in plant cells or target tissues. Such methods can be used to administer nucleic acids encoding components of a nucleic acid-targeting system to cells in culture, or in a host organism. Non-viral vector delivery systems include DNA plasmids, RNA (e.g. a transcript of a vector described herein), naked nucleic acid, and nucleic acid complexed with a delivery vehicle, such as a liposome. Viral vector delivery systems include DNA and RNA viruses, which have either episomal or integrated genomes after delivery to the cell.

In some embodiments, one or more vectors described herein are used to produce a non-human transgenic animal or transgenic plant. In some embodiments, the transgenic animal is a mammal, such as a mouse, rat, or rabbit. Methods for producing transgenic animals and plants are known in the art, and generally begin with a method of cell transfection, such as described herein. In one aspect, the disclosure provides for methods of modifying a target polynucleotide in a eukaryotic cell. In some embodiments, the method comprises allowing a CRISPR-associated transposase to effect cleavage of said target polynucleotide thereby modifying the target polynucleotide.

Use of Nucleic Acid-Targeting System in Plants

The nucleic acid-targeting systems disclosed herein can be used in conjunction with recent advances in crop genomics. The systems described herein can be used to perform efficient and cost effective plant gene or genome interrogation or editing or manipulation. The nucleic acid-targeting systems can be used with regard to plants in Site-Directed Integration (SDI) or Gene Editing (GE) or any near reverse breeding or reverse breeding techniques. Aspects of utilizing the herein described nucleic acid-targeting systems may be analogous to the use of the CRISPR-Cas (e.g. CRISPR-Cas9) system in plants, and mention is made of the University of Arizona web site “CRISPR-PLANT” (http://www.genome.arizona.edu/crispr/) (supported by Penn State and AGI).

The methods for genome editing using the nucleic acid-targeting system as described herein can be used to confer desired traits on essentially any plant. A wide variety of plants and plant cell systems may be engineered for the desired physiological and agronomic characteristics described herein using the nucleic acid constructs of the present disclosure and the various transformation methods mentioned above.

In some embodiments, the polynucleotides encoding the components of the nucleic acid-targeting system are introduced for stable integration into the genome of a plant cell. In these embodiments, the design of the transformation vector or the expression system can be adjusted depending on for when, where and under what conditions the guide RNA and/or the CRISPR-associated transposase are expressed.

In some embodiments, the polynucleotides encoding the components of the nucleic acid-targeting system are transiently expressed in a plant, plant tissue, or plant cell. In these embodiments, the nucleic acid-targeting system can ensure modification of a target gene only when the CRISPR-associated transposase is present in a cell, such that genomic modification can further be controlled. As the expression of the CRISPR-associated transposase is transient, plants regenerated from such plant cells typically contain no foreign DNA. In particular embodiments, the CRISPR-associated transposase is stably expressed by the plant cell and a guide RNA is transiently expressed. In particular embodiments the CRISPR-associated transposase is stably expressed by the plant cell and the guide RNA is provided directly to the plant cell by any method described herein.

DNA construct(s) encoding components of the nucleic acid-targeting system, and, where applicable, template sequence, may be introduced into a plant, plant part, or plant cell by a variety of conventional techniques.

In particular embodiments, nucleic acid-targeting system components can be introduced in the plant cells using a plant viral vector. In some embodiments, the viral vector is a vector from a DNA virus. For example, geminivirus (e.g., cabbage leaf curl virus, bean yellow dwarf virus, wheat dwarf virus, tomato leaf curl virus, maize streak virus, tobacco leaf curl virus, or tomato golden mosaic virus) or nanovirus (e.g., Fava bean necrotic yellow virus). In some embodiments, the viral vector is a vector from an RNA virus. For example, tobravirus (e.g., tobacco rattle virus, tobacco mosaic virus), potexvirus (e.g., potato virus X), or hordeivirus (e.g., barley stripe mosaic virus). The replicating genomes of plant viruses are non-integrative vectors.

The methods described herein generally result in the generation of plants comprising one or more desirable traits compared to the wild-type plant. In some embodiments, the plants, plant cells or plant parts obtained are transgenic plants, comprising an exogenous DNA sequence incorporated into the genome of all or part of the cells of the plant. In other embodiments, non-transgenic genetically modified plants, plant parts or cells are obtained, in that no exogenous DNA sequence is incorporated into the genome of any of the plant cells of the plant. In such embodiments, the plants are non-transgenic. Where only the modification of an endogenous gene is ensured and no foreign genes are introduced or maintained in the plant genome; the resulting genetically modified plants contain no non-native genes.

In some embodiments the nucleic acid-targeting system is targeted to a chloroplast. In some embodiments, targeting may be achieved by the presence of an N-terminal extension, called a chloroplast transit peptide (CTP) or plastid transit peptide.

REFERENCES

-   Bland C, et al. CRISPR Recognition Tool (CRT): a tool for automatic     detection of clustered regularly interspaced palindromic repeats.     BMC Bioinformatics. 2007 Jun. 18; 8(1):209. -   Chen and Zhao, Nucleic Acids Research, 2005 33:e154. -   Edgar R C. Search and clustering orders of magnitude faster than     BLAST. Bioinformatics. 2010 Oct. 1; 26(19):2460-1. -   Eddy, S. R., HMMER3 beta test: User's Guide, Version 3.0b3; November     2009, at the web site hmmer.org. -   Geissmann, Q. PLoS One 8, 2013. -   Guo et al., J. Mol Biol. 2010 400(1):96-107. -   Kapitonov et al. ISC, a Novel Group of Bacterial and Archaeal DNA     Transposons That Encode Cas9 Homologs., J Bacteriol. 2016 Mar. 1;     198(5): 797-807. -   Karvelis et al. Genome Biology (2015) 16:253. -   Kleinstiver, et al., Nature 2015 523:481-485. -   Shmakov et al. Molecular Cell (2015) 60:1-13. -   Wang et al. (Restriction-ligation-free (RLF) cloning: a     high-throughput cloning method by in vivo homologous recombination     of PCR products. 2015 Genet. Mol. Res., 14, 12306-12315. -   Yin, P. et al. Structural basis for the modular recognition of     single-stranded RNA by PPR proteins. 2013 Nature 504, 168-171. -   Zetsche et al. Cell, 2015 163:759-771. -   Zhang and Muench et al. A Nucleolar PUF RNA-binding Protein with     Specificity for a Unique RNA Sequence. J Biol Chem. 2015 Dec. 11;     290(50):30108-18. -   Zhu et al. Journal of Genetics and Genomics 43 (2016) 25-36.

The following Examples, while indicating embodiments of the invention, are provided for illustrative purposes only and should not be used to limit the invention.

EXAMPLES Example 1: Identification of Bacterial Sequences Encoding CRISPR-Associated Transposases

A number of sequences encoding transposases were identified based on their close proximity to a CRISPR (repeat element) locus. Polynucleotide sequences encoding transposases were identified by bioinformatic searching of bacterial genomes from Lysinibacillus sp., Brevibacillus sp., Sphingobium sp., Undibacterium sp., Bacillus sp., Chryseobacterium sp., Sphingomonas sp., Labrys sp., Brevibacillus laterosporus, Bacillus thuringiensis, Bacillus weihenstephanensis, Bacillus megaterium, Enterococcus faecalis, Brevibacillus brevis, Undibacterium pigrum, Novosphingobium rosa, Labrys methylaminiphdus, Brevibacillus parabrevis, Paenibacillus sp., Paenibacillus thiaminolyticus, Paenibacillus lentimorbus, Paenibacillus terrae, Streptomyces sp., and Stenotrophomonas sp.

A search of 15980 bacterial genomes for CRISPR sequences using the CRISPR recognition toolv1.1 was completed (Bland, 2007; web address: room220.com/crt). From this search, 20467 CRISPR loci were identified, of which 622 CRISPR loci were identified within 2 kb of the coding regions annotated as putative transposases. The CRISPR loci were further prioritized and narrowed down to 521 unique loci by excluding loci that: were associated with known Cas proteins; occurred within a coding region; or originated from an undesirable bacterial strain. The prioritization resulted in identification of 123 unique CRISPR-associated transposase proteins (SEQ ID NO: 124-246) with at least 300 amino acids (encoded by nucleotide sequences SEQ ID NO: 1-123).

The transposase protein sequences (SEQ ID NO: 124-246) were aligned using the USEARCH tool at 50% sequence identity cutoff (Edgar, 2010) and 12 sequence alignment clusters were identified, as shown in Table 1. From the 12 sequence alignment clusters, 23 transposase proteins were selected to represent protein diversity and the respective associated CRISPR array polynucleotide sequences are provided in Table 2.

The transposase protein sequences in each cluster can be aligned to further demonstrate sequence similarities among them and one example is provided in FIG. 1 for cluster 4 (SEQ ID NO: 228-231). Sequence identity percentages among protein sequences in cluster 4 are presented in Table 3. Each cell in the table shows the percentage identity for the transposase protein in the corresponding row (query sequence) as compared to the transposase protein in the corresponding column (subject sequence) divided by the total length of the query sequence, and the number in parenthesis is the total number of identical residues between the query and subject sequences. As can be seen from Table 3 and FIG. 1, the percentage identity among protein sequences for these transposases in cluster 4 ranges from about 86% to about 98% identity.

TABLE 1 Sequence clusters identified among the 123 transposases. DNA sequences PRT sequences Cluster ID (SEQ ID NO:) (SEQ ID NO:)  1  1-97 124-220  2  98-100 221-223  3 101-104 224-227  4 105-109 228-232  5 110-113 233-236  6 114 237  7 115-116 238-239  8 117 240  9 118 241 10 119 242 11 120-122 243-245 12 123 246

TABLE 2 Transposases and the associated CRISPR arrays selected for representing protein diversity across the 12 clusters. Transposase Associated CRISPR protein sequences arrays (SEQ IN NO:) (SEQ ID NO:) 125 247 128 248 146 249 178 250 184 251 193 252 212 253, 254 222 255 224 256 225 257 228 258 232 259 234 260, 261 236 262 237 263, 264 238 265 239 266 240 267, 268 241 269, 270 242 271 243 272 245 273 246 274

TABLE 3 Percent identity comparison of protein sequences for each of the transposase proteins in cluster ID 4. Se- quence 1 2 3 4 5 1 SEQ- — 95.2 (334) 93.2 (327) 98.6 (346) 87.2 (306) 228 2 SEQ- 96.3 (334) — 95.4 (331) 95.1 (330) 88.5 (307) 229 3 SEQ- 96.5 (327) 97.6 (331) — 95.3 (323) 89.4 (303) 230 4 SEQ- 98.6 (346) 94.0 (330) 92.0 (323) — 86.6 (304) 231 5 SEQ- 94.2 (306) 94.5 (307) 93.2 (303) 93.5 (304) — 232

A transposase protein sequence encoded by a polynucleotide sequence as described herein may also be designed or chosen to have one or more amino acid substitution(s) known to be chemically and/or structurally conservative (for example, replacing one amino acid with another having similar chemical or physical properties, such as hydrophobicity, polarity, charge, steric effect, acid/base chemistry, similar side chain group, such as hydroxyl, sulfhydryl, amino, etc.) to avoid or minimize structural changes to the protein that might affect its function. Examples of conservative amino acid substitutions are presented in Table 4. A transposase protein sequence encoded by a polynucleotide sequence as described herein may include proteins that differ in one or more amino acids from those of a CRISPR-associated transposase of SEQ ID NOs: 124-246 or similar sequence as a result of deletion(s) and/or insertion(s) involving one or more amino acids, and may also be designed or chosen based on known transposase protein sequences and their conserved amino acid residues and domains. Amino acid mutations may be made as a single amino acid substitution in the protein or in combination with one or more other mutation(s), such as one or more other amino acid substitution(s), deletions, or additions. Mutations may be made by any method known to those of skill in the art.

TABLE 4 Amino Acid Substitutions. Conservative Conservative Residue Substitutions Residue Substitutions Ala Ser Leu Ile; Val Arg Lys Lys Arg; Gln Asn Gln; His Met Leu; Ile Asp Glu Phe Met; Leu; Tyr Gln Asn Ser Thr; Gly Cys Ser Thr Ser; Val Glu Asp Trp Tyr Gly Pro Tyr Trp; Phe His Asn; Gln Val Ile; Leu Ile Leu; Val Additional CRISPR-associated transposases were further identified by using the same bioinformatics procedure as described above, with the following change to the searching criteria. In the initial search parameters, transposases that were 300 amino acids or longer and within 2 kb of CRISPR loci were selected. In this round, additional transposases were selected if they were within 2.2 kb of CRISPR loci, regardless of the protein length. A total of 13 additional transposase proteins were identified, SEQ ID NOs: 275-287.

Example 2: Sequence Analysis for the Identified CRISPR-Associated Transposases

Pfam annotation of the identified 136 sequences encoding CRISPR-associated transposases is presented in Table 5. For each protein, the domain ID is indicated (for example, PUF, OrfB_IS605, or OrfB_Zn_ribbon), then the domain E-value, then the pfam domain coordinates (from and to), followed by the endpoint coordinate symbols. For each pair of query and target endpoint coordinates, the endpoint coordinate symbols have the following meaning: both ends of the alignment ended internally is represented by “..”; both ends of the alignment were full-length flush to the ends of the query and target is represented by “[ ]”; where only the left or right end was flush/full-length is represented by “[.” Or “.],” respectively (Eddy, 2009; web site hmmer.org).

TABLE 5 Pfam annotation of the transposases (SEQ ID NOs: 124-246, 275-287). PRT DNA SEQ ID SEQ ID Pfam domainID: (domain E-value_from . . . to_endpoint NO NO Organism coordinate symbols) Pfam domains are separated by “;” 124 1 Bacillus sp. C1_1: (0.00069_368 . . . 412 . . . ); OrfB_IS605: multi (0.00012_203 . . . 338_ . . . ); OrfB_Zn_ribbon: (6.2e−24_349 . . . 418_ . . . ); PUF: (0.018_308 . . . 335_ . . . ); RNA_POL_M_15KD: (2.1_379 . . . 410_ . . . ); RNA_POL_M_15KD: (3.4_373 . . . 388_ . . . ); zf-Mss51: (0.041_354 . . . 415_ . . . ); zn-ribbon_14: (0.25_377 . . . 393_ . . . ); zn-ribbon_14: (0.47_397 . . . 409_ . . . ) 125 2 Bacillus sp. C1_1: (0.00069_368 . . . 412_ . . . ); OrfB_IS605: multi (0.00012_203 . . . 338_ . . . ); OrfB_Zn_ribbon: (6.2e−24_349 . . . 418_ . . . ); PUF: (0.018_308 . . . 335_ . . . ); RNA_POL_M_15KD: (2.1_379 . . . 410_ . . . ); RNA_POL_M_15KD: (3.4_373 . . . 388_ . . . ); zf-Mss51: (0.041_354 . . . 415_ . . . ); zn-ribbon_14: (0.25_377 . . . 393_ . . . ); zn-ribbon_14: (0.47_397 . . . 409_ . . . ) 126 3 Bacillus sp. C1_1: (0.00069_368 . . . 412_ . . . ); OrfB_IS605: multi (0.00012_203 . . . 338_ . . . ); OrfB_Zn_ribbon: (6.2e−24_349 . . . 418_ . . . ); PUF: (0.018_308 . . . 335_ . . . ); RNA_POL_M_15KD: (2.1_379 . . . 410_ . . . ); RNA_POL_M_15KD: (3.4_373 . . . 388_ . . . ); zf-Mss51: (0.041_354 . . . 415_ . . . ); zn-ribbon_14: (0.25_377 . . . 393_ . . . ); zn-ribbon_14: (0.47_397 . . . 409_ . . . ) 127 4 Bacillus sp. C1_1: (0.00069_368 . . . 412_ . . . ); OrfB_IS605: multi (0.00016_204 . . . 338_ . . . ); OrfB_Zn_ribbon: (6.2e−24_349 . . . 418_ . . . ); PUF: (0.0052_308 . . . 335_ . . . ); RNA_POL_M_15KD: (2.1_379 . . . 410_ . . . ); RNA_POL_M_15KD: (3.4_373 . . . 388_ . . . ); zf-Mss51: (0.043_353 . . . 416_ . . . ); zn-ribbon_14: (0.25_377 . . . 393_ . . . ); zn-ribbon_14: (0.47_397 . . . 409_ . . . ) 128 5 Bacillus sp. C1_1: (0.00069_368 . . . 412_ . . . ); OrfB_IS605: multi (0.00016_204 . . . 338_ . . . ); OrfB_Zn_ribbon: (6.2e−24_349 . . . 418_ . . . ); PUF: (0.0052_308 . . . 335_ . . . ); RNA_POL_M_15KD: (2.1_379 . . . 410_ . . . ); RNA_POL_M_15KD: (3.4_373 . . . 388_ . . . ); zf-Mss51: (0.043_353 . . . 416_ . . . ); zn-ribbon_14: (0.25_377 . . . 393_ . . . ); zn-ribbon_14: (0.47_397 . . . 409_ . . . ) 129 6 Bacillus sp. C1_1: (0.00069_368 . . . 412_ . . . ); OrfB_IS605: multi (0.00015_204 . . . 338_ . . . ); OrfB_Zn_ribbon: (6.2e−24_349 . . . 418_ . . . ); PUF: (0.0052_308 . . . 335_ . . . ); RNA_POL_M_15KD: (2.1_379 . . . 410_ . . . ); RNA_POL_M_15KD: (3.4_373 . . . 388_ . . . ); zf-Mss51: (0.043_353 . . . 416_ . . . ); zn-ribbon_14: (0.25_377 . . . 393_ . . . ); zn-ribbon_14: (0.47_397 . . . 409_ . . . ) 130 7 Bacillus sp. C1_1: (0.00052_367 . . . 412_ . . . ); OrfB_IS605: multi (0.00016_204 . . . 338_ . . . ); OrfB_Zn_ribbon: (1.5e−22_349 . . . 418_ . . . ); PUF: (0.0052_308 . . . 335_ . . . ); RNA_POL_M_15KD: (2.1_379 . . . 410_ . . . ); RNA_POL_M_15KD: (3.4_373 . . . 388_ . . . ) ; zf-Mss51: (0.042_353 . . . 417_ . . . ); zn-ribbon_14: (0.25_377 . . . 393_ . . . ); zn-ribbon_14: (0.47_397 . . . 409_ . . . ) 131 8 Bacillus sp. C1_1: (0.00065_361 . . . 407_ . . . ); OrfB_IS605: multi (0.00011_196 . . . 331_ . . . ); OrfB_Zn_ribbon: (3.9e−23_342 . . . 411_ . . . ); PUF: (0.018_301 . . . 328_ . . . ); RNA_POL_M_15KD: (2.5_372 . . . 403_ . . . ); RNA_POL_M_15KD: (3.7_367 . . . 381_ . . . ); zf-Mss51: (0.036_347 . . . 407_ . . . ); zn-ribbon_14: (0.25_370 . . . 386_ . . . ); zn-ribbon_14: (0.46_390 . . . 402_ . . . ) 132 9 Bacillus sp. C1_1: (0.00065_361 . . . 407_ . . . ); OrfB_IS605: multi (9.3e−05_196 . . . 331_ . . . ); OrfB_Zn_ribbon: (3.9e−23_342 . . . 411_ . . . ); PUF: (0.0051_301 . . . 328_ . . . ); RNA_POL_M_15KD: (2.5_372 . . . 403_ . . . ); RNA_POL_M_15KD: (3.7_367 . . . 381_ . . . ); zf-Mss51: (0.037_346 . . . 409_ . . . ); zn-ribbon_14: (0.25_370 . . . 386_ . . . ); zn-ribbon_14: (0.46_390 . . . 402_ . . . ) 133 10 Bacillus sp OrfB_IS605: (9.2e−05_196 . . . 331_ . . . ); OrfB_Zn_ribbon: multi (9.5e−24_342 . . . 411_ . . . ); PUF: (0.0044_301 . . . 328_ . . . ); RNA_POL_M_15KD : (3.1_366 . . . 381_ . . . ); RNA_POL_M_15KD: (3.3_372 . . . 403_ . . . ); zf-Mss51: (0.044_347 . . . 408_ . . . ); zn-ribbon_14: (0.25_370 . . . 386_ . . . ); zn-ribbon_14: (0.46_390 . . . 402_ . . . ) 134 11 Bacillus C1_1: (0.00067_368 . . . 414_ . . . ); OrfB_IS605: thuringiensis (9.6e−05_203 . . . 338_ . . . ); OrfB_Zn_ribbon: (4e−23_349 . . . 418_ . . . ); PUF: (0.0052_308 . . . 335_ . . . ); RNA_POL_M_15KD: (2.6_379 . . . 410_ . . . ); RNA_POL_M_15KD: (3.8_374 . . . 388_ . . . ); zf-Mss51: (0.039_353 . . . 416_ . . .); zn-ribbon_14: (0.25_377 . . . 393_ . . . ); zn-ribbon_14: (0.47_397 . . . 409_ . . . ) 135 12 Bacillus sp. OrfB_IS605: (9.5e−05_203 . . . 338_ . . . ); multi OrfB_Zn_ribbon: (9.7e−24_349 . . . 418_ . . . ); PUF: (0.0044_308 . . . 335_ . . . ); RNA_POL_M_15KD: (3.2_373 . . . 388_ . . . ); RNA_POL_M_15KD: (3.4_379 . . . 410_ . . . ); zf-Mss51: (0.045_354 . . . 415_ . . . ); zn-ribbon_14: (0.25_377 . . . 393_ . . . ); zn-ribbon_14: (0.47_397 . . . 409_ . . . ) 136 13 Bacillus sp. OrfB_IS605: (9.5e−05_203 . . . 338_ . . . ); OrfB_Zn_ribbon: multi (9.7e−24_349 . . . 418_ . . . ); PUF: (0.0044_308 . . . 335_ . . . ); RNA_POL_M_15KD: (3.2_373 . . . 388_ . . . ); RNA_POL_M_15KD: (3.4_379 . . . 410_ . . . ); zf-Mss51: (0.045_354 . . . 415_ . . . ); zn-ribbon_14: (0.25_377 . . . 393_ . . . ); zn-ribbon_14: (0.47_397 . . . 409_ . . . ) 137 14 Bacillus sp. OrfB_IS605: (9.5e−05_203 . . . 338_ . . . ); OrfB_Zn_ribbon: multi (9.7e−24_349 . . . 418_ . . . ); PUF: (0.0044_308 . . . 335_ . . . ); RNA_POL_M_15KD: (3.2_373 . . . 388_ . . . ); RNA_POL_M_15KD: (3.4_379 . . . 410_ . . . ); zf-Mss51: (0.045_354 . . . 415_ . . . ); zn-ribbon_14: (0.25_377 . . . 393_ . . . ); zn-ribbon_14: (0.47_397 . . . 409_ . . . ) 138 15 Bacillus sp. C1_1: (0.00065_361 . . . 407_ . . . ); OrfB_IS605: multi (0.00014_196 . . . 331_ . . . ); OrfB_Zn_ribbon: (3.9e−23_342 . . . 411_ . . . ); PUF: (0.0051_301 . . . 328_ . . . ); RNA_POL_M_15KD: (2.5_372 . . . 403_ . . . ); RNA_POL_M_15KD: (3.7_367 . . . 381_ . . . ); zf-Mss51: (0.037_346 . . . 409_ . . . ); zn-ribbon_14: (0.25_370 . . . 386_ . . . ); zn-ribbon_14: (0.46_390 . . . 402_ . . . ) 139 16 Bacillus sp. C1_1: (0.00065_361 . . . 407_ . . . ); OrfB_IS605: multi (9.3e−05_196 . . . 331_ . . . ); OrfB_Zn_ribbon: (3.9e−23_342 . . . 411_ . . . ); PUF: (0.0051_301 . . . 328_ . . . ); RNA_POL_M_15KD: (2.5_372 . . . 403_ . . . ); RNA_POL_M_15KD: (3.7_367 . . . 381_ . . . ); zf-Mss51: (0.037_346 . . . 409_ . . . ); zn-ribbon_14: (0.25_370 . . . 386_ . . . ); zn-ribbon_14: (0.46_390 . . . 402_ . . . ) 140 17 Bacillus sp. C1_1: (0.00068_368 . . . 414_ . . . ); OrfB_IS605: multi (0.00018_204 . . . 338_ . . . ); OrfB_Zn_ribbon: (4.8e−24_349 . . . 418_ . . . ); PUF: (0.0044_308 . . . 335_ . . . ); RNA_POL_M_15KD: (2.6_379 . . . 410_ . . . ); RNA_POL_M_15KD: (3.8_374 . . . 388_ . . . ); zf-Mss51: (0.033_353 . . . 415_ . . . ); zn-ribbon_14: (0.25_377 . . . 393_ . . . ); zn-ribbon_14: (0.47_397 . . . 409_ . . . ) 141 18 Bacillus sp. C1_1: (0.00067_361 . . . 407_ . . . ); OrfB_IS605: multi (0.00017_197 . . . 331_ . . . ); OrfB_Zn_ribbon: (4.7e−24_342 . . . 411_ . . . ); PUF: (0.0044_301 . . . 328_ . . . ); RNA_POL_M_15KD: (2.5_372 . . . 403_ . . . ); RNA_POL_M_15KD: (3.7_367 . . . 381_ . . . ); zf-Mss51: (0.03_346 . . . 408_ . . . ); zn-ribbon_14: (0.25_370 . . . 386_ . . . ); zn-ribbon_14: (0.46_390 . . . 402_ . . . ) 142 19 Bacillus sp. C1_1: (0.00067_361 . . . 405_ . . . ); OrfB_IS605: multi (0.00026_195 . . . 331_ . . . ); OrfB_Zn_ribbon: (6e−24_342 . . . 411_ . . . ); PUF: (0.005_301 . . . 328_ . . . ); RNA_POL_M_15KD: (2_372 . . . 403_ . . . ); RNA_POL_M_15KD: (3.4_366 . . . 381_ . . . ); zf-Mss51: (0.047_346 . . . 409_ . . . ); zn-ribbon_14: (0.25_370 . . . 386_ . . . ); zn-ribbon_14: (0.46_390 . . . 402_ . . . ) 143 20 Bacillus sp. OrfB_IS605: (9.5e−05_203 . . . 338_ . . . ); OrfB_Zn_ribbon: multi (9.7e−24_349 . . . 418_ . . . ); PUF: (0.0044_308 . . . 335_ . . . ); RNA_POL_M_15KD: (3.2_373 . . . 388_ . . . ); RNA_POL_M_15KD: (3.4_379 . . . 410_ . . . ); zf-Mss51: (0.045_354 . . . 415_ . . . ); zn-ribbon_14: (0.25_377 . . . 393_ . . . ); zn-ribbon_14: (0.47_397 . . . 409_ . . . ) 144 21 Bacillus sp. C1_1: (0.00068_368 . . . 414_ . . . ); OrfB_IS605: multi (0.00018_204 . . . 338_ . . . ); OrfB_Zn_ribbon: (4.8e−24_349 . . . 418_ . . . ); PUF: (0.0044_308 . . . 335_ . . . ); RNA_POL_M_15KD: (2.6_379 . . . 410_ . . . ); RNA_POL_M_15KD: (3.8_374 . . . 388_ . . . ); zf-Mss51: (0.033_353 . . . 415_ . . . ); zn-ribbon_14: (0.25_377 . . . 393_ . . . ); zn-ribbon_14: (0.47_397 . . . 409_ . . . ) 145 22 Bacillus sp. OrfB_IS605: (0.0014_203 . . . 338_ . . . ); multi OrfB_Zn_ribbon: (9.7e−24_349 . . . 418_ . . . ); PUF: (0.0044_308 . . . 335_ . . . ); RNA_POL_M_15KD: (3.2_373 . . . 388_ . . . ); RNA_POL_M_15KD: (3.4_379 . . . 410_ . . . ); zf-Mss51: (0.045_354 . . . 415_ . . . ); zn-ribbon_14: (0.25_377 . . . 393_ . . . ); zn-ribbon_14: (0.47_397 . . . 409_ . . . ) 146 23 Bacillus sp. OrfB_IS605: (0.00036_204 . . . 338_ . . . ); OrfB_Zn_ribbon: multi (9.7e−24_349 . . . 418_ . . . ); PUF: (0.0044_308 . . . 335_ . . . ); RNA_POL_M_15KD: (3.2_373 . . . 388_ . . . ); RNA_POL_M_15KD: (3.4_379 . . . 410_ . . . ); zf-Mss51: (0.048_353 . . . 417_ . . . ); zn-ribbon_14: (0.25_377 . . . 393_ . . . ); zn-ribbon_14: (0.47_397 . . . 409_ . . . ) 147 24 Bacillus sp. C1_1: (0.00068_361 . . . 405_ . . . ); OrfB_IS605: multi (0.00016_196 . . . 331_ . . . ); OrfB_Zn_ribbon: (1.4e−23_342 . . . 411_ . . . ); PUF: (0.018_301 . . . 328_ . . . ); RNA_POL_M_15KD: (2.1_372 . . . 403_ . . . ); RNA_POL_M_15KD: (3.4_366 . . . 381_ . . . ); zf-Mss51: (0.037_347 . . . 407_ . . . ); zn-ribbon_14: (0.25_370 . . . 386_ . . . ); zn-ribbon_14: (0.46_390 . . . 402_ . . . ) 148 25 Bacillus sp. C1_1: (0.00073_368 . . . 414_ . . . ); OrfB_IS605: multi (0.00018_204 . . . 338_ . . . ); OrfB_Zn_ribbon: (7.3e−23_349 . . . 418_ . . . ); PUF: (0.0044_308 . . . 335_ . . . ); RNA_POL_M_15KD: (2.6_379 . . . 410_ . . . ); RNA_POL_M_15KD: (3.8_374 . . . 388_ . . . ); zf-Mss51: (0.037_354 . . . 414_ . . . ); zn-ribbon_14: (0.25_377 . . . 393_ . . . ); zn-ribbon_14: (0.47_397 . . . 409_ . . . ) 149 26 Bacillus sp. C1_1: (0.00066_361 . . . 407_ . . . ); OrfB_IS605: multi (9.1e−05_196 . . . 331_ . . . ); OrfB_Zn_ribbon: (1.8e−23_342 . . . 411_ . . . ); PUF: (0.0044_301 . . . 328_ . . . ); RNA_POL_M_15KD: (2.1_372 . . . 403_ . . . ); RNA_POL_M_15KD: (3.4_366 . . . 381_ . . . ); zf-Mss51: (0.044_346 . . . 409_ . . . ); zn-ribbon_14: (0.25_370 . . . 386_ . . . ); zn-ribbon_14: (0.46_390 . . . 402_ . . . ) 150 27 Bacillus sp. C1_1: (0.00089_361 . . . 407_ . . . ); OrfB_IS605: multi (0.00022_195 . . . 331_ . . . ); OrfB_Zn_ribbon: (3.2e−23_342 . . . 411_ . . . ); PUF: (0.0051_301 . . . 328_ . . . ); RNA_POL_M_15KD: (2.8_367 . . . 380_ . . . ); RNA_POL_M_15KD: (3.1_372 . . . 403_ . . . ); zf-Mss51: (0.091_350 . . . 407_ . . . ); zn-ribbon_14: (0.26_370 . . . 385_ . . . ); zn-ribbon_14: (0.46_390 . . . 402_ . . . ) 151 28 Bacillus sp. OrfB_IS605: (9.7e−05_203 . . . 338_ . . . ); OrfB_Zn_ribbon: multi (9.7e−24_349 . . . 418_ . . . ); PUF: (0.0044_308 . . . 335_ . . . ); RNA_POL_M_15KD: (3.2_373 . . . 388_ . . . ); RNA_POL_M_15KD: (3.4_379 . . . 410_ . . . ); zf-Mss51: (0.045_354 . . . 415_ . . . ); zn-ribbon_14: (0.25_377 . . . 393_ . . . ); zn-ribbon_14: (0.47_397 . . . 409_ . . . ) 152 29 Bacillus sp. OrfB_IS605: (0.00018_196 . . . 331_ . . . ); OrfB_Zn_ribbon: multi (2.1e−23_342 . . . 411_ . . . ); PUF: (0.0044_301 . . . 328_ . . . ); RNA_POL_M_15KD: (3.3_367 . . . 381_ . . . ); RNA_POL_M_15KD: (3.4_372 . . . 403_ . . . ); zf-Mss51: (0.028_346 . . . 410_ . . . ); zn-ribbon_14: (0.25_370 . . . 386_ . . . ); zn-ribbon_14: (0.46_390 . . . 402_ . . . ) 153 30 Bacillus sp. C1_1: (0.00067_368 . . . 414_ . . . ); OrfB_IS605: multi (0.00011_203 . . . 338_ . . . ); OrfB_Zn_ribbon: (3.2e−23_349 . . . 418_ . . . ); PUF: (0.0052_308 . . . 335_ . . . ); RNA_POL_M_15KD: (2.6_379 . . . 410_ . . . ); RNA_POL_M_15KD: (3.8_374 . . . 388_ . . . ); zf-Mss51: (0.036_355 . . . 417_ . . . ); zn-ribbon_14: (0.25_377 . . . 393_ . . . ); zn-ribbon_14: (0.47_397 . . . 409_ . . . ) 154 31 Bacillus sp. C1_1: (0.00068_368 . . . 414_ . . . ); OrfB_IS605: multi (0.00014_204 . . . 338_ . . . ); OrfB_Zn_ribbon: (4.8e−24_349 . . . 418_ . . . ); PUF: (0.0044_308 . . . 335_ . . . ); RNA_POL_M_15KD: (2.6_379 . . . 410_ . . . ); RNA_POL_M_15KD: (3.8_374 . . . 388_ . . . ); zf-Mss51: (0.033_353 . . . 415_ . . . ); zn-ribbon_14: (0.25_377 . . . 393_ . . . ); zn-ribbon_14: (0.47_397 . . . 409_ . . . ) 155 32 Bacillus sp. HypA: (0.0032_322 . . . 415_ . . . ); multi OrfB_IS605: (0.0002_196 . . . 331_ . . . ); OrfB_Zn_ribbon: (4.8e−23_342 . . . 410_ . . . ); PUF: (0.0044_301 . . . 328_ . . . ); RNA_POL_M_15KD: (3.2_372 . . . 403_ . . . ); RNA_POL_M_15KD: (3.4_367 . . . 381_ . . . ); zf-Mss51: (0.083_349 . . . 407_ . . . ); zn-ribbon_14: (0.26_370 . . . 385_ . . . ); zn-ribbon_14: (0.46_390 . . . 402_ . . . ) 156 33 Bacillus sp. OrfB_IS605: (0.00018_196 . . . 331_ . . . ); OrfB_Zn_ribbon: multi (9.5e−24_342 . . . 411_ . . . ); PUF: (0.0044_301 . . . 328_ . . . ); RNA_POL_M_15KD: (3.1_366 . . . 381_ . . . ); RNA_POL_M_15KD: (3.3_372 . . . 403_ . . . ); zf-Mss51: (0.046_346 . . . 410_ . . . ); zn-ribbon_14: (0.25_370 . . . 386_ . . . ); zn-ribbon_14: (0.46_390 . . . 402_ . . . ) 157 34 Bacillus sp. OrfB_IS605: (7.4e−05_195 . . . 331_ . . . ); OrfB_Zn_ribbon: multi (6.3e−24_342 . . . 411_ . . . ); PUF: (0.0051_301 . . . 328_ . . . ); RNA_POL_M_15KD: (2.5_372 . . . 403_ . . . ); RNA_POL_M_15KD: (3_366 . . . 381_ . . . ); zf-Mss51: (0.1_346 . . . 410_ . . . ); zn-ribbon_14: (0.26_370 . . . 385_ . . . ); zn-ribbon_14: (0.46_390 . . . 402_ . . . ) 158 35 Bacillus sp. OrfB_IS605: (0.00018_204 . . . 338_ . . . ); OrfB_Zn_ribbon: multi (2.2e−23_349 . . . 418_ . . . ); PUF: (0.0044_308 . . . 335_ . . . ); RNA_POL_M_15KD: (3.3_374 . . . 388_ . . . ); RNA_POL_M_15KD: (3.4_379 . . . 410_ . . . ); zf-Mss51: (0.03_353 . . . 417_ . . . ); zn-ribbon_14: (0.25_377 . . . 393_ . . . ); zn-ribbon_14: (0.47_397 . . . 409_ . . . ) 159 36 Bacillus sp. C1_1: (0.00068_361 . . . 405_ . . . ); OrfB_IS605: multi (0.00027_195 . . . 331_ . . . ); OrfB_Zn_ribbon: (6.1e−24_342 . . . 411_ . . . ); PUF: (0.0051_301 . . . 328_ . . . ); RNA_POL_M_15KD: (2.1_372 . . . 403_ . . . ); RNA_POL_M_15KD: (3.4_366 . . . 381_ . . . ); zf-Mss51: (0.046_346 . . . 409_ . . . ); zn-ribbon_14: (0.25_370 . . . 386_ . . . ); zn-ribbon_14: (0.46_390 . . . 402_ . . . ) 160 37 Bacillus sp. C1_1: (0.00089_361 . . . 407_ . . . ); OrfB_IS605: multi (0.00012_195 . . . 331_ . . . ); OrfB_Zn_ribbon: (3.2e−23_342 . . . 411_ . . . ); PUF: (0.0051_301 . . . 328_ . . . ); RNA_POL_M_15KD: (2.8_367 . . . 380_ . . . ); RNA_POL_M_15KD: (3.1_372 . . . 403_ . . . ); zf-Mss51: (0.091_350 . . . 407_ . . . ); zn-ribbon_14: (0.26_370 . . . 385_ . . . ); zn-ribbon_14: (0.46_390 . . . 402_ . . . ) 161 38 Bacillus sp. C1_1: (0.00067_368 . . . 414_ . . . ); OrfB_IS605: multi (9.4e−05_204 . . . 338_ . . . ); OrfB_Zn_ribbon: (1.9e−23_349 . . . 418_ . . . ); PUF: (0.0025_308 . . . 335_ . . . ); RNA_POL_M_15KD: (2.1_379 . . . 410_ . . . ); RNA_POL_M_15KD: (3.4_373 . . . 388_ . . . ); zf-Mss51: (0.043_353 . . . 416_ . . . ); zn-ribbon_14: (0.25_377 . . . 393_ . . . ); zn-ribbon_14: (0.47_397 . . . 409_ . . . ) 162 39 Bacillus sp. C1_1: (0.00066_362 . . . 408_ . . . ); OrfB_IS605: multi (4.3e−05_203 . . . 332_ . . . ); OrfB_Zn_ribbon: (1.8e−23_343 . . . 412_ . . . ); PUF: (0.0044_302 . . . 329_ . . . ); RNA_POL_M_15KD: (2.1_373 . . . 404_ . . . ); RNA_POL_M_15KD: (3.4_367 . . . 382_ . . . ); zf-Mss51: (0.04_348 . . . 409_ . . . ); zn-ribbon_14: (0.25_371 . . . 387_ . . . ); zn-ribbon_14: (0.46_391 . . . 403_ . . . ) 163 40 Bacillus sp. C1_1: (0.00067_368 . . . 414_ . . . ); OrfB_IS605: multi (9.3e−05_200 . . . 338_ . . . ); OrfB_Zn_ribbon: (1.9e−23_349 . . . 418_ . . . ); PUF: (0.0052_308 . . . 335_ . . . ); RNA_POL_M_15KD: (2.1_379 . . . 410_ . . . ); RNA_POL_M_15KD: (3.4_373 . . . 388_ . . . ); zf-Mss51: (0.043_353 . . . 416_ . . . ); zn-ribbon_14: (0.25_377 . . . 393_ . . . ); zn-ribbon_14: (0.47_397 . . . 409_ . . . ) 164 41 Bacillus sp. C1_1: (0.00089_361 . . . 407_ . . . ); OrfB_IS605: multi (8.3e−06_197 . . . 331_ . . . ); OrfB_Zn_ribbon: (1.5e−23_342 . . . 411_ . . . ); PUF: (0.0051_301 . . . 328_ . . . ); RNA_POL_M_15KD: (3_366 . . . 381_ . . . ); RNA_POL_M_15KD: (3_372 . . . 403_ . . . ); TipE: (1.7e−05_358 . . . 441_ . . . ); zf-Mss51: (0.1_348 . . . 407_ . . . ); zn-ribbon_14: (0.26_370 . . . 385_ . . . ); zn-ribbon_14: (0.46_390 . . . 402_ . . . ) 165 42 Bacillus sp. C1_1: (0.00067_368 . . . 414_ . . . ); OrfB_IS605: multi (9.4e−05_204 . . . 338_ . . . ); OrfB_Zn_ribbon: (1.9e−23_349 . . . 418_ . . . ); PUF: (0.0025_308 . . . 335_ . . . ); RNA_POL_M_15KD: (2.1_379 . . . 410_ . . . ); RNA_POL_M_15KD: (3.4_373 . . . 388_ . . . ); zf-Mss51: (0.043_353 . . . 416_ . . . ); zn-ribbon_14: (0.25_377 . . . 393_ . . . ); zn-ribbon_14: (0.47_397 . . . 409_ . . . ) 166 43 Bacillus sp. OrfB_IS605: (7.9e−05_195 . . . 331_ . . . ); OrfB_Zn_ribbon: multi (9.5e−23_342 . . . 411_ . . . ); PUF: (0.0051_301 . . . 328_ . . . ); RNA_POL_M_15KD: (2.5_372 . . . 403_ . . . ); RNA_POL_M_15KD: (3_366 . . . 381_ . . . ); zf-Mss51: (0.1_346 . . . 407_ . . . ); zf-Mss51: (9.6_268 . . . 296_ . . . ); zn-ribbon_14: (0.26_370 . . . 385_ . . . ); zn-ribbon_14: (0.46_390 . . . 402_ . . . ) 167 44 Bacillus sp. C1_1: (0.00066_361 . . . 407_ . . . ); OrfB_IS605: multi (9.2e−05_197 . . . 331_ . . . ); OrfB_Zn_ribbon: (1.8e−23_342 . . . 411_ . . . ); PUF: (0.0025_301 . . . 328_ . . . ); RNA_POL_M_15KD: (2.1_372 . . . 403_ . . . ); RNA_POL_M_15KD: (3.4_366 . . . 381_ . . . ); zf-Mss51: (0.044_346 . . . 409_ . . . ); zn-ribbon_14: (0.25_370 . . . 386_ . . . ); zn-ribbon_14: (0.46_390 . . . 402_ . . . ) 168 45 Bacillus sp. C1_1: (0.0019_368 . . . 414_ . . . ); DUF3336: multi (0.0094_292 . . . 335_ . . . ); DUF3336: (0.65_177 . . . 226_ . . . ); DUF3336: (8.2e−05_407 . . . 455_.]); OrfB_IS605: (9.7e−05_203 . . . 338_ . . . ); OrfB_Zn_ribbon: (9.9e−24_349 . . . 418_ . . . ); PUF: (0.0045_308 . . . 335_ . . . ); RNA_POL_M_15KD: (3.2_373 . . . 388_ . . . ); RNA_POL_M_15KD: (3.4_379 . . . 410_ . . . ); zf-Mss51: (0.043_354 . . . 415_ . . . ); zn-ribbon_14: (0.26_377 . . . 393_ . . . ); zn-ribbon_14: (0.48_397 . . . 409_ . . . ) 169 46 Bacillus sp. OrfB_IS605: (0.00012_197 . . . 331_ . . . ); OrfB_Zn_ribbon: multi (6.3e−24_342 . . . 411_ . . . ); RNA_POL_M_15KD: (2.5_372 . . . 403_ . . . ); RNA_POL_M_15KD: (3_366 . . . 381_ . . . ); zf-Mss51: (0.1_346 . . . 410_ . . . ); zn-ribbon_14: (0.26_370 . . . 385_ . . . ); zn-ribbon_14: (0.46_390 . . . 402_ . . . ) 170 47 Bacillus sp. OrfB_IS605: (4.3e−05_203 . . . 332_ . . . ); OrfB_Zn_ribbon: multi (9.5e−24_343 . . . 412_ . . . ); PUF: (0.0044_302 . . . 329_ . . . ); RNA_POL_M_15KD: (3.1_367 . . . 382_ . . . ); RNA_POL_M_15KD: (3.4_373 . . . 404_ . . . ); zf-Mss51: (0.044_348 . . . 409_ . . . ); zn-ribbon_14: (0.25_371 . . . 387_ . . . ); zn-ribbon_14: (0.46_391 . . . 403_ . . . ) 171 48 Bacillus sp. OrfB_IS605: (4.3e−05_203 . . . 332_ . . . ); OrfB_Zn_ribbon: multi (9.5e−24_343 . . . 412_ . . . ); PUF: (0.0044_302 . . . 329_ . . . ); RNA_POL_M_15KD: (3.1_367 . . . 382_ . . . ); RNA_POL_M_15KD: (3.4_373 . . . 404_ . . . ); zf-Mss51: (0.044_348 . . . 409_ . . . ); zn-ribbon_14: (0.25_371 . . . 387_ . . . ); zn-ribbon_14: (0.46_391 . . . 403_ . . . ) 172 49 Bacillus sp. DsrC: (0.023_36 . . . 109_ . . . ); DsrC: (5.8e−05_146 . . . 203_ . . . ); multi HypA: (0.0062_340 . . . 422_ . . . ); OrfB_IS605: (0.00022_203 . . . 338_ . . . ); OrfB_Zn_ribbon: (2.7e−22_349 . . . 417_ . . . ); PUF: (0.0044_308 . . . 335_ . . . ); RNA_POL_M_15KD: (3.2_379 . . . 410_ . . . ); RNA_POL_M_15KD: (3.5_374 . . . 388_ . . . ); zf-Mss51: (0.098_357 . . . 414_ . . . ); zn-ribbon_14: (0.27_377 . . . 392_ . . . ); zn-ribbon_14: (0.47_397 . . . 409_ . . . ) 173 50 Bacillus sp. OrfB_IS605: (1.5e−05_196 . . . 325_ . . . ); OrfB_Zn_ribbon: multi (9.3e−24_336 . . . 405_ . . . ); PUF: (0.0043_295 . . . 322_ . . . ); RNA_POL_M_15KD: (3.1_360 . . . 375_ . . . ); RNA_POL_M_15KD: (3.3_366 . . . 397_ . . . ); zf-Mss51: (0.042_341 . . . 404_ . . . ); zn-ribbon_14: (0.25_364 . . . 380_ . . . ); zn-ribbon_14: (0.46_384 . . . 396_ . . . ) 174 51 Bacillus sp. HypA: (0.0039_330 . . . 415_ . . . ); OrfB_IS605: multi (0.00017_196 . . . 331_ . . . ); OrfB_Zn_ribbon: (4.8e−23_342 . . . 410_ . . . ); PUF: (0.0044_301 . . . 328_ . . . ); RNA_POL_M_15KD: (3.2_372 . . . 403_ . . . ); RNA_POL_M_15KD: (3.4_367 . . . 381_ . . . ); zf-Mss51: (0.083_349 . . . 407_ . . . ); zn-ribbon_14: (0.26_370 . . . 385_ . . . ); zn-ribbon_14: (0.46_390 . . . 402_ . . . ) 175 52 Bacillus sp. OrfB_IS605: (4.3e−05_203 . . . 332_ . . . ); OrfB_Zn_ribbon: multi (9.5e−24_343 . . . 412_ . . . ); PUF: (0.0044_302 . . . 329_ . . . ); RNA_POL_M_15KD: (3.1_367 . . . 382_ . . . ); RNA_POL_M_15KD: (3.4_373 . . . 404_ . . . ); zf-Mss51: (0.044_348 . . . 409_ . . . ); zn-ribbon_14: (0.25_371 . . . 387_ . . . ); zn-ribbon_14: (0.46_391 . . . 403_ . . . ) 176 53 Paenibacillus OrfB_IS605: (1.6e−05_203 . . . 332_ . . . ); OrfB_Zn_ribbon: sp. novel (9.5e−24_343 . . . 412_ . . . ); PUF: (0.0044_302 . . . 329_ . . . ); RNA_POL_M_15KD: (3.1_367 . . . 382_ . . . ); RNA_POL_M_15KD: (3.4_373 . . . 404_ . . . ); zf-Mss51: (0.044_348 . . . 409_ . . . ); zn-ribbon_14: (0.25_371 . . . 387_ . . . ); zn-ribbon_14: (0.46_391 . . . 403_ . . . ) 177 54 Bacillus C1_1: (0.00079_360 . . . 405_ . . . ); OrfB_IS605: thuringiensis (0.00014_195 . . . 331_ . . . ); OrfB_Zn_ribbon: (6.4e−23_342 . . . 411_ . . . ); PUF: (0.0025_301 . . . 328_ . . . ); RNA_POL_M_15KD: (0.018_378 . . . 403_ . . . ); RNA_POL_M_15KD: (3.3_364 . . . 381_ . . . ); zf-Mss51: (0.11_350 . . . 408_ . . . ); zn-ribbon_14: (0.26_370 . . . 385_ . . . ); zn-ribbon_14: (0.46_390 . . . 402_ . . . ) 178 55 Bacillus sp. C1_1: (0.00081_367 . . . 412_ . . . ); OrfB_IS605: multi (0.00016_203 . . . 338_ . . . ); OrfB_Zn_ribbon: (6.6e−23_349 . . . 418_ . . . ); PUF: (0.0025_308 . . . 335_ . . . ); RNA_POL_M_15KD: (0.019_385 . . . 410_ . . . ); RNA_POL_M_15KD: (3.4_371 . . . 388_ . . . ); zf-Mss51: (0.12_358 . . . 417_ . . . ); zn-ribbon_14: (0.27_377 . . . 392_ . . . ); zn-ribbon_14: (0.47_397 . . . 409_ . . . ) 179 56 Bacillus sp. C1_1: (0.00079_360 . . . 405_ . . . ); OrfB_IS605: multi (0.00016_196 . . . 331_ . . . ); OrfB_Zn_ribbon: (6.4e−23_342 . . . 411_ . . . ); PUF: (0.0025_301 . . . 328_ . . . ); RNA_POL_M_15KD: (0.018_378 . . . 403_ . . . ); RNA_POL_M_15KD: (3.3_364 . . . 381_ . . . ); zf-Mss51: (0.11_350 . . . 408_ . . . ); zn-ribbon_14: (0.26_370 . . . 385_ . . . ); zn-ribbon_14: (0.46_390 . . . 402_ . . . ) 180 57 Bacillus sp. C1_1: (0.00079_360 . . . 405_ . . . ); OrfB_IS605: multi (0.00016_195 . . . 331_ . . . ); OrfB_Zn_ribbon: (6.4e−23_342 . . . 411_ . . . ); PUF: (0.0025_301 . . . 328_ . . . ); RNA_POL_M_15KD: (0.018_378 . . . 403_ . . . ); RNA_POL_M_15KD: (3.3_364 . . . 381_ . . . ); zf-Mss51: (0.11_350 . . . 408_ . . . ); zn-ribbon_14: (0.26_370 . . . 385_ . . . ); zn-ribbon_14: (0.46_390 . . . 402_ . . . ) 181 58 Bacillus sp. C1_1: (0.00079_360 . . . 405_ . . . ); OrfB_IS605: multi (0.0001_196 . . . 331_ . . . ); OrfB_Zn_ribbon: (6.4e−23_342 . . . 411_ . . . ); PUF: (0.0025_301 . . . 328_ . . . ); RNA_POL_M_15KD: (0.018_378 . . . 403_ . . . ); RNA_POL_M_15KD: (3.3_364 . . . 381_ . . . ); zf-Mss51: (0.11_350 . . . 408_ . . . ); zn-ribbon_14: (0.26_370 . . . 385_ . . . ); zn-ribbon_14: (0.46_390 . . . 402_ . . . ) 182 59 Bacillus sp. C1_1: (0.0018_362 . . . 408_ . . . ); OrfB_IS605: multi (1.5e−05_203 . . . 332_ . . . ); OrfB_Zn_ribbon: (9.3e−24_343 . . . 412_ . . . ); PUF: (0.0043_302 . . . 329_ . . . ); RNA_POL_M_15KD: (3.2_367 . . . 382_ . . . ); RNA_POL_M_15KD: (3.2_373 . . . 404_ . . . ); zf-Mss51: (0.042_348 . . . 411_ . . . ); zn-ribbon_14: (0.25_371 . . . 387_ . . . ); zn-ribbon_14: (0.46_391 . . . 403_ . . . ) 183 60 Bacillus sp. C1_1: (0.0008_360 . . . 405_ . . . ); DUF3336: multi (0.012_283 . . . 327_ . . . ); DUF3336: (0.35_164 . . . 220_ . . . ); DUF3336: (7e−05_397 . . . 448_.]); OrfB_IS605: (0.00016_196 . . . 331_ . . . ); OrfB_Zn_ribbon: (6.5e−23_342 . . . 411_ . . . ); PUF: (0.0025_301 . . . 328_ . . . ); RNA_POL_M_15KD: (0.019_378 . . . 403_ . . . ); RNA_POL_M_15KD: (3.3_364 . . . 381_ . . . ); zf-Mss51: (0.12_351 . . . 410_ . . . ); zn-ribbon_14: (0.27_370 . . . 385_ . . . ); zn-ribbon_14: (0.47_390 . . . 402_ . . . ) 184 61 Bacillus sp. C1_1: (0.0016_313 . . . 359_ . . . ); OrfB_IS605: multi (3.5e−05_153 . . . 283_ . . . ); OrfB_Zn_ribbon: (8e−24_294 . . . 363_ . . . ); PUF: (0.0038_253 . . . 280_ . . . ); RNA_POL_M_15KD: (3_318 . . . 333_ . . . ); RNA_POL_M_15KD: (3_324 . . . 355_ . . . ); zf-Mss51: (0.041_298 . . . 362_ . . . ); zn-ribbon_14: (0.22_322 . . . 338_ . . . ); zn-ribbon_14: (0.41_342 . . . 354_ . . . ) 185 62 Bacillus sp. C1_1: (0.0015_368 . . . 413_ . . . ); C1_2: multi (0.0013_362 . . . 407_ . . . ); HypA: (0.0022_316 . . . 421_ . . . ); Lar_restr_allev: (0.006_371 . . . 420_ . . . ); Lar_restr_allev: (0.031_90 . . . 111_ . . . ); Lar_restr_allev: (2.2_299 . . . 346_ . . . ); OrfB_Zn_ribbon: (1.4e−24_348 . . . 416_ . . . ); PUF: (0.00047_307 . . . 333_ . . . ); PUF: (1_36 . . . 55_ . . . ); Tnp_zf-ribbon_2: (0.0001_376 . . . 406_ . . . ); Tnp_zf-ribbon_2: (3.3_276 . . . 327_ . . . ) 186 63 Bacillus sp. C1_1: (0.002_361 . . . 404_ . . . ); C1_2: multi (0.00047_355 . . . 400_ . . . ); C1_3: (0.019_369 . . . 400_ . . . ); HypA: (0.0015_309 . . . 414_ . . . ); OrfB_IS605: (0.00069_204 . . . 330_ . . . ); OrfB_Zn_ribbon: (1.9e−24_341 . . . 410_ . . . ); PUF: (0.51_29 . . . 49_ . . . ); PUF: (3.1e−05_300 . . . 327_ . . . ); PUF: (6.6_414 . . . 431_ . . . ); Tnp_zf-ribbon_2: (2.4_292 . . . 320_ . . . ); Tnp_zf-ribbon_2: (3.6e−05_344 . . . 399_ . . . ) 187 64 Bacillus sp. C1_1: (0.0021_371 . . . 414_ . . . ); C1_2: multi (0.00048_365 . . . 410_ . . . ); C1_3: (0.02_379 . . . 410_ . . . ); HypA: (0.0015_319 . . . 424_ . . . ); OrfB_IS605: (0.00072_214 . . . 340_ . . . ); OrfB_Zn_ribbon: (1.9e−24_351 . . . 420_ . . . ); PUF: (0.53_39 . . . 59_ . . . ); PUF: (3.1e−05_310 . . . 337_ . . . ); PUF: (6.7_424 . . . 441_ . . . ); Tnp_zf-ribbon_2: (2.4_302 . . . 330_ . . . ); Tnp_zf-ribbon_2: (3.7e−05_354 . . . 409_ . . . ) 188 65 Bacillus sp. C1_1: (0.002_368 . . . 411_ . . . ); C1_2: (0.00048_362 . . . 407_ . . . ); multi C1_3: (0.019_376 . . . 407_ . . . ); HypA: (0.0015_316 . . . 421_ . . . ); OrfB_IS605: (0.00071_211 . . . 337_ . . . ); OrfB_Zn_ribbon: (1.9e−24_348 . . . 417_ . . . ); PUF: (0.52_36 . . . 56_ . . . ); PUF: (3.1e−05_307 . . . 334_ . . . ); PUF: (6.7_421 . . . 438_ . . . ); Tnp_zf-ribbon_2: (2.4_299 . . . 327_ . . . ); Tnp_zf-ribbon_2: (3.7e−05_351 . . . 406_ . . . ) 189 66 Bacillus sp. C1_1: (0.0019_362 . . . 405_ . . . ); C1_2: (0.00053_355 . . . 400_ . . . ); multi C1_3: (0.019_369 . . . 400_ . . . ); C1_3: (5.7_364 . . . 379_ . . . ); CEBP_ZZ: (0.051_358 . . . 410_ . . . ); CEBP_ZZ: (1.1_283 . . . 324_ . . . ); OrfB_IS605: (0.0007_204 . . . 330_ . . . ); OrfB_Zn_ribbon: (3e−25_341 . . . 410_ . . . ); PUF: (0.51_29 . . . 49_ . . . ); PUF: (3.1e−05_300 . . . 327 . . . ); Tnp_zf-ribbon_2: (2.4_292 . . . 320_ . . . ); Tnp_zf-ribbon_2: (3.6e−05_344 . . . 399_ . . . ) 190 67 Bacillus sp. C1_1: (0.0018_369 . . . 411_ . . . ); C1_2: (0.00054_362 . . . 407_ . . . ); multi C1_3: (0.021_376 . . . 407_ . . . ); C1_3: (5.8_371 . . . 386_ . . . ); CEBP_ZZ: (0.053_365 . . . 416_ . . . ); CEBP_ZZ: (1.1_290 . . . 331_ . . . ); HypA: (0.0012_316 . . . 421_ . . . ); OrfB_IS605: (0.00071_211 . . . 337_ . . . ); OrfB_Zn_ribbon: (3.4e−25_348 . . . 417_ . . . ); PUF: (0.52_36 . . . 56_ . . . ); PUF: (3.1e−05_307 . . . 334_ . . . ); PUF: (6.7_421 . . . 438_ . . . ); Tnp_zf-ribbon_2: (2.4_299 . . . 327_ . . . ); Tnp_zf-ribbon_2: (3.6e−05_351 . . . 406_ . . . ) 191 68 Bacillus sp. C1_1: (0.0018_369 . . . 411_ . . . ); C1_2: (0.00054_362 . . . 407_ . . . ); multi C1_3: (0.021_376 . . . 407_ . . . ); C1_3: (5.8_371 . . . 386_ . . . ); CEBP_ZZ: (0.053_365 . . . 416_ . . . ); CEBP_ZZ: (1.1_290 . . . 331_ . . . ); HypA: (0.0012_316 . . . 421_ . . . ); OrfB_IS605: (0.00071_211 . . . 337_ . . . ); OrfB_Zn_ribbon: (3.4e−25_348 . . . 417_ . . . ); PUF: (0.46_36 . . . 56_ . . . ); PUF: (3.1e−05_307 . . . 334_ . . . ); PUF: (6.7_421 . . . 438_ . . . ); Tnp_zf-ribbon_2: (2.4_299 . . . 327_ . . . ); Tnp_zf-ribbon_2: (3.6e−05_351 . . . 406_ . . . ) 192 69 Bacillus sp. C1_1: (0.0017_362 . . . 404_ . . . ); C1_2: (0.00053_355 . . . 400_ . . . ); multi C1_3: (0.019_369 . . . 400_ . . . ); C1_3: (5.7_364 . . . 379_ . . . ); CEBP_ZZ: (0.052_358 . . . 409_ . . . ); CEBP_ZZ: (1.1_283 . . . 324_ . . . ); HypA: (0.0012_309 . . . 414_ . . . ); OrfB_IS605: (0.00069_204 . . . 330_ . . . ); OrfB_Zn_ribbon: (3.3e−25_341 . . . 410_ . . . ); PUF: (0.51_29 . . . 49_ . . . ); PUF: (3.1e−05_300 . . . 327_ . . . ); PUF: (6.6_414 . . . 431_ . . . ); Tnp_zf-ribbon_2: (2.4_292 . . . 320_ . . . ); Tnp_zf-ribbon_2: (3.6e−05_344 . . . 399_ . . . ) 193 70 Bacillus sp. C1_2: (0.0011_362 . . . 407_ . . . ); C1_3: (0.0092_376 . . . 407_ . . . ); multi DCAF15_WD40: (0.53_146 . . . 224_ . . . ); DCAF15_WD40: (1.6e−06_345 . . . 429_ . . . ); OrfB_IS605: (0.00066_211 . . . 337_ . . . ); OrfB_Zn_ribbon: (1.4e−24_348 . . . 417_ . . . ); PUF: (0.75_36 . . . 56_ . . . ); PUF: (3.1e−05_307 . . . 334_ . . . ); Tnp_zf-ribbon_2: (0.0086_376 . . . 406_ . . . ); Tnp_zf-ribbon_2: (1.2_351 . . . 383_ . . . ); Tnp_zf-ribbon_2: (2.4_299 . . . 327_ . . . ) 194 71 Bacillus sp. C1_1: (0.0011_369 . . . 411_ . . . ); C1_2: (0.00048_360 . . . 407_ . . . ); multi C1_3: (0.02_376 . . . 407_ . . . ); C1_3: (6_372 . . . 386_ . . . ); CEBP_ZZ: (0.048_365 . . . 416_ . . . ); CEBP_ZZ: (1.1_290 . . . 331_ . . . ); HypA: (0.0012_316 . . . 421_ . . . ); OrfB_IS605: (0.00093_211 . . . 337_ . . . ); OrfB_Zn_ribbon: (3.9e−25_348 . . . 417_ . . . ); PUF: (0.52_36 . . . 56_ . . . ); PUF: (3.6e−05_307 . . . 333_ . . . ); Salp15: (2.5_269 . . . 428_ . . . ); Tnp_zf-ribbon_2: (2_297 . . . 327_ . . . ); Tnp_zf-ribbon_2: (7.6e−05_376 . . . 406_ . . . ) 195 72 Bacillus C1_1: (0.0018_369 . . . 411_ . . . ); C1_2: (0.00051_361 . . . 407_ . . . ); thuringiensis C1_3: (0.021_376 . . . 407_ . . . ); C1_3: (5.8_371 . . . 386_ . . . ); CEBP_ZZ: (0.053_365 . . . 416_ . . . ); CEBP_ZZ: (1.1_290 . . . 331_ . . . ); HypA: (0.00089_315 . . . 421_ . . . ); OrfB_IS605: (0.00071_211 . . . 337_ . . . ); OrfB_Zn_ribbon: (3e−25_348 . . . 417_ . . . ); PUF: (0.52_36 . . . 56_ . . . ); PUF: (3.1e−05_307 . . . 334_ . . . ); PUF: (6.7_421 . . . 438_ . . . ); Tnp_zf-ribbon_2: (2.4_299 . . . 327_ . . . ); Tnp_zf-ribbon_2: (3.9e−05_351 . . . 406_ . . . ) 196 73 Bacillus sp. C1_1: (0.0018_369 . . . 411_ . . . ); C1_2: (0.00054_362 . . . 407_ . . . ); multi C1_3: (0.021_376 . . . 407_ . . . ); C1_3: (5.8_371 . . . 386_ . . . ); CEBP_ZZ: (0.053_365 . . . 416_ . . . ); CEBP_ZZ: (1.1_290 . . . 331_ . . . ) ;HypA: (0.0012_316 . . . 421_ . . . ); OrfB_IS605: (0.00071_211 . . . 337_ . . . ); OrfB_Zn_ribbon: (3.4e−25_348 . . . 417_ . . . ); PUF: (0.52_36 . . . 56_ . . . ); PUF: (3.1e−05_307 . . . 334_ . . . ); PUF: (6.7_421 . . . 438_ . . . ); Tnp_zf-ribbon_2: (2.4_299 . . . 327_ . . . ); Tnp_zf-ribbon_2: (3.6e−05_351 . . . 406_ . . . ) 197 74 Bacillus sp. C1_1: (0.0018_369 . . . 411_ . . . ); C1_2: (0.00054_362 . . . 407_ . . .); multi C1_3: (0.021_376 . . . 407_ . . . ); C1_3: (5.8_371 . . . 386_ . . . ); CEBP_ZZ: (0.052_365 . . . 416_ . . . ); CEBP_ZZ: (1.1_290 . . . 331_ . . . ); HypA: (0.0017_316 . . . 421_ . . . ); OrfB_IS605: (0.00071_211 . . . 337_ . . . ); OrfB_Zn_ribbon: (2.3e−25_348 . . . 417_ . . . ); PUF: (0.52_36 . . . 56_ . . . ); PUF: (3.1e−05_307 . . . 334_ . . . ); PUF: (6.7_421 . . . 438_ . . . ); Tnp_zf-ribbon_2: (2.4_299 . . . 327_ . . . ); Tnp_zf-ribbon_2: (3.6e−05_351 . . . 406_ . . . ) 198 75 Bacillus sp. C1_1: (0.00092_317 . . . 359_ . . . ); C1_2: (0.00041_309 . . . 355_ . . . ); multi C1_3: (0.017_324 . . . 355_ . . . ); C1_3: (5.6_320 . . . 333_ . . . ); CEBP_ZZ: (0.044_313 . . . 364_ . . . ); CEBP_ZZ: (0.94_238 . . . 279_ . . . ); HypA: (0.00094_262 . . . 369_ . . . ); OrfB_IS605: (0.0012_159 . . . 285_ . . . ); OrfB_Zn_ribbon: (1.4e−25_296 . . . 365_ . . . ); PUF: (3.1e−05_255 . . . 281_ . . . ); Salp15: (3.8_219 . . . 376_ . . . ); Tnp_zf-ribbon_2: (0.00028_324 . . . 354_ . . . ); Tnp_zf-ribbon_2: (1.1_299 . . . 331_ . . . ); Tnp_zf-ribbon_2: (1.8_245 . . . 275_ . . . ) 199 76 Bacillus sp. C1_1: (0.0011_369 . . . 411_ . . . ); C1_2: (0.00039_361 . . . 407_ . . . ); multi C1_3: (0.02_376 . . . 407_ . . . ); C1_3: (5.7_370 . . . 386_ . . . ); HypA: (0.00079_315 . . . 421_ . . . ); OrfB_IS605: (0.00071_211 . . . 337_ . . . ); OrfB_Zn_ribbon: (7.3e−25_348 . . . 417_ . . . ); PUF: (0.52_36 . . . 56_ . . . ); PUF: (3.1e−05_307 . . . 334_ . . . ); Salp15: (3.2_274 . . . 427_ . . . ); Tnp_zf-ribbon_2: (2.4_299 . . . 327_ . . . ); Tnp_zf-ribbon_2: (6.4e−06_351 . . . 406_ . . . ) 200 77 Bacillus sp. C1_1: (0.0018_369 . . . 411_ . . . ); C1_2: (0.00054_362 . . . 407_ . . . ); multi C1_3: (0.021_376 . . . 407_ . . . ); C1_3: (5.8_371 . . . 386_ . . . ); CEBP_ZZ: (0.052_365 . . . 416_ . . . ); CEBP_ZZ: (1.1_290 . . . 331_ . . . ) ; HypA: (0.0017_316 . . . 421_ . . . ); OrfB_IS605: (0.00041_211 . . . 337_ . . . ); OrfB_Zn_ribbon: (2.3e−25_348 . . . 417_ . . . ); PUF: (0.52_36 . . . 56_ . . . ); PUF: (3.1e−05_307 . . . 334_ . . . ); PUF: (6.7_421 . . . 438_ . . . ); Tnp_zf-ribbon_2: (2.4_299 . . . 327_ . . . ); Tnp_zf-ribbon_2: (3.6e−05_351 . . . 406_ . . . ) 201 78 Bacillus sp. C1_1: (0.00046_360 . . . 413_ . . . ); C1_2: (0.0009_358 . . . 407_ . . . ); multi HypA: (0.00096_314 . . . 421_ . . . ); Lar_restr_al1ev: (0.0052_365 . . . 421_ . . . ); Lar_restr_allev: (0.027_87 . . . 111_ . . . ); Lar_restr_allev: (8.6_303 . . . 339_ . . . ); OrfB_IS605: (0.00029_210 . . . 337_ . . . ); OrfB_Zn_ribbon: (3.3e−25_348 . . . 416_ . . . ); PUF: (1.3_36 . . . 56_ . . . ); PUF: (4.1e−05_307 . . . 333_ . . . ); Tnp_zf-ribbon_2: (1.2e−05_351 . . . 406_ . . . ); Tnp_zf-ribbon_2: (2.5_299 . . . 327_ . . . ) 202 79 Bacillus sp. C1_1: (0.0029_369 . . . 411_ . . . ); C1_2: (0.001_362 . . . 407_ . . . ); multi C1_3: (0.13_378 . . . 407_ . . . ); C1_3: (2.8_370 . . . 387_ . . . ); CEBP_ZZ: (0.053_365 . . . 416_ . . . ); CEBP_ZZ: (1.1_290 . . . 331_ . . . ); OrfB_IS605: (0.00081_211 . . . 337_ . . . ); OrfB_Zn_ribbon: (5.4e−24_348 . . . 417_ . . . ); PUF: (0.52_36 . . . 56_ . . . ); PUF: (3.1e−05_307 . . . 334_ . . . ); PUF: (6.7_421 . . . 438_ . . . ); Tnp_zf-ribbon_2: (0.0034_376 . . . 406_ . . . ); Tnp_zf-ribbon_2: (2.1_351 . . . 383_ . . . ); Tnp_zf-ribbon_2: (2.4_299 . . . 327_ . . . ) 203 80 Bacillus sp. C1_1: (0.0018_369 . . . 411_ . . . ); C1_2: (0.00054_362 . . . 407_ . . . ); multi C1_3: (0.021_376 . . . 407_ . . . ); C1_3: (5.8_371 . . . 386_ . . . ); CEBP_ZZ: (0.053_365 . . . 416_ . . . ); CEBP_ZZ: (1.1_290 . . . 331_ . . . ); HypA: (0.0012_316 . . . 421_ . . . ); OrfB_IS605: (0.00071_211 . . . 337_ . . . ); OrfB_Zn_ribbon: (3.4e−25_348 . . . 417_ . . . ); PUF: (0.75_36 . . . 56_ . . . ); PUF: (3.1e−05_307 . . . 334_ . . . ); PUF: (6.7_421 . . . 438_ . . . ); Tnp_zf-ribbon_2: (2.4_299 . . . 327_ . . . ); Tnp_zf-ribbon_2: (3.6e−05_351 . . . 406_ . . . ) 204 81 Bacillus sp. C1_1: (0.0029_369 . . . 411_ . . . ); C1_2: (0.001_362 . . . 407_ . . . ); multi C1_3: (0.13_378 . . . 407_ . . . ); C1_3: (2.8_370 . . . 387_ . . . ); CEBP_ZZ: (0.053_365 . . . 416_ . . . ); CEBP_ZZ: (1.1_290 . . . 331_ . . . ); OrfB_IS605: (0.00071_211 . . . 337_ . . . ); OrfB_Zn_ribbon: (5.4e−24_348 . . . 417_ . . . ); PUF: (0.52_36 . . . 56_ . . . ); PUF: (3.1e−05_307 . . . 334_ . . . ); PUF: (6.7_421 . . . 438_ . . . ); Tnp_zf-ribbon_2: (0.0034_376 . . . 406_ . . . ); Tnp_zf-ribbon_2: (2.1_351 . . . 383_ . . . ); Tnp_zf-ribbon_2: (2.4_299 . . . 327_ . . . ) 205 82 Bacillus sp. C1_2: (0.0011_355 . . . 400_ . . . ); C1_3: (0.0091_369 . . . 400_ . . . ); multi DCAF15_WD40: (0.91_140 . . . 214_ . . . ); DCAF15_WD40: (4.2e−06_338 . . . 421_ . . . ); OrfB_IS605: (0.0008_204 . . . 330_ . . . ); OrfB_Zn_ribbon: (1.4e−24_341 . . . 410_ . . . ); PUF: (0.74_29 . . . 49_ . . . ); PUF: (3.1e−05_300 . . . 327_ . . . ); Tnp_zf-ribbon_2: (0.0091_369 . . . 399_ . . . ); Tnp_zf-ribbon_2: (0.79_344 . . . 378_ . . . ); Tnp_zf-ribbon_2: (2.4_292 . . . 320_ . . . ) 206 83 Bacillus sp. C1_1: (0.0018_369 . . . 411_ . . . ); C1_2: (0.00054_362 . . . 407_ . . . ); C1_3: multi (0.021_376 . . . 407_ . . . ); C1_3: (5.8_371 . . . 386_ . . . ); CEBP_ZZ: (0.053_365 . . . 416_ . . . ); CEBP_ZZ: (0.92_290 . . . 334_ . . . ); HypA: (0.0012_316 . . . 421_ . . . ); OrfB_IS605: (0.0013_211 . . . 337_ . . . ); OrfB_Zn_ribbon: (3.4e−25_348 . . . 417_ . . . ); PUF: (0.00031_307 . . . 333_ . . . ); PUF: (0.52_36 . . . 56_ . . . ); PUF: (6.7_421 . . . 438_ . . . ); Tnp_zf-ribbon_2: (2.4_299 . . . 327_ . . . ); Tnp_zf-ribbon_2: (3.6e−05_351 . . . 406_ . . . ) 207 84 Bacillus sp. C1_1: (0.0011_362 . . . 404_ . . . ); C1_2: (0.00047_354 . . . 400_ . . . ); multi C1_3: (0.02_369 . . . 400_ . . . ); C1_3: (6_365 . . . 379_ . . . ); CEBP_ZZ: (0.047_358 . . . 409_ . . . ); CEBP_ZZ: (1.1_283 . . . 324_ . . . ); HypA: (0.0011_308 . . . 414_ . . . ); OrfB_IS605: (0.00065_204 . . . 330_ . . . ); OrfB_Zn_ribbon: (1.6e−25_341 . . . 410_ . . . ); PUF: (0.51_29 . . . 49_ . . . ); PUF: (3.5e−05_300 . . . 326_ . . . ); Salp15: (3.6_262 . . . 418_ . . . ); Tnp_zf-ribbon_2: (2.1_290 . . . 320_ . . . ); Tnp_zf-ribbon_2: (8.7e−06_344 . . . 399_ . . . ) 208 85 Bacillus sp. C1_1: (0.0011_369 . . . 411_ . . . ); C1_2: (0.00048_361 . . . 407_ . . . ); multi C1_3: (0.02_376 . . . 407_ . . . ); C1_3: (6_372 . . . 386_ . . . ); CEBP_ZZ: (0.048_365 . . . 416_ . . . ); CEBP_ZZ: (1.1_290 . . . 331_ . . . ) ; HypA: (0.0012_315 . . . 421_ . . . ); OrfB_IS605: (0.00067_211 . . . 337_ . . . ); OrfB_Zn_ribbon: (1.6e−25_348 . . . 417_ . . . ); PUF: (0.52_36 . . . 56_ . . . ); PUF: (3.6e−05_307 . . . 333_ . . . ); Salp15: (3.6_266 . . . 427_ . . . ); Tnp_zf-ribbon_2: (2.2_297 . . . 327_ . . . ); Tnp_zf-ribbon_2: (8.9e−06_351 . . . 406_ . . . ) 209 86 Bacillus sp. C1_1: (0.0011_369 . . . 411_ . . . ); C1_2: (0.00048_361 . . . 407_ . . . ); multi C1_3: (0.02_376 . . . 407_ . . . ); C1_3: (6_372 . . . 386_ . . . ); CEBP_ZZ: (0.048_365 . . . 416_ . . . ); CEBP_ZZ: (1.1_290 . . . 331_ . . . ); HypA: (0.0012_315 . . . 421_ . . . ); OrfB_IS605: (0.00067_211 . . . 337_ . . . ); OrfB_Zn_ribbon: (1.6e−25_348 . . . 417_ . . . ); PUF: (0.52_36 . . . 56_ . . . ); PUF: (3.6e−05_307 . . . 333_ . . . ); Salp15: (3.7_269 . . . 425_ . . . ); Tnp_zf-ribbon_2: (2.2_297 . . . 327_ . . . ); Tnp_zf-ribbon_2: (8.9e−06_351 . . . 406_ . . . ) 210 87 Bacillus sp. C1_1: (0.0029_369 . . . 411_ . . . ); C1_2: (0.001_362 . . . 407_ . . . ); multi C1_3: (0.13_378 . . . 407_ . . . ); C1_3: (2.8_370 . . . 387_ . . . ); CEBP_ZZ: (0.053_365 . . . 416_ . . . ); CEBP_ZZ: (1.1_290 . . . 331_ . . . ); OrfB_IS605: (0.00071_211 . . . 337_ . . . ); OrfB_Zn_ribbon: (5.4e−24_348 . . . 417_ . . . ); PUF: (0.52_36 . . . 56_ . . . ); PUF: (3.1e−05_307 . . . 334_ . . . ); PUF: (6.7_421 . . . 438_ . . . ); Tnp_zf-ribbon_2: (0.0034_376 . . . 406_ . . . ); Tnp_zf-ribbon_2: (2.1_351 . . . 383_ . . . ); Tnp_zf-ribbon_2: (2.4_299 . . . 327_ . . . ) 211 88 Bacillus sp. C1_2: (0.0016_362 . . . 407_ . . . ); CEBP_ZZ: (0.06_365 . . . 415_ . . . ); multi CEBP_ZZ: (1.1_289 . . . 331_ . . . ); DUF5118: (1.2e−05_182 . . . 219_ . . . ); HypA: (0.00072_314 . . . 421_ . . . ); Lar_restr_allev: (0.015_368 . . . 420_ . . . ); Lar_restr_allev: (0.027_87 . . . 111_ . . . ); Lar_restr_allev: (8.9_304 . . . 339_ . . . ); OrfB_IS605: (0.00012_210 . . . 337_ . . . ); OrfB_Zn_ribbon: (1.8e−25_348 . . . 416_ . . . ); PUF: (0.52_36 . . . 56_ . . . ); PUF: (3.1e−05_307 . . . 334_ . . . ); Tnp_zf-ribbon_2: (1.8_276 . . . 327_ . . . ); Tnp_zf-ribbon_2: (7e−05_351 . . . 406_ . . . ) 212 89 Bacillus sp. C1_1: (0.0011_369 . . . 411_ . . . ); C1_2: (0.00048_361 . . . 407_ . . . ); multi C1_3: (0.02_376 . . . 407_ . . . ); C1_3: (6_372 . . . 386_ . . . ); CEBP_ZZ: (0.048_365 . . . 416_ . . . ); CEBP_ZZ: (1.1_290 . . . 331_ . . . ); HypA: (0.0012_315 . . . 421_ . . . ); OrfB_IS605: (0.00068_211 . . . 337_ . . . ); OrfB_Zn_ribbon: (1.6e−25_348 . . . 417_ . . . ); PUF: (0.52_36 . . . 56_ . . . ); PUF: (3.6e−05_307 . . . 333_ . . . ); Salp15: (4.4_268 . . . 425_ . . . ); Tnp_zf-ribbon_2: (2.2_297 . . . 327_ . . . ); Tnp_zf-ribbon_2: (8.9e−06_351 . . . 406_ . . . ) 213 90 Bacillus sp. C1_1: (0.0029_369 . . . 411_ . . . ); C1_2: (0.001_362 . . . 407_ . . . ); multi C1_3: (0.13_378 . . . 407_ . . . ); C1_3: (2.8_370 . . . 387_ . . . ); CEBP_ZZ: (0.053_365 . . . 416_ . . . ); CEBP_ZZ: (1.1_290 . . . 331_ . . . ); OrfB_IS605: (0.00071_211 . . . 337_ . . . ); OrfB_Zn_ribbon: (5.4e−24_348 . . . 417_ . . . ); PUF: (0.52_36 . . . 56_ . . . ); PUF: (3.1e−05_307 . . . 334_ . . . ); PUF: (6.7_421 . . . 438_ . . . ); Tnp_zf-ribbon_2: (0.0034_376 . . . 406_ . . . ); Tnp_zf-ribbon_2: (2.1_351 . . . 383_ . . . ); Tnp_zf-ribbon_2: (2.4_299 . . . 327_ . . . ) 214 91 Bacillus sp. C1_2: (0.0013_354 . . . 400_ . . . ); C1_3: (0.014_369 . . . 400_ . . . ); multi OrfB_IS605: (0.00069_204 . . . 330_ . . . ); OrfB_Zn_ribbon: (8.7e−25_341 . . . 410_ . . . ); PUF: (0.51_29 . . . 49_ . . . ); PUF: (6.8e−05_300 . . . 326_ . . . ); Tnp_zf-ribbon_2: (0.049_369 . . . 399_ . . . ); Tnp_zf-ribbon_2: (2.2_344 . . . 376_ . . . ) 215 92 Bacillus sp. C1_1: (0.0028_369 . . . 411_ . . . ); C1_2: (0.00058_362 . . . 407_ . . . ); multi C1_3: (0.082_376 . . . 407_ . . . ); C1_3: (3.1_371 . . . 387_ . . . ); CEBP_ZZ: (0.054_365 . . . 416_ . . . ); CEBP_ZZ: (1.1_290 . . . 331_ . . . ); OrfB_IS605: (0.00081_211 . . . 337_ . . . ); OrfB_Zn_ribbon: (6.7e−24_348 . . . 417_ . . . ); PUF: (0.52_36 . . . 56_ . . . ); PUF: (3.1e−05_307 . . . 334_ . . . ); PUF: (6.7_421 . . . 438_ . . . ); Tnp_zf-ribbon_2: (0.00021_376 . . . 406_ . . . ); Tnp_zf-ribbon_2: (2.4_299 . . . 327_ . . . ) 216 93 Bacillus sp. C1_1: (0.0029_369 . . . 411_ . . . ); C1_2: (0.001_362 . . . 407_ . . . ); multi C1_3: (0.13_378 . . . 407_ . . . ); C1_3: (2.8_370 . . . 387_ . . . ); CEBP_ZZ: (0.053_365 . . . 416_ . . . ); CEBP_ZZ: (1.1_290 . . . 331_ . . . ); OrfB_IS605: (0.00071_211 . . . 337_ . . . ); OrfB_Zn_ribbon: (5.4e−24_348 . . . 417_ . . . ); PUF: (0.52_36 . . . 56_ . . . ); PUF: (3.1e−05_307 . . . 334_ . . . ); PUF: (6.7_421 . . . 438_ . . . ); Tnp_zf-ribbon_2: (0.0034_376 . . . 406_ . . . ); Tnp_zf-ribbon_2: (2.1_351 . . . 383_ . . . ); Tnp_zf-ribbon_2: (2.4_299 . . . 327_ . . . ) 217 94 Bacillus sp. C1_1: (0.014_372 . . . 413_ . . . ); C1_2: (0.0062_366 . . . 409_ . . . ); multi C1_3: (0.019_378 . . . 409_ . . . ); DUF5118: (3.6e−05_184 . . . 218_ . . . ); HypA: (0.0025_317 . . . 423_ . . . ); OrfB_IS605: (3.7e−05_211 . . . 339_ . . . ); OrfB_Zn_ribbon: (6.4e−25_350 . . . 419_ . . . ); PUF: (0.46_38 . . . 58_ . . . ); PUF: (3.6e−05_309 . . . 335_ . . . ); Tnp_zf-ribbon_2: (0.00017_353 . . . 408_ . . . ); Tnp_zf-ribbon_2: (9.3_278 . . . 329_ . . . ) 218 95 Bacillus sp. C1_2: (0.0016_362 . . . 407_ . . . ); HypA: (0.0016_316 . . . 421_ . . . ); multi OrfB_IS605: (0.003_211 . . . 337_ . . . ); OrfB_Zn_ribbon: (1.5e−25_348 . . . 417_ . . . ); PUF: (0.52_36 . . . 56_ . . . ); PUF: (3.1e−05_307 . . . 334_ . . . ); PUF: (6.7_421 . . . 438_ . . . ); Tnp_zf-ribbon_2: (0.00012_351 . . . 406_ . . . ); Tnp_zf-ribbon_2: (2.4_299 . . . 327_ . . . ); Zn_Tnp_IS1595: (0.00084_372 . . . 403_ . . . ) 219 96 Bacillus sp. C1_1: (0.0019_370 . . . 413_ . . . ); C1_2: (0.00055_364 . . . 409_ . . . ); multi C1_3: (0.021_378 . . . 409_ . . . ); C1_3: (5.8_373 . . . 388_ . . . ); CEBP_ZZ: (0.053_367 . . . 418_ . . . ); CEBP_ZZ: (1.1_291 . . . 333_ . . . ); DUF5118: (3.6e−05_184 . . . 218_ . . . ); HypA: (0.0012_317 . . . 423_ . . . ); OrfB_IS605: (0.00024_212 . . . 339_ . . . ); OrfB_Zn_ribbon: (3.9e−25_350 . . . 419_ . . . ); PUF: (1.7_38 . . . 58_ . . . ); PUF: (3.6e−05_309 . . . 335_ . . . ); Tnp_zf-ribbon_2: (2_278 . . . 329_ . . . ); Tnp_zf-ribbon_2: (3.6e−05_353 . . . 408_ . . . ) 220 97 Bacillus sp. C1_1: (0.00066_360 . . . 413_ . . . ); C1_2: (0.0015_358 . . . 407_ . . . ); multi HypA: (0.0012_313 . . . 421_ . . . ); Lar_restr_allev: (0.0081_365 . . . 421_ . . . ); Lar_restr_allev: (0.027_87 . . . 111_ . . . ); Lar_restr_allev: (8.6_303 . . . 339_ . . . ); OrfB_IS605: (0.00018_210 . . . 337_ . . . ); OrfB_Zn_ribbon: (2.5e−25_348 . . . 416_ . . . ); PUF: (1.3_36 . . . 56_ . . . ); PUF: (4.1e−05_307 . . . 333_ . . . ); Tnp_zf-ribbon_2: (2.5_298 . . . 327_ . . . ); Tnp_zf-ribbon_2: (5e−05_351 . . . 406_ . . . ) 221 98 Bacillus sp. CDC50: (1.4e−05_97 . . . 280_ . . . ); HTH_7: (1.3e−07_287 . . . 321_ . . . ); multi HTH_Tnp_ISL3: (1.7e−05_296 . . . 328_ . . . ); PDDEXK_2: (1.3e−84_40 . . . 278_ . . . ) 222 99 Bacillus sp. HTH_15: (2e−05_299 . . . 331_1); PDDEXK_2: multi (7.2e−84_48 . . . 286_ . . . ) 223 100 Bacillus DUF2802: (4.1e−05_232 . . . 328_ . . . ); PDDEXK_2: thuringiensis (7.2e−84_48 . . . 286_ . . . ) 224 101 Bacillus Atg14: (0.054_322 . . . 399_ . . . ); Atg14: (1.3e−05_5 . . . 247_ . . . ); megaterium DUF1311: (0.042_14 . . . 160_ . . . ); DUF1311: (0.31_322 . . . 373_ . . . ); DUF1896: (4.4e−07_76 . . . 197_ . . . ); MADF_DNA_bdg: (0.00064_66 . . . 146_ . . . ); MADF_DNA_bdg: (0.13_332 . . . 399_ . . . ); MADF_DNA_bdg: (0.17_321 . . . 362_ . . . ); OmpH: (0.00021_51 . . . 178_ . . . ); OmpH: (0.091_315 . . . 388_ . . . ); OrfB_IS605: (5.1_92 . . . 158_ . . . ); OrfB_IS605: (6.9e−07_275 . . . 401_ . . . ); OrfB_Zn_ribbon: (7.1e−22_413 . . . 487_ . . . ); Seryl_tRNA_N: (0.00081_37 . . . 151_ . . . ); Seryl_tRNA_N: (0.11_321 . . . 382_ . . . ); Seryl_tRNA_N: (0.51_394 . . . 445_ . . . ); zf-tcix: (1.8e−05_441 . . . 476_ . . . ) 225 102 Bacillus sp. Amidase: (0.00058_9 . . . 120_ . . . ); Amidase: (0.21_297 . . . 481_ . . . ); multi DUF2098: (0.021_22 . . . 119_ . . . ); DUF2098: (0.06_443 . . . 495_ . . . ); DUF2385: (0.00041_31 . . . 134_ . . . ); DUF2385: (0.91_290 . . . 314_ . . . ); OmpH: (0.00027_19 . . . 135_ . . . ); OmpH: (0.029_292 . . . 366_ . . . ); OmpH: (0.38_387 . . . 485_ . . . ); OrfB_IS605: (6.9e−06_247 . . . 369_ . . . ); OrfB_Zn_ribbon: (4e−22_383 . . . 452_ . . . ) 226 103 Bacillus sp. Amidase: (0.0012_9 . . . 120_ . . . ); Amidase: (0.14_327 . . . 490_ . . . ); multi NuA4: (0.32_298 . . . 316_ . . . ); NuA4: (0.64_445 . . . 487_ . . . ); NuA4: (7e−06_64 . . . 159_ . . . ); OmpH: (0.00025_18 . . . 133_ . . . ); OmpH: (0.075_292 . . . 366_ . . . ); OmpH: (0.23_415 . . . 487_ . . . ); OrfB_IS605: (8.1e−06_247 . . . 369_ . . . ); OrfB_Zn_ribbon: (2.7e−23_383 . . . 452_ . . . ); Seryl_tRNA_N: (0.0014_20 . . . 118_ . . . ); Seryl_tRNA_N: (0.096_439 . . . 492_ . . . ); Seryl_tRNA_N: (0.15_292 . . . 346_ . . . ); Zn_Tnp_IS1595: (0.00011_406 . . . 438_ . . . ) 227 104 Bacillus sp. NuA4: (0.32_298 . . . 316_ . . . ); NuA4: (0.64_445 . . . 487_ . . . ); NuA4: multi (1.4e−05_64 . . . 159_ . . . ); OmpH: (0.00038_18 . . . 133_ . . . ); OmpH: (0.075_292 . . . 366_ . . . ); OmpH: (0.23_415 . . . 487_ . . . ); OrfB_IS605: (8.1e−06_247 . . . 369_ . . . ); OrfB_Zn_ribbon: (2.7e−23_383 . . . 452_ . . . ); Seryl_tRNA_N: (0.00073_20 . . . 119_ . . . ); Seryl_tRNA_N: (0.096_439 . . . 492_ . . . ); Seryl_tRNA_N: (0.15_292 . . . 346_ . . . ); Zn_Tnp_IS1595: (0.00011_406 . . . 438_ . . . ) 228 105 Paenibacillus Transposase_31: (6.9e−37_13 . . . 224_ . . . ); Yae1_N: thiaminolyticus (7.7e−05_292 . . . 319_ . . . ); Yae1_N: (9.6e−06_267 . . . 296_ . . . ) (multi) 229 106 Paenibacillus Transposase_31: (6.7e−37_13 . . . 224_ . . . ); Yae1_N: thiaminolyticus (1.2e−06_267 . . . 307_ . . . ); Yae1_N: (5e−05_286 . . . 317_ . . . ) (multi) 230 107 Paenibacillus Transposase_31: (8.1e−37_13 . . . 224_ . . . ); Yae1_N: sp. (7.8e−05_263 . . . 306_ . . . ) multi 231 108 Paenibacillus Transposase_31: (3.8e−36_13 . . . 224_ . . . ); Yae1_N: lentimorbus (4.6e−06_267 . . . 291_ . . . ); Yae1_N: (6.8e−06_284 . . . 319_ . . . ) (multi) 232 109 Paenibacillus Transposase_31: (1.2e−35_13 . . . 224_ . . . ); Yae1_N: thiaminolyticus (2.2e−05_267 . . . 295_ . . . ) (multi) 233 110 Paenibacillus Transposase_31: (4.4e−37_13 . . . 224_ . . . ); Yae1_N: thiaminolyticus (6.2e−06_263 . . . 309_ . . . ) (multi) 234 111 Paenibacillus Transposase_31: (6.7e−37_13 . . . 224_ . . . ); Yae1_N: thiaminolyticus (1.4e−06_288 . . . 315_ . . . ); Yae1_N: (1.8e−05_267 . . . 291_ . . . ) (multi) 235 112 Paenibacillus Transposase_31: (9.6e−37_13 . . . 224_ . . . ); Yae1_N: terrae (1.2e−05_267 . . . 292_ . . . ); Yae1_N: (1.4e−06_290 . . . 319_ . . . ) 236 113 Paenibacillus Transposase_31: (9.1e−37_13 . . . 224_ . . . ) thiaminolyticus (multi) 237 114 Paenibacillus DEDD_Tnp_IS110: (2.3e−43_23 . . . 183_ . . . ); Transposase_20: thiaminolyticus (5.8e−26_290 . . . 376_ . . . ) (multi) 238 115 Bacillus sp. AAA_11: (0.0012_3 . . . 147_ . . . ); AAA_11: multi (0.042_295 . . . 477_ . . . ); DUF2526: (0.25_443 . . . 476_ . . . ); DUF2526: (0.91_361 . . . 390_ . . . ); DUF2526: (6e−05_2 . . . 64_ . . . ); DUF4407: (0.00022_1 . . . 186_[.); HIPIP: (0.00015_387 . . . 440_ . . . ); HIPIP: (0.36_446 . . . 473_ . . . ); OrfB_Zn_ribbon: (1e−24_383 . . . 452_ . . . ); PRP1_N: (0.00042_20 . . . 160_ . . . ); PRP1_N: (0.19_292 . . . 344_ . . . ) 239 116 Bacillus sp. DUF106: (0.0022_43 . . . 162_ . . . ); DUF106: (0.017_279 . . . 370_ . . . ); multi DUF16: (0.0066_14 . . . 145_ . . . ); DUF16: (0.011_439 . . . 473_ . . . ); DUF16: (0.017_132 . . . 178_ . . . ); DUF16: (1_203 . . . 234_ . . . ); DUF4337: (0.0016_55 . . . 140_ . . . ); DUF4337: (0.28_349 . . . 397_ . . . ); DUF632: (2.6e−05_11 . . . 149_ . . . ); NPV_P10: (0.0013_56 . . . 122_ . . . ); NPV_P10: (0.039_239 . . . 300_ . . . ); NPV_P10: (0.15_108 . . . 155_ . . . ); OrfB_IS605: (1.3e−05_249 . . . 370_ . . . ); OrfB_Zn_ribbon: (8.3e−24_384 . . . 453_ . . . ); zf-AD: (0.069_321 . . . 363_ . . . ); zf-AD: (0.17_289 . . . 312_ . . . ); zf-AD: (2.2e−05_386 . . . 460_ . . . ); Zn_Tnp_IS1595: (0.00027_407 . . . 439_ . . . ) 240 117 Streptomyces DEDD_Tnp_IS110: (0.57_212 . . . 287_ . . . ); DEDD_Tnp_IS110: sp. (1.1_324 . . . 369_ . . . ); DEDD_Tnp_IS110: (7.9e−50_6 . . . 160_ . . . ); multi ROK: (0.0038_177 . . . 264_ . . . ); ROK: (0.16_79 . . . 112_ . . . ); ROK: (4.5e−05_5 . . . 55_ . . . ); Transposase_20: (0.34_76 . . . 121_ . . . ); Transposase_20: (1.4e−23_265 . . . 352_ . . . ) 241 118 Bacillus sp. Phage_integrase: (0.41_86 . . . 140_ . . . ); Phage_integrase: multi (1.2e−34_172 . . . 353_ . . . ); Phage_int_SAM_1: (0.75_143 . . . 200_ . . . ); Phage_int_SAM_1: (1.5e−11_27 . . . 122_ . . . ); Phage_int_SAM_4: (0.14_88 . . . 160_ . . . ); Phage_int_SAM_4: (1.5e−07_28 . . . 122_ . . . ) 242 119 Bacillus sp. 4HB_MCP_1: (0.017_111 . . . 207_ . . . ); 4HB_MCP_1: multi (3.2e−06_492 . . . 559_ . . . ); DDE_Tnp_Tn3: (9.8e−154_597 . . . 983_ . . . ); DUF4158: (3e−34_1 . . . 167_[.); DUF4337: (0.00016_282 . . . 360_ . . . ); DUF4337: (0.017_181 . . . 288_ . . . ); DUF4337: (0.79_378 . . . 432_ . . . ); TPR_21: (1.4e−06_154 . . . 283_ . . . ); UPF0054: (0.28_270 . . . 350_ . . . ); UPF0054: (4e−06_497 . . . 600_ . . . ) 243 120 Bacillus sp. HypA: (0.00065_358 . . . 462_ . . . ); OrfB_IS605: multi (1.9e−06_259 . . . 384_ . . . ); OrfB_IS605: (2.1_54 . . . 146_ . . . ); OrfB_Zn_ribbon: (6.9e−24_397 . . . 466_ . . . ) 244 121 Bacillus sp. HypA: (0.00061_356 . . . 462_ . . . ); OrfB_IS605: (1.2_52 . . . 146_ . . . ); multi OrfB_IS605: (2.8e−07_259 . . . 384_ . . . ); OrfB_Zn_ribbon: (6.9e−24_397 . . . 466_ . . . ) 245 122 Bacillus sp. Bap31: (0.00011_40 . . . 129_ . . . ); Bap31: (0.054_303 . . . 372_ . . . ); multi Coat_F: (0.00032_119 . . . 165_ . . . ); Coat_F: (0.0075_55 . . . 79_ . . . ); Coat_F: (0.13_347 . . . 362_ . . . ); Coat_F: (0.23_92 . . . 121_ . . . ); DUF1548: (0.025_361 . . . 427_ . . . ); DUF1548: (0.38_337 . . . 372_ . . . ); DUF1548: (4.5e−05_27 . . . 120_ . . . ); HypA: (0.00023_349 . . . 463_ . . . ); IncA: (0.00029_44 . . . 154_ . . . ); IncA: (0.08_303 . . . 398_ . . . ); OrfB_IS605: (8.1e−07_253 . . . 384_ . . . ); OrfB_Zn_ribbon: (3.9e−26_397 . . . 466_ . . . ); TF_Zn_Ribbon: (2.6e−05_425 . . . 462_ . . . ) 246 123 Lysinibacillus ERp29: (0.079_480 . . . 542_ . . . ); ERp29: (0.15_552 . . . 603_ . . . ); sp. ERp29: (1.5e−05_364 . . . 442_ . . . ); HTH_24: (6.9e−06_385 . . . 410_ . . . ); multi HTH_29: (0.55_242 . . . 265_ . . . ); HTH_29: (2.1e−05_377 . . . 411_ . . . ); HTH_38: (0.39_420 . . . 434_ . . . ); HTH_38: (0.57_10 . . . 25_ . . . ); HTH_38: (7.4e−07_377 . . . 411_ . . . ); HTH_Tnp_ISL3: (4e−05_379 . . . 412_ . . . ); Sigma70_r4: (2.5e−05_380 . . . 413_ . . . ); TniQ: (0.12_355 . . . 448_ . . . ); TniQ: (1.3e−16_3 . . . 155_ . . . ); TnsD: (1.1e−61_194 . . . 551_ . . . ) 275 604 Bacillus sp. Caskin-Pro-rich: (1.2e−05_246 . . . 329_ . . . ); DDE_Tnp_1: multi (6.7e−52_118 . . . 385_ . . . ); DUF2489: (0.17_281 . . . 312_ . . . ); DUF2489: (2.5e−06_382 . . . 469_ . . . ) 276 605 Streptomyces DDE_Tnp_1: (0.085_63 . . . 101_ . . . ); DDE_Tnp_1: sp. (1.4e−15_102 . . . 260_ . . . ); DDE_Tnp_1_2: (3.2e−16_182 . . . 262_ . . . ); multi DUF4096: (2.2e−31_11 . . . 92_ . . . ) 277 606 Bacillus sp. C1_1: (0.0028_362 . . . 404_ . . . ); C1_2: (0.001_355 . . . 400_ . . . ); multi C1_3: (0.13_371 . . . 400_ . . . ); C1_3: (2.8_363 . . . 380_ . . . ); CEBP_ZZ: (0.052_358 . . . 409_ . . . ); CEBP_ZZ: (1.1_283 . . . 324_ . . . ); OrfB_IS605: (0.00069_204 . . . 330_ . . . ); OrfB_Zn_ribbon: (5.3e−24_341 . . . 410_ . . . ); PUF: (0.51_29 . . . 49_ . . . ); PUF: (3.1e−05_300 . . . 327_ . . . ); PUF: (6.6_414 . . . 431_ . . . ); Tnp_zf-ribbon_2: (0.0034_369 . . . 399 . . . ); Tnp_zf-ribbon_2: (1.7_344 . . . 377_ . . . ); Tnp_zf-ribbon_2: (2.4_292 . . . 320_ . . . ) 278 612 Bacillus sp. C1_1: (0.0029_372 . . . 414_ . . . ); C1_2: (0.0011_365 . . . 410_ . . . ); multi C1_3: (0.13_381 . . . 410_ . . . ); C1_3: (2.8_373 . . . 390_ . . . ); CEBP_ZZ: (0.053_368 . . . 419_ . . . ); CEBP_ZZ: (1.1_293 . . . 334_ . . . ); OrfB_IS605: (0.00072_214 . . . 340_ . . . ); OrfB_Zn_ribbon: (5.4e−24_351 . . . 420_ . . . ); PUF: (0.53_39 . . . 59_ . . . ); PUF: (3.1e−05_310 . . . 337_ . . . ); PUF: (6.7_424 . . . 441_ . . . ); Tnp_zf-ribbon_2: (0.0035_379 . . . 409_ . . . ); Tnp_zf-ribbon_2: (2.1_354 . . . 386_ . . . ); Tnp_zf-ribbon_2: (2.4_302 . . . 330_ . . . ) 279 613 Bacillus sp. C1_1: (0.00059_189 . . . 232_ . . . ); C1_2: (0.00024_181 . . . 227_ . . . ); multi C1_3: (0.012_196 . . . 227_ . . . ); C1_3: (3.6_190 . . . 205_ . . . ); CEBP_ZZ: (0.027_185 . . . 236_ . . . ); CEBP_ZZ: (0.54_109 . . . 152_ . . . ); HypA: (0.00043_131 . . . 241_ . . . ); OrfB_IS605: (0.00053_31 . . . 157_ . . . ); OrfB_Zn_ribbon: (7.1e−26_168 . . . 237_ . . . ); PUF: (1.9e−05_127 . . . 153_ . . . ); Salp15: (0.092_93 . . . 182_ . . . ); Salp15: (0.15_172 . . . 246_ . . . ); Tnp_zf-ribbon_2: (0.00019_196 . . . 226_ . . . ); Tnp_zf-ribbon_2: (0.6_171 . . . 204_ . . . ); Tnp_zf-ribbon_2: (1.1_117 . . . 147_ . . . ) 280 614 Bacillus sp. C1_1: (0.0018_369 . . . 411_ . . . ); C1_2: (0.00054_362 . . . 407_ . . . ); multi C1_3: (0.021_376 . . . 407_ . . . ); C1_3: (5.8_371 . . . 386_ . . . ); CEBP_ZZ: (0.053_365 . . . 416_ . . . ); CEBP_ZZ: (1.1_290 . . . 331_ . . . ); HypA: (0.0012_316 . . . 421_ . . . ); OrfB_IS605: (0.00071_211 . . . 337_ . . . ); OrfB_Zn_ribbon: (3.4e−25_348 . . . 417_ . . . ); PUF: (0.52_36 . . . 56_ . . . ); PUF: (3.1e−05_307 . . . 334_ . . . ); PUF: (6.7_421 . . . 438_ . . . ); Tnp_zf-ribbon_2: (2.4_299 . . . 327_ . . . ); Tnp_zf-ribbon_2: (3.6e−05_351 . . . 406_ . . . ) 281 621 Bacillus sp. C1_1: (0.00023_18 . . . 63_ . . . ); C1_2: (0.00066_14 . . . 57_ . . . ); multi C1_3: (0.0015_35 . . . 57_ . . . ); C1_3: (0.19_17 . . . 37_ . . . ); DUF2387: (0.003_7 . . . 69_ . . . ); DUF2387: (0.02_25 . . . 100_.]); HypA: (0.00028_3 . . . 71_ . . . ); OrfB_Zn_ribbon: (2.2e−25_1 . . . 67_[.); Tnp_zf-ribbon_2: (0.0064_26 . . . 56_ . . . ); Tnp_zf-ribbon_2: (0.11_1 . . . 35_[.); zf-C2H2_11: (0.0031_23 . . . 34_ . . . ); zf-C2H2_11: (0.0058_41 . . . 53_ . . . ); zf-Mss51: (0.024_4 . . . 63_ . . . ); zf-Mss51: (5_78 . . . 100_.]) 282 622 Bacillus sp. C1_2: (0.0011_355 . . . 400_ . . . ); C1_3: (0.0091_369 . . . 400_ . . . ); multi DCAF15_WD40: (0.52_139 . . . 217_ . . . ); DCAF15_WD40: (1.6e−06_338 . . . 422_ . . . ); OrfB_IS605: (0.00064_204 . . . 330_ . . . ); OrfB_Zn_ribbon: (1.4e−24_341 . . . 410_ . . . ); PUF: (0.74_29 . . . 49_ . . . ); PUF: (3.1e−05_300 . . . 327_ . . . ); Tnp_zf-ribbon_2: (0.0091_369 . . . 399_ . . . ); Tnp_zf-ribbon_2: (0.79_344 . . . 378_ . . . ); Tnp_zf-ribbon_2: (2.4_292 . . . 320_ . . . ) 283 623 Bacillus sp. C1_1: (0.0018_369 . . . 411_ . . . ); C1_2: (0.00054_362 . . . 407_ . . . ); multi C1_3: (0.021_376 . . . 407_ . . . ); C1_3: (5.8_371 . . . 386_ . . . ); CEBP_ZZ: (0.053_365 . . . 416_ . . . ); CEBP_ZZ: (0.085_290 . . . 332_ . . . ); HypA: (0.00085_313 . . . 421_ . . . ); OrfB_IS605: (0.0014_215 . . . 337_ . . . );. OrfB_Zn_ribbon: (34e−25_348 . . . 417_ . . . ); PUF: (0.52_36 . . . 56_ . . . ); PUF: (1.8e−05_307 . . . 334_ . . . ); PUF: (6.7_421 . . . 438_ . . . ); Tnp_zf-ribbon_2: (2.5_299 . . . 327_ . . . ); Tnp_zf-ribbon_2: (3.6e−05_351 . . . 406_ . . . ) 284 624 Paenibacillus FoP_duplication: (2.2e−06_124 . . . 181_ . . . ); Transposase_31: thiaminolyticus (2.4e−09_1 . . . 88_[.); Uso1_p115_head: (1.1e−05_10 . . . 132_ . . . ); (multi) Yae1_N: (9.5e−06_127 . . . 168_ . . .) 285 625 Paenibacillus Transposase_31: (5.6e−20_1 . . . 129_[.); Yae1_N: lentimorbus (3.1e−05_172 . . . 198_ . . . ) (multi) 286 626 Paenibacillus Transposase_31: (1.7e−17_2 . . . 113_ . . . ); Uso1_p115_head: thiaminolyticus (8.4e−06_30 . . . 159_ . . . ) (multi) 287 627 Stenotrophomonas Y1_Tnp: (2.3e−16_14 . . . 127_ . . . ) sp. multi Protein Clustering

The CRISPR-associated transposase protein sequences (SEQ ID NOs: 124-246, 275-287) were aligned using the USEARCH tool at 50% sequence identity cutoff (Edgar, 2010) and 13 sequence alignment clusters were identified, as shown in Table 6. The majority of the identified transposases belong to cluster 1, and the Pfam annotation in Table 5 indicates that the cluster 1 member proteins comprise the OrfB_IS605, OrfB_Zn_ribbon, and Puf domains.

TABLE 6 Protein sequence alignment clusters identified for SEQ ID NOs: 124-246, 275-287. Unique Protein Sequences protein Cluster ID (SEQ ID NO:) count 1 124-220, 277-283 104 2 221-223 3 3 224-227, 238-239 6 4 228-236, 284-286 12 5 276 1 6 237 1 7 287 1 8 240 1 9 241 1 10 242 1 11 243-245 3 12 246 1 13 275 1 Polynucleotide Sequences Encoding Transposases

For the transposase proteins SEQ ID NOs: 124-246, 275-287, the corresponding polynucleotide coding regions were also identified, see Table 7. A single protein sequence may be encoded by one or more different nucleotide sequences because the sequences were identified from different bacterial species or strains. For example, for protein SEQ ID NO: 127, the corresponding DNA sequences are SEQ ID NO: 4, 288, 289, 290, and 291.

TABLE 7 Protein sequences SEQ ID NOs: 124-246, 275-287 and the corresponding DNA sequence of the respective coding region. DNA PRT (SEQ ID (SEQ ID NO:) NO:) 124 1 125 2 126 3 127 4 127 288 127 289 127 290 127 291 128 5 129 6 129 292 129 293 129 294 130 7 130 295 130 296 130 297 130 298 131 8 132 9 132 299 132 300 132 301 132 302 133 10 134 11 134 303 135 12 136 13 136 304 136 305 136 306 136 307 136 308 136 309 136 310 136 311 136 312 136 313 136 314 136 315 136 316 136 317 136 318 136 319 136 320 136 321 136 322 136 323 137 14 138 15 139 16 140 17 140 324 140 325 140 326 140 327 140 328 141 18 141 329 141 330 142 19 143 20 143 331 143 332 143 333 143 334 144 21 144 335 144 336 144 337 144 338 144 339 144 340 144 341 144 342 144 343 144 344 144 345 144 346 144 347 144 348 144 349 144 350 144 351 144 352 144 353 144 354 144 355 144 356 144 357 144 358 144 359 144 360 144 361 144 362 144 363 144 364 144 365 144 366 144 367 144 368 144 369 144 370 144 371 144 372 144 373 144 374 144 375 144 376 144 377 144 378 144 379 144 380 144 381 144 382 144 383 144 384 144 385 144 386 144 387 144 388 144 389 144 390 144 391 144 392 144 393 144 394 144 395 144 396 144 397 144 398 144 399 144 400 144 401 144 402 144 403 144 404 144 405 144 406 144 407 144 408 144 409 144 410 144 411 144 412 144 413 144 414 144 415 144 416 144 417 144 418 144 419 144 420 144 421 144 422 144 423 144 424 144 425 144 426 144 427 144 428 144 429 144 430 144 431 144 432 144 433 144 434 144 435 144 436 144 437 144 438 144 439 144 440 144 441 144 442 144 443 144 444 144 445 144 446 144 447 144 448 145 22 146 23 147 24 148 25 149 26 149 449 150 27 151 28 151 450 151 451 152 29 153 30 154 31 154 452 155 32 156 33 156 453 157 34 157 454 158 35 159 36 160 37 160 455 160 456 160 457 160 458 160 459 161 38 162 39 163 40 164 41 165 42 165 460 166 43 167 44 168 45 169 46 170 47 171 48 171 461 171 462 171 463 171 464 171 465 171 466 171 467 172 49 173 50 173 468 174 51 174 469 174 470 175 52 175 471 175 472 175 473 176 53 176 474 176 475 176 476 176 477 176 478 176 479 176 480 176 481 177 54 178 55 178 482 178 483 179 56 179 484 179 485 179 486 179 487 179 488 179 489 179 490 179 491 179 492 179 493 179 494 179 495 179 496 179 497 179 498 179 499 179 500 179 501 179 502 179 503 179 504 180 57 181 58 182 59 183 60 184 61 185 62 186 63 186 505 187 64 188 65 188 506 188 507 188 508 188 509 188 510 188 511 188 512 188 513 188 514 188 515 188 516 188 517 189 66 190 67 191 68 192 69 192 518 193 70 193 519 193 520 193 521 193 522 194 71 194 523 194 524 194 525 194 526 194 527 194 528 194 529 194 530 194 531 195 72 196 73 197 74 197 532 197 533 197 534 197 535 197 536 197 537 197 538 197 539 197 540 197 541 197 542 198 75 198 543 198 544 198 545 198 546 198 547 198 548 198 549 198 550 198 551 198 552 198 553 198 554 198 555 198 556 198 557 198 558 199 76 200 77 201 78 201 559 201 560 201 561 202 79 203 80 204 81 205 82 205 562 206 83 207 84 208 85 209 86 210 87 210 563 210 564 210 565 210 566 210 567 210 568 210 569 210 570 210 571 210 572 210 573 210 574 210 575 210 576 210 577 210 578 210 579 210 580 210 581 210 582 210 583 211 88 211 584 212 89 213 90 213 585 213 586 213 587 213 588 213 589 213 590 214 91 215 92 216 93 216 591 216 592 216 593 217 94 218 95 219 96 220 97 220 594 221 98 222 99 223 100 223 595 223 596 223 597 224 101 225 102 225 598 226 103 227 104 228 105 229 106 230 107 231 108 232 109 232 599 232 600 232 601 233 110 234 111 235 112 236 113 237 114 238 115 238 602 239 116 240 117 241 118 241 603 242 119 243 120 244 121 245 122 246 123 275 604 276 605 277 606 277 607 277 608 277 609 277 610 277 611 278 612 279 613 280 614 281 615 281 616 281 617 281 618 281 619 281 620 281 621 282 622 283 623 284 624 285 625 286 626 287 627 CRISPR Sequences Associated with the Transposases

CRISPR sequences associated with the transposes were identified, see Table 8. Each CRISPR sequence includes 50 nucleotides of genomic sequence extended from both the upstream 5′ end and the downstream 3′ end of the CRISPR region (except for SEQ ID NO: 816, which does not contain the extra 50 nucleotides at the 5′ end). For some transposases, multiple associated CRISPR sequences were identified, for example, the polynucleotide sequence (SEQ ID NO: 559 encoding protein sequence of SEQ ID NO: 201) is associated with two CRISPR sequences—SEQ ID NOs: 987 and 988. Additionally, a single CRISPR sequence may be associated with two or more transposase protein coding regions, for example, the polynucleotide sequences SEQ ID NO: 98 and SEQ ID NO: 16 are associated with the same CRISPR sequence of SEQ ID NO: 679. This is also observed for the polynucleotide pairs of SEQ ID NOs: 99 and 9 are both associated with CRISPR sequence SEQ ID NO: 647, SEQ ID NOs: 100 and 301 are both associated with CRISPR sequence SEQ ID NO: 647, SEQ ID NOs: 595 and 11 are both associated with CRISPR sequence SEQ ID NO: 653, SEQ ID NOs: 596 and 302 are both associated with CRISPR sequence SEQ ID NO: 651, and SEQ ID NOs: 597 and 303 are both associated with CRISPR sequence SEQ ID NO: 654.

TABLE 8 CRISPR sequences associated with transposases (SEQ ID NOs: 124-246, 275-287). PRT DNA Associated (SEQ ID (SEQ ID CRISPR NO:) NO:) (SEQ ID NO:) 124 1 628 125 2 629 126 3 630 127 4 631 127 288 632 127 289 633 127 290 634 127 291 635 128 5 636 129 6 637 129 292 638 129 293 639 129 294 640 130 7 641 130 295 642 130 296 643 130 297 644 130 298 645 131 8 646 132 9 647 132 299 648 132 300 649 132 301 650 132 302 651 133 10 652 134 11 653 134 303 654 135 12 655 136 13 656 136 305 657 136 306 658 136 307 659 136 308 660 136 309 661 136 304 662 136 310 663 136 311 664 136 312 665 136 313 666 136 314 667 136 315 668 136 316 669 136 317 670 136 318 671 136 319 672 136 320 673 136 321 674 136 322 675 136 323 676 137 14 677 138 15 678 139 16 679 140 17 680 140 324 681 140 325 682 140 326 683 140 327 684 140 328 685 141 18 686 141 329 687 141 330 688 142 19 689 143 20 690 143 331 691 143 332 692 143 333 693 143 334 694 144 21 695 144 335 696 144 336 697 144 337 698 144 338 699 144 339 700 144 340 701 144 341 702 144 342 703 144 343 704 144 344 705 144 345 706 144 346 707 144 347 708 144 348 709 144 349 710 144 350 711 144 351 712 144 352 713 144 353 714 144 354 715 144 355 716 144 356 717 144 357 718 144 358 719 144 359 720 144 360 721 144 361 722 144 362 723 144 363 724 144 364 725 144 365 726 144 366 727 144 367 728 144 368 729 144 369 730 144 370 731 144 371 732 144 372 733 144 373 734 144 374 735 144 375 736 144 376 737 144 377 738 144 378 739 144 379 740 144 380 741 144 381 742 144 382 743 144 383 744 144 384 745 144 385 746 144 386 747 144 387 748 144 388 749 144 389 750 144 390 751 144 391 752 144 392 753 144 393 754 144 394 755 144 395 756 144 396 757 144 397 758 144 398 759 144 399 760 144 400 761 144 401 762 144 402 763 144 403 764 144 404 765 144 405 766 144 406 767 144 407 768 144 408 769 144 409 770 144 410 771 144 411 772 144 412 773 144 413 774 144 414 775 144 415 776 144 416 777 144 417 778 144 418 779 144 419 780 144 420 781 144 421 782 144 422 783 144 423 784 144 424 785 144 425 786 144 426 787 144 427 788 144 428 789 144 429 790 144 430 791 144 431 792 144 432 793 144 433 794 144 434 795 144 435 796 144 436 797 144 437 798 144 438 799 144 439 800 144 440 801 144 441 802 144 442 803 144 443 804 144 444 805 144 445 806 144 446 807 144 447 808 144 448 809 145 22 810 146 23 811 147 24 812 148 25 813 149 26 814 149 449 815 150 27 816 151 28 817 151 450 818 151 451 819 152 29 820 153 30 821 154 31 822 154 452 823 155 32 824 156 33 825 156 453 826 157 34 827 157 454 828 158 35 829 159 36 830 160 37 831 160 455 832 160 456 833 160 457 834 160 458 835 160 459 836 161 38 837 162 39 838 163 40 839 164 41 840 165 42 841 165 460 842 166 43 843 167 44 844 168 45 845 169 46 846 170 47 847 171 48 848 171 461 849 171 462 850 171 463 851 171 464 852 171 465 853 171 466 854 171 467 855 172 49 856 173 50 857 173 468 858 174 51 859 174 469 860 174 470 861 175 52 862 175 471 863 175 472 864 175 473 865 176 53 866 176 474 867 176 475 868 176 476 869 176 477 870 176 478 871 176 479 872 176 480 873 176 481 874 177 54 875 178 55 876 178 482 877 178 483 878 179 56 879 179 484 880 179 485 881 179 486 882 179 487 883 179 488 884 179 489 885 179 490 886 179 491 887 179 492 888 179 493 889 179 494 890 179 495 891 179 496 892 179 497 893 179 498 894 179 499 895 179 500 896 179 501 897 179 502 898 179 503 899 179 504 900 180 57 901 181 58 902 182 59 903 183 60 904 184 61 905 185 62 906 186 63 907 186 505 908 187 64 909 188 65 910 188 506 911 188 507 912 188 508 913 188 509 914 188 510 915 188 511 916 188 512 917 188 513 918 188 514 919 188 515 920 188 516 921 188 517 922 189 66 923 190 67 924 191 68 925 191 68 926 192 69 927 192 518 928 193 519 929 193 520 930 193 521 931 193 70 932 193 522 933 194 71 934 194 523 935 194 524 936 194 525 937 194 526 938 194 527 939 194 528 940 194 529 941 194 530 942 194 531 943 194 531 944 195 72 945 196 73 946 196 73 947 197 74 948 197 532 949 197 532 950 197 533 951 197 533 952 197 534 953 197 534 954 197 535 955 197 535 956 197 536 957 197 536 958 197 537 959 197 537 960 197 538 961 197 539 962 197 540 963 197 541 964 197 542 965 198 75 966 198 543 967 198 544 968 198 545 969 198 546 970 198 547 971 198 548 972 198 549 973 198 550 974 198 551 975 198 552 976 198 553 977 198 554 978 198 555 979 198 556 980 198 557 981 198 558 982 199 76 983 200 77 984 201 78 985 201 78 986 201 559 987 201 559 988 201 560 989 201 560 990 201 561 991 201 561 992 202 79 993 202 79 994 203 80 995 204 81 996 205 82 997 205 562 998 206 83 999 207 84 1000 208 85 1001 209 86 1002 210 573 1003 210 574 1004 210 87 1005 210 575 1006 210 576 1007 210 577 1008 210 563 1009 210 564 1010 210 565 1011 210 578 1012 210 579 1013 210 566 1014 210 567 1015 210 568 1016 210 580 1017 210 569 1018 210 581 1019 210 570 1020 210 571 1021 210 582 1022 210 572 1023 210 583 1024 211 88 1025 211 584 1026 212 89 1027 212 89 1028 213 90 1029 213 90 1030 213 585 1031 213 586 1032 213 587 1033 213 588 1034 213 588 1035 213 589 1036 213 589 1037 213 590 1038 213 590 1039 214 91 1040 214 91 1041 215 92 1042 216 93 1043 216 93 1044 216 591 1045 216 591 1046 216 592 1047 216 592 1048 216 593 1049 216 593 1050 217 94 1051 218 95 1052 218 95 1053 219 96 1054 220 97 1055 220 594 1056 221 98 679 222 99 647 223 100 650 223 595 653 223 596 651 223 597 654 224 101 1057 225 598 1058 225 102 1059 226 103 1060 227 104 1061 228 105 1062 229 106 1063 230 107 1064 230 107 1065 231 108 1066 231 108 1067 232 599 1068 232 109 1069 232 600 1070 232 601 1071 233 110 1072 233 110 1073 234 111 1074 234 111 1075 235 112 1076 236 113 1077 237 114 1078 237 114 1079 238 602 1080 238 115 1081 239 116 1082 240 117 1083 241 118 1084 241 118 1085 241 603 1086 241 603 1087 242 119 1088 243 120 1089 244 121 1090 245 122 1091 246 123 1092 276 605 1093 277 606 1094 277 607 1095 277 608 1096 277 609 1097 277 610 1098 277 611 1099 278 612 1100 279 613 1101 280 614 1102 281 615 1103 281 616 1104 281 617 1105 281 618 1106 281 619 1107 281 620 1108 281 621 1109 282 622 1110 283 623 1111 284 624 1112 285 625 1113 286 626 1114 287 627 1115 CRIPSR Repeat and Spacer Coordinates within Each CRISPR Sequence

The repeat and spacer positions within each CRIPSR sequence were identified using bioinformatic analysis. For a representative CRISPR sequence selected for each transposase, The repeat and spacer sequences of the CRISPR regions were identified using the CRISPR recognition tool (Bland, 2007), then the sequences were manually examined to adjust the repeat and spacer sequences. The curated repeat and spacer sequence coordinates are provided in Table 9 for a representative CRISPR sequence selected for each transposase (SEQ ID NOs: 124-246, 275-287).

TABLE 9 Repeat and spacer coordinates identified for a representative CRISPR sequence for each transposase (SEQ ID NOs: 124-246, 275-287). PRT DNA CRISPR SEQ ID SEQ ID SEQ ID NO NO NO Repeat coordinates within CRISPR Spacer coordinates within CRISPR 124 1 628 [51 . . . 73]; [139 . . . 161]; [197 . . . 226]; [74 . . . 138]; [162 . . . 196]; [227 . . . 262]; [263 . . . 292]; [329 . . . 358] [293 . . . 328]; [359 . . . 394] 125 2 629 [51 . . . 73]; [139 . . . 161]; [197 . . . 226]; [74 . . . 138]; [162 . . . 196]; [227 . . . 262]; [263 . . . 292]; [329 . . .358] [293 . . . 328]; [359 . . . 394] 126 3 630 [51 . . . 73]; [107 . . . 138]; [173 . . . 204] [74 . . . 106]; [139 . . . 172]; [205 . . . 238] 127 4 631 [51 . . . 71]; [108 . . . 136]; [174 . . . 203]; [72 . . . 107]; [137 . . . 173]; [204 . . . 238]; [239 . . . 268]; [303 . . . 332]; [368 . . . 397] [269 . . . 302]; [333 . . . 367]; [398 . . . 434] 128 5 636 [51 . . . 71]; [108 . . . 136]; [174 . . . 203]; [72 . . . 107]; [137 . . . 173]; [204 . . . 238]; [239 . . . 268]; [303 . . . 332]; [368 . . . 397] [269 . . . 302]; [333 . . . 367]; [398 . . . 434] 129 6 637 [51 . . . 71]; [108 . . . 136]; [174 . . . 203]; [72 . . . 107]; [137 . . . 173]; [204 . . . 238]; [239 . . . 268]; [303 . . . 332]; [368 . . . 397] [269 . . . 302]; [333 . . . 367]; [398 . . . 434] 130 7 641 [51 . . . 71]; [108 . . . 136]; [174 . . . 230] [72 . . . 107]; [137 . . . 173]; [204 . . . 238] [239 . . . 268]; [303 . . . 332]; [368 . . . 397] [269 . . . 302]; [333 . . . 367]; [398 . . . 434] 131 8 646 [51 . . . 80]; [116 . . . 145]; [180 . . . 209] [81 . . . 115]; [146 . . . 179]; [210 . . . 238] 132 9 647 [51 . . . 71]; [110 . . . 138]; [174 . . . 203]; [72 . . . 109]; [139 . . . 173]; [204 . . . 238]; [239 . . . 268]; [303 . . . 332]; [368 . . . 397]; [269 . . . 302]; [333 . . . 367]; [398 . . . 432]; [433 . . . 462]; [499 . . . 528] [463 . . . 498]; [529 . . . 550] 133 10 652 [51 . . . 71]; [108 . . . 136]; [174 . . . 203]; [72 . . . 107]; [137 . . . 173]; [204 . . . 238]; [239 . . . 268]; [303 . . . 332]; [368 . . . 397] [269 . . . 302]; [333 . . . 367]; [398 . . . 434] 134 11 653 [51 . . . 72]; [110 . . . 139]; [175 . . . 204]; [73 . . . 109]; [140 . . . 174]; [205 . . . 239]; [240 . . . 269]; [304 . . . 333]; [369 . . . 398]; [270 . . . 303]; [334 . . . 368]; [399 . . . 433]; [434 . . . 463] [464 . . . 499] 135 12 655 [51 . . . 71]; [108 . . . 136]; [172 . . . 201] [72 . . . 107]; [137 . . . 171]; [202 . . . 238] 136 304 662 [42 . . . 71]; [107 . . . 136]; [174 . . . 203]; [72 . . . 106]; [137 . . . 173]; [204 . . . 238]; [239 . . . 268]; [304 . . . 333] [269 . . . 303]; [334 . . . 370] 137 14 677 [51 . . . 73]; [110 . . . 138]; [174 . . . 203]; [74 . . . 109]; [139 . . . 173]; [204 . . . 240]; [241 . . . 270]; [306 . . . 335]; [370 . . . 399]; [271 . . . 305]; [336 . . . 369]; [400 . . . 434]; [435 . . . 464] [465 . . . 501] 138 15 678 [51 . . . 72]; [111 . . . 139]; [175 . . . 204]; [73 . . . 110]; [140 . . . 174]; [205 . . . 239]; [240 . . . 269]; [304 . . . 333]; [369 . . . 398]; [270 . . . 303]; [334 . . . 368]; [399 . . . 434]; [435 . . . 464] [465 . . . 500] 139 16 679 [51 . . . 72]; [111 . . . 139]; [175 . . . 204]; [73 . . . 110]; [140 . . . 174]; [205 . . . 239]; [240 . . . 269]; [304 . . . 333]; [369 . . . 398]; [270 . . . 303]; [334 . . . 368]; [399 . . . 434]; [435 . . . 464] [465 . . . 500] 140 17 680 [51 . . . 80]; [116 . . . 145]; [181 . . . 210]; [81 . . . 115]; [146 . . . 180]; [211 . . . 246]; [247 . . . 276]; [313 . . . 342] [277 . . . 312]; [343 . . . 377] 141 18 686 [51 . . . 80]; [116 . . . 145]; [181 . . . 210]; [81 . . . 115]; [146 . . . 180]; [211 . . . 246]; [247 . . . 276]; [313 . . . 342] [277 . . . 312]; [343 . . . 377] 142 19 689 [51 . . . 70]; [105 . . . 134]; [171 . . . 200] [71 . . . 104]; [135 . . . 170]; [201 . . . 234] 143 20 690 [51 . . . 71]; [108 . . . 136]; [174 . . . 203]; [72 . . . 107]; [137 . . . 173]; [204 . . . 238]; [239 . . . 268]; [303 . . . 332]; [368 . . . 397] [269 . . . 302]; [333 . . . 367]; [398 . . . 434] 144 21 695 [51 . . . 80]; [116 . . . 145]; [181 . . . 210]; [81 . . . 115]; [146 . . . 180]; [211 . . . 246]; [247 . . . 276]; [313 . . . 342] [277 . . . 312]; [343 . . . 377] 145 22 810 [51 . . . 73]; [110 . . . 138]; [174 . . . 203]; [74 . . . 109]; [139 . . . 173]; [204 . . . 240]; [241 . . . 270]; [306 . . . 335]; [371 . . . 400] [271 . . . 305]; [336 . . . 370]; [401 . . . 437] 146 23 811 [51 . . . 80]; [116 . . . 145]; [181 . . . 210]; [81 . . . 115]; [146 . . . 180]; [211 . . . 247]; [248 . . . 277]; [314 . . . 343]; [381 . . . 410] [278 . . . 313]; [344 . . . 380]; [411 . . . 447] 147 24 812 [51 . . . 71]; [109 . . . 138]; [174 . . . 203]; [72 . . . 108]; [139 . . . 173]; [204 . . . 240]; [241 . . . 270]; [306 . . . 335]; [370 . . . 399] [271 . . . 305]; [336 . . . 369]; [400 . . . 434] 148 25 813 [51 . . . 80]; [116 . . . 145] [81 . . . 115]; [146 . . . 180] 149 26 814 [51 . . . 71]; [107 . . . 136]; [172 . . . 201]; [72 . . . 106]; [137 . . . 171]; [202 . . . 236]; [237 . . . 266]; [302 . . . 332] [267 . . . 301]; [333 . . . 368] 150 27 816 [1 . . . 20]; [58 . . . 87]; [124 . . . 153]; [21 . . . 57]; [88 . . . 123]; [154 . . . 189]; [190 . . . 219]; [254 . . . 273] [220 . . . 253]; [274 . . . 309] 151 28 817 [51 . . . 71]; [108 . . . 136]; [174 . . . 203]; [72 . . . 107]; [137 . . . 173]; [204 . . . 238]; [239 . . . 268]; [303 . . . 332]; [368 . . . 397] [269 . . . 302]; [333 . . . 367]; [398 . . . 434] 152 29 820 [51 . . . 73]; [109 . . . 138]; [174 . . . 203]; [74 . . . 108]; [139 . . . 173]; [204 . . . 239]; [240 . . . 269]; [306 . . . 335] [270 . . . 305]; [336 . . . 370] 153 30 821 [51 . . . 80]; [117 . . . 146]; [183 . . . 212]; [81 . . . 116]; [147 . . . 182]; [213 . . . 248]; [249 . . . 278]; [306 . . . 335] [279 . . . 305]; [336 . . . 365] 154 31 822 [51 . . . 70]; [106 . . . 135]; [172 . . . 201]; [71 . . . 105]; [136 . . . 171]; [202 . . . 236]; [237 . . . 266]; [303 . . . 332]; [369 . . . 398] [267 . . . 302]; [333 . . . 368]; [399 . . . 433] 155 32 824 [51 . . . 71]; [107 . . . 136]; [173 . . . 202]; [72 . . . 106]; [137 . . . 172]; [203 . . . 237]; [238 . . . 266]; [305 . . . 333] [267 . . . 304]; [334 . . . 359] 156 33 825 [51 . . . 71]; [108 . . . 137]; [173 . . . 202]; [72 . . . 107]; [138 . . . 172]; [203 . . . 236]; [237 . . . 266]; [303 . . . 332] [267 . . . 302]; [333 . . . 369] 157 34 827 [51 . . . 80]; [116 . . . 145]; [180 . . . 209] [81 . . . 115]; [146 . . . 179]; [210 . . . 245] 158 35 829 [51 . . . 73]; [109 . . . 138]; [174 . . . 203]; [74 . . . 108]; [139 . . . 173]; [204 . . . 239]; [240 . . . 269]; [306 . . . 335] [270 . . . 305]; [336 . . . 370] 159 36 830 [51 . . . 70]; [105 . . . 134]; [171 . . . 200] [71 . . . 104]; [135 . . . 170]; [201 . . . 234] 160 37 831 [51 . . . 75]; [112 . . . 141]; [177 . . . 206]; [76 . . . 111]; [142 . . . 176]; [207 . . . 243]; [244 . . . 273]; [324 . . . 353]; [390 . . . 419]; [274 . . . 323]; [354 . . . 389]; [420 . . . 455]; [456 . . . 485] [486 . . . 521] 161 38 837 [51 . . . 80]; [115 . . . 144]; [170 . . . 199]; [81 . . . 114]; [145 . . . 169]; [200 . . . 234]; [235 . . . 264]; [300 . . . 329]; [366 . . . 395] [265 . . . 299]; [330 . . . 365]; [396 . . . 429] 162 39 838 [51 . . . 71]; [108 . . . 136]; [174 . . . 203]; [72 . . . 107]; [137 . . . 173]; [204 . . . 238]; [239 . . . 268]; [303 . . . 332]; [368 . . . 397] [269 . . . 302]; [333 . . . 367]; [398 . . . 434] 163 40 839 [51 . . . 79]; [115 . . . 144]; [179 . . . 209] [80 . . . 114]; [145 . . . 178]; [210 . . . 243] 164 41 840 [51 . . . 79]; [115 . . . 144]; [179 . . . 209] [80 . . . 114]; [145 . . . 178]; [210 . . . 245] 165 42 841 [51 . . . 81]; [115 . . . 145]; [170 . . . 200]; [82 . . . 114]; [146 . . . 169]; [201 . . . 234]; [235 . . . 265] [266 . . . 298] 166 43 843 [51 . . . 80]; [116 . . . 145]; [180 . . . 209]; [81 . . . 115]; [146 . . . 179]; [210 . . . 244]; [245 . . . 274]; [311 . . . 340]; [377 . . . 406] [275 . . . 310]; [341 . . . 376]; [407 . . . 442] 167 44 844 [51 . . . 80]; [115 . . . 144]; [170 . . . 199]; [81 . . . 114]; [145 . . . 169]; [200 . . . 234]; [235 . . . 264]; [300 . . . 329]; [366 . . . 395] [265 . . . 299]; [330 . . . 365]; [396 . . . 429] 168 45 845 [51 . . . 71]; [107 . . . 136]; [174 . . . 203]; [72 . . . 106]; [137 . . . 173]; [204 . . . 237]; [238 . . . 267]; [303 . . . 332] [268 . . . 302]; [333 . . . 369] 169 46 846 [51 . . . 70]; [106 . . . 135]; [172 . . . 201]; [71 . . . 105]; [136 . . . 171]; [202 . . . 236]; [237 . . . 266]; [303 . . . 332]; [369 . . . 398] [267 . . . 302]; [333 . . . 368]; [399 . . . 433] 170 47 847 [51 . . . 73]; [110 . . . 138]; [174 . . . 203]; [74 . . . 109]; [139 . . . 173]; [204 . . . 240]; [241 . . . 270]; [306 . . . 335]; [371 . . . 400] [271 . . . 305]; [336 . . . 370]; [401 . . . 437] 171 461 849 [51 . . . 71]; [108 . . . 136]; [174 . . . 203]; [72 . . . 107]; [137 . . . 173]; [204 . . . 238]; [239 . . . 268]; [304 . . . 333] [269 . . . 303]; [334 . . . 370] 172 49 856 [51 . . . 71]; [107 . . . 136]; [173 . . . 202]; [72 . . . 106]; [137 . . . 172]; [203 . . . 237]; [238 . . . 266] [267 . . . 304] 173 50 857 [51 . . . 71]; [107 . . . 136]; [174 . . . 203]; [72 . . . 106]; [137 . . . 173]; [204 . . . 238]; [239 . . . 268]; [303 . . . 332]; [269 . . . 302]; [333 . . . 367]; [398 . . . 434] [368 . . . 397] 174 51 859 [51 . . . 71]; [107 . . . 136]; [173 . . . 202]; [72 . . . 106]; [137 . . . 172]; [203 . . . 237]; [238 . . . 266]; [305 . . . 333] [267 . . . 304]; [334 . . . 368] 175 52 862 [51 . . . 71]; [107 . . . 136]; [174 . . . 203]; [72 . . . 106]; [137 . . . 173]; [204 . . . 238]; [239 . . . 268]; [303 . . . 332]; [368 . . . 397] [269 . . . 302]; [333 . . . 367]; [398 . . . 434] 176 53 866 [51 . . . 73]; [110 . . . 138]; [174 . . . 203]; [74 . . . 109]; [139 . . . 173]; [204 . . . 240]; [241 . . . 270]; [306 . . . 335]; [271 . . . 305]; [336 . . . 369]; [400 . . . 434]; [370 . . . 399]; [435 . . . 464] [465 . . . 501] 177 54 875 [51 . . . 76]; [112 . . . 141]; [177 . . . 206]; [77 . . . 111]; [142 . . . 176]; [207 . . . 243]; [244 . . . 273]; [329 . . . 358]; [274 . . . 328]; [359 . . . 393]; [394 . . . 424]; [460 . . . 490]; [425 . . . 459]; [491 . . . 518]; [519 . . . 544] [545 . . . 581] 178 55 876 [51 . . . 76]; [112 . . . 141]; [177 . . . 206]; [77 . . . 111]; [142 . . . 176]; [207 . . . 243]; [244 . . . 273]; [324 . . . 353]; [389 . . . 419]; [274 . . . 323]; [354 . . . 388]; [420 . . . 454]; [455 . . . 485]; [514 . . . 539] [486 . . . 513]; [540 . . . 576] 179 56 879 [51 . . . 76]; [112 . . . 141]; [177 . . . 206]; [77 . . . 111]; [142 . . . 176]; [207 . . . 243]; [244 . . . 273]; [324 . . . 353]; [274 . . . 323]; [354 . . . 388]; [420 . . . 454]; [389 . . . 419]; [455 . . . 485]; [486 . . . 513]; [540 . . . 576] [514 . . . 539] 180 57 901 [51 . . . 76]; [112 . . . 141]; [177 . . . 206]; [77 . . . 111]; [142 . . . 176]; [207 . . . 243]; [244 . . . 273]; [324 . . . 353]; [274 . . . 323]; [354 . . . 388]; [389 . . . 419]; [455 . . . 485]; [420 . . . 454]; [486 . . . 513]; [514 . . . 539] [540 . . . 576] 181 58 902 [51 . . . 80]; [117 . . . 146]; [182 . . . 211]; [81 . . . 116]; [147 . . . 181]; [212 . . . 245]; [246 . . . 275] [276 . . . 311] 182 59 903 [51 . . . 71]; [109 . . . 138]; [174 . . . 203]; [72 . . . 108]; [139 . . . 173]; [204 . . . 238]; [239 . . . 268] [269 . . . 305] 183 60 904 [51 . . . 76]; [112 . . . 141]; [177 . . . 206]; [77 . . . 111]; [142 . . . 176]; [207 . . . 243]; [244 . . . 273]; [324 . . . 353] [274 . . . 323]; [354 . . . 388] 184 61 905 [51 . . . 74]; [111 . . . 139]; [175 . . . 204]; [75 . . . 110]; [140 . . . 174]; [205 . . . 241]; [242 . . . 271]; [307 . . . 336] [272 . . . 306]; [337 . . . 373] 185 62 906 [51 . . . 77]; [114 . . . 143]; [180 . . . 209] [78 . . . 113]; [144 . . . 179]; [210 . . . 246] 186 63 907 [51 . . . 80]; [109 . . . 146]; [175 . . . 210]; [81 . . . 108]; [147 . . . 174]; [211 . . . 247]; [248 . . . 277] [278 . . . 312] 187 64 909 [51 . . . 80]; [117 . . . 146]; [181 . . . 210]; [81 . . . 116]; [147 . . . 180]; [211 . . . 247]; [248 . . . 277] [278 . . . 312] 188 65 910 [51 . . . 80]; [117 . . . 146]; [181 . . . 210]; [81 . . . 116]; [147 . . . 180]; [211 . . . 247]; [248 . . . 277] [278 . . . 312] 189 66 923 [51 . . . 70]; [107 . . . 136]; [71 . . . 106]; [137 . . . 172]; [203 . . . 237] [173 . . . 202] 190 67 924 [51 . . . 81]; [116 . . . 146]; [184 . . . 214] [82 . . . 115]; [147 . . . 183]; [215 . . . 248] 191 68 925 [51 . . . 74]; [109 . . . 139]; [173 . . . 203] [75 . . . 108]; [140 . . . 172]; [204 . . . 237] 191 68 926 [51 . . . 70]; [105 . . . 134]; [170 . . . 199]; [71 . . . 104]; [135 . . . 169]; [200 . . . 236]; [237 . . . 267] [268 . . . 302] 192 69 927 [51 . . . 81]; [116 . . . 146]; [184 . . . 214] [82 . . . 115]; [147 . . . 183]; [215 . . . 248] 193 519 929 [51 . . . 80]; [116 . . . 145]; [181 . . . 210]; [81 . . . 115]; [146 . . . 180]; [211 . . . 246]; [247 . . . 276]; [312 . . . 341] [277 . . . 311]; [342 . . . 376] 194 71 934 [51 . . . 81]; [117 . . . 147]; [182 . . . 212] [82 . . . 116]; [148 . . . 181]; [213 . . . 246] 195 72 945 [51 . . . 80]; [118 . . . 147]; [183 . . . 212]; [81 . . . 117]; [148 . . . 182]; [213 . . . 248]; [249 . . . 278] 279 . . . 313] 196 73 946 [51 . . . 81]; [117 . . . 147]; [182 . . . 212]; [82 . . . 116]; [148 . . . 181]; [213 . . . 245]; [246 . . . 276] [277 . . . 310] 196 73 947 [51 . . . 70]; [105 . . . 134]; [170 . . . 199]; [71 . . . 104]; [135 . . . 169]; [200 . . . 236]; [237 . . . 267] [268 . . . 302[ 197 532 949 [51 . . . 80]; [118 . . . 147]; [183 . . . 212]; [81 . . . 117]; [148 . . . 182]; [213 . . . 248]; [249 . . . 278] [279 . . . 313] 197 532 950 [51 . . . 80]; [115 . . . 144]; [180 . . . 209]; [81 . . . 114]; [145 . . . 179]; [210 . . . 245]; [246 . . . 275] [276 . . . 324] 198 547 971 [51 . . . 81]; [117 . . . 147] [82 . . . 116]; [148 . . . 181[ 199 76 983 [51 . . . 74]; [110 . . . 139]; [174 . . . 203] [75 . . . 109]; [140 . . . 173]; [204 . . . 238] 200 77 984 [51 . . . 80]; [118 . . . 147]; [183 . . . 212]; [81 . . . 117]; [148 . . . 182]; [213 . . . 248]; [249 . . . 278] [279 . . . 313] 201 78 985 [51 . . . 80]; [115 . . . 144]; [181 . . . 210]; [81 . . . 114]; [145 . . . 180]; [211 . . . 246]; [247 . . . 276]; [313 . . . 342] [277 . . . 312]; [343 . . . 377] 201 78 986 [51 . . . 80]; [117 . . . 146]; [183 . . . 212]; [81 . . . 116]; [147 . . . 182]; [213 . . . 246]; [247 . . . 276]; [313 . . . 342]; [277 . . . 312]; [343 . . . 378]; [379 . . . 408]; [444 . . . 473] [409 . . . 443]; [474 . . . 510] 202 79 993 [51 . . . 80]; [118 . . . 147]; [184 . . . 213]; [81 . . . 117]; [148 . . . 183]; [214 . . . 248]; [249 . . . 278] [279 . . . 313] 202 79 994 [51 . . . 80]; [117 . . . 146]; [182 . . . 211] [81 . . . 116]; [147 . . . 181]; [212 . . . 246] 203 80 995 [51 . . . 80]; [117 . . . 146]; [184 . . . 213] [81 . . . 116]; [147 . . . 183]; [214 . . . 248] 204 81 996 [51 . . . 70]; [106 . . . 135]; [173 . . . 203] [71 . . . 105]; [136 . . . 172]; [204 . . . 238] 205 82 997 [51 . . . 71]; [105 . . . 136] [72 . . . 104]; [137 . . . 169] 206 83 999 [51 . . . 70]; [106 . . . 135]; [173 . . . 203] [71 . . . 105]; [136 . . . 172]; [204 . . . 238] 207 84 1000 [51 . . . 78]; [116 . . . 144]; [181 . . . 209]; [79 . . . 115]; [145 . . . 180]; [210 . . . 246]; [247 . . . 276] [277 . . . 311] 208 85 1001 [51 . . . 78]; [115 . . . 144]; [180 . . . 209]; [79 . . . 114]; [145 . . . 179]; [210 . . . 246]; [247 . . . 276]; [312 . . . 341] [277 . . . 311]; [342 . . . 378]; 209 86 1002 [51 . . . 78]; [115 . . . 144]; [180 . . . 209]; [79 . . . 114]; [145 . . . 179]; [210 . . . 246]; [247 . . . 276] [277 . . . 311] 210 87 1005 [51 . . . 70; [106 . . .135]; [173 . . . 203] [71 . . . 105]; [136 . . . 172]; [204 . . . 238] 211 88 1025 [51 . . . 70; [106 . . .135]; [172 . . . 201]; [71 . . . 105]; [136 . . . 171]; [269 . . . 304] [239 . . . 268] 212 89 1027 [51 . . . 80]; [116 . . . 145]; [183 . . . 212]; [81 . . . 115]; [146 . . . 182]; [213 . . . 247]; [248 . . . 266]; [293 . . . 322] [267 . . . 292]; [323 . . . 357] 212 89 1028 [51 . . . 72]; [110 . . . 139] [73 . . .109]; [140 . . . 175] 213 90 1029 [51 . . . 80]; [118 . . . 147]; [183 . . . 212]; [81 . . . 117]; [148 . . . 182]; [213 . . . 248]; [249 . . . 278] [279 . . . 313] 213 90 1030 [51 . . . 80]; [117 . . . 146]; [182 . . . 211] [81 . . . 116]; [147 . . . 181]; [212 . . . 246] 214 91 1040 [51 . . . 81]; [117 . . . 147]; [182 . . . 212] [82 . . . 116]; [148 . . . 181]; 213 . . . 246] 214 91 1041 [51 . . . 80]; [117 . . . 146] [81 . . . 116]; [147 . . . 181] 215 92 1042 [51 . . . 80]; [118 . . . 147]; [184 . . . 213]; [81 . . . 117]; [148 . . . 183]; [214 . . . 248]; [249 . . . 278] [279 . . . 313] 216 93 1043 [51 . . . 80]; [118 . . . 147]; [184 . . . 213]; [81 . . . 117]; [148 . . . 182]; [213 . . . 248]; [249 . . . 278] [279 . . . 313] 216 93 1044 [51 . . . 80]; [117 . . . 146]; [182 . . . 211]; [81 . . . 116]; [147 . . . 181]; [212 . . . 246] 217 94 1051 [51 . . . 80]; [117 . . . 146]; [183 . . . 212]; [81 . . . 116]; [147 . . . 182]; [213 . . . 246]; [247 . . . 276] [277 . . . 313] 218 95 1052 [51 . . . 80]; [118 . . . 147]; [183 . . . 212] [81 . . . 117]; [148 . . . 182]; [213 . . . 247]; 218 95 1053 [51 . . . 81]; [116 . . . 146]; [180 . . . 210]; [82 . . . 115]; [147 . . . 179]; [211 . . . 246]; [247 . . . 277] [278 . . . 310] 219 96 1054 [51 . . . 70; [106 . . . 135] [71 . . . 105]; [136 . . . 171] 220 97 1055 [51 . . . 81]; [118 . . . 148]; [184 . . . 214] [82 . . . 117]; [149 . . . 183]; [215 . . . 248] 221 98 679 [51 . . . 72]; [111 . . . 139]; [175 . . . 204]; [73 . . . 110]; [140 . . . 174]; [205 . . . 239]; [240 . . . 269]; [304 . . . 333]; [270 . . . 303]; [334 . . . 368]; [399 . . . 434]; [369 . . . 398]; [435 . . . 464] [465 . . . 500] 222 99 647 [51 . . . 71]; [110 . . . 138]; [174 . . . 203]; [72 . . . 109]; [139 . . . 173]; [204 . . . 238]; [239 . . . 268]; [303 . . . 332]; [269 . . . 302]; [333 . . . 367]; [368 . . . 397]; [433 . . . 462]; [398 . . . 432]; [463 . . . 498]; [499 . . . 528] [529 . . . 550] 223 595 653 [51 . . . 72]; [110 . . . 139]; [175 . . . 204]; [73 . . . 109]; [140 . . . 174]; [205 . . . 239]; [240 . . . 269]; [304 . . . 333]; [270 . . . 303]; [334 . . . 368]; [369 . . . 398]; [434 . . . 463] [399 . . . 433]; [464 . . . 499] 224 101 1057 [51 . . . 83]; [118 . . . 150]; [185 . . . 217]; [84 . . . 117]; [151 . . . 184]; [218 . . . 251]; [252 . . . 284]; [318 . . . 350]; [285 . . . 317]; [351 . . . 383]; [417 . . . 449]; [384 . . . 416]; [450 . . . 482]; [483 . . . 515]; [549 . . . 581]; [516 . . . 548]; [582 . . . 614] [615 . . . 648] 225 598 1058 [51 . . . 78]; [116 . . . 144]; [79 . . . 115]; [145 . . . 180]; [181 . . . 209] [210 . . . 244] 226 103 1060 [51 . . . 79]; [116 . . . 144]; [181 . . . 209]; [80 . . . 115]; [145 . . . 180]; [210 . . . 246]; [247 . . . 275]; [311 . . . 339]; [276 . . . 310]; [340 . . . 376]; [406 . . . 439]; [377 . . . 405]; [440 . . . 468]; [469 . . . 505]; [535 . . . 569]; [506 . . . 534]; [570 . . . 598]; [599 . . . 634]; [664 . . . 701]; [635 . . . 663]; [702 . . . 730]; [731 . . . 765]; [795 . . . 829]; [766 . . . 794]; [830 . . . 858]; [859 . . . 894]; [924 . . . 959]; [895 . . . 923]; [960 . . . 988]; [989 . . . 1024]; [1054 . . . 1090]; [1025 . . . 1053]; [1091 . . . 1119] [1120 . . . 1155] 227 104 1061 [51 . . . 79]; [116 . . . 144]; [181 . . . 209]; [80 . . . 115]; [145 . . . 180]; [210 . . . 246]; [247 . . . 275]; [311 . . . 339]; [276 . . . 310]; [340 . . . 376]; [377 . . . 405]; [440 . . . 468]; [406 . . . 439]; [469 . . . 505]; [506 . . . 534]; [570 . . . 598]; [535 . . . 569]; [599 . . . 634]; [635 . . . 663]; [702 . . . 730]; [664 . . . 701]; [731 . . . 765]; [766 . . . 794]; [830 . . . 858]; [795 . . . 829]; [859 . . . 894]; [895 . . . 923]; [960 . . . 988]; [924 . . . 959]; [989 . . . 1024]; [1025 . . . 1053]; [1091 . . . 1119] [1054 . . . 1090]; [1120 . . . 1155] 228 105 1062 [1 . . . 24]; [58 . . . 89]; [126 . . . 157]; [25 . . . 57]; [90 . . . 125]; [158 . . . 194]; [195 . . . 226]; [262 . . . 293]; [329 . . . 360]; [227 . . . 261]; [294 . . . 328]; [361 . . . 393]; [394 . . . 425]; [460 . . . 491]; [525 . . . 556]; [426 . . . 459]; [492 . . . 524]; [557 . . . 590]; [591 . . . 622]; [655 . . . 686]; [721 . . . 752]; [623 . . . 654]; [687 . . . 720]; [753 . . . 786]; [787 . . . 818]; [854 . . . 885]; [920 . . . 951]; [819 . . . 853]; [886 . . . 919]; [952 . . . 987]; [988 . . . 1019]; [1056 . . . 1087]; [1020 . . . 1055]; [1088 . . . 1125]; [1126 . . . 1157]; [1193 . . . 1224]; [1158 . . . 1192]; [1225 . . . 1258]; [1259 . . . 1290]; [1325 . . . 1356]; [1291 . . . 1324]; [1357 . . . 1391]; [1392 . . . 1423]; [1457 . . . 1488] [1424 . . . 1456]; [1489 . . . 1521] 229 106 1063 [51 . . . 82]; [120 . . . 151]; [187 . . . 218]; [83 . . . 119]; [152 . . . 186]; [219 . . . 253]; [254 . . . 285]; [320 . . . 351]; [286 . . . 319]; [352 . . . 385]; [418 . . . 451]; [386 . . . 417]; [452 . . . 483]; [484 . . . 517]; [550 . . . 583]; [616 . . . 650]; [518 . . . 549]; [584 . . . 615]; [683 . . . 716] [651 . . . 682] 230 107 1064 [1 . . . 25]; [60 . . . 91]; [126 . . . 157]; [26 . . . 59]; [92 . . . 125]; [158 . . . 192]; [193 . . . 224]; [260 . . . 291]; [225 . . . 259]; [292 . . . 326]; [359 . . . 391]; [327 . . . 358]; [392 . . . 423]; [424 . . . 456]; [489 . . . 521]; [554 . . . 589]; [457 . . . 488]; [522 . . . 553]; [622 . . . 657]; [690 . . . 723]; [756 . . . 789]; [590 . . . 621]; [658 . . . 689]; [822 . . . 859]; [892 . . . 926]; [959 . . . 992]; [724 . . . 755]; [790 . . . 821]; [1025 . . . 1060]; [1093 . . . 1125]; [860 . . . 891]; [927 . . . 958]; [1158 . . . 1191]; [1224 . . . 1258]; [993 . . . 1024]; [1061 . . . 1092]; [1291 . . . 1324]; [1357 . . . 1390]; [1126 . . . 1157]; [1192 . . . 1223]; [1423 . . . 1457]; [1490 . . . 1522] [1259 . . . 1290]; [1325 . . . 1356]; [1391 . . . 1422]; [1458 . . . 1489] 230 107 1065 [51 . . . 82]; [120 . . . 151]; [190 . . . 221]; [83 . . . 119]; [152 . . . 189]; [222 . . . 258]; [259 . . . 290]; [325 . . . 356]; [291 . . . 324]; [357 . . . 390]; [391 . . . 422] [423 . . . 456] 231 108 1066 [51 . . . 82]; [118 . . . 149]; [184 . . . 215]; [83 . . . 117]; [150 . . . 183]; [216 . . . 248]; [249 . . . 280]; [315 . . . 346]; [281 . . . 314]; [347 . . . 379]; [380 . . . 411]; [447 . . . 478]; [412 . . . 446]; [479 . . . 515]; [516 . . . 547]; [581 . . . 612]; [548 . . . 580]; [613 . . . 649]; [650 . . . 681]; [716 . . . 747]; [682 . . . 715]; [748 . . . 782]; [783 . . . 814]; [849 . . . 880]; [815 . . . 848]; [881 . . . 914]; [915 . . . 946]; [980 . . . 1011]; [947 . . . 979]; [1012 . . . 1043]; [1044 . . . 1075]; [1112 . . . 1143]; [1076 . . . 1111]; [1144 . . . 1176]; [1177 . . . 1208]; [1245 . . . 1276]; [1209 . . . 1244]; [1277 . . . 1310]; [1311 . . . 1342]; [1377 . . . 1408]; [1343 . . . 1376]; [1409 . . . 1444]; [1445 . . . 1476]; [1510 . . . 1541]; [1477 . . . 1509]; [1542 . . . 1575]; [1576 . . . 1607]; [1642 . . . 1673]; [1608 . . . 1641]; [1674 . . . 1708]; [1709 . . . 1740]; [1776 . . . 1807]; [1741 . . . 1775]; [1808 . . . 1841]; [1842 . . . 1873]; [1908 . . . 1939]; [1874 . . . 1907]; [1940 . . . 1973]; [1974 . . . 2005]; [2041 . . . 2072]; [2006 . . . 2040]; [2073 . . . 2106]; [2107 . . . 2138]; [2174 . . . 2205]; [2139 . . . 2173]; [2206 . . . 2239]; [2240 . . . 2271]; [2307 . . . 2338]; [2272 . . . 2306]; [2339 . . . 2373]; [2374 . . . 2405]; [2439 . . . 2470]; [2406 . . . 2438]; [2471 . . . 2506]; [2507 . . . 2538] [2539 . . . 2572] 231 108 1067 [51 . . . 82]; [118 . . . 149]; [183 . . . 214]; [83 . . . 117]; [150 . . . 182]; [215 . . . 249]; [250 . . . 281]; [318 . . . 349]; [282 . . . 317]; [350 . . . 385]; [418 . . . 451]; [386 . . . 417]; [452 . . . 483]; [484 . . . 518]; [551 . . . 584]; [519 . . . 550]; [585 . . . 616]; [617 . . . 652]; [685 . . . 719]; [653 . . . 684]; [720 . . . 751]; [752 . . . 786]; [819 . . . 852]; [787 . . . 818]; [853 . . . 884]; [885 . . . 918]; [951 . . . 983]; [919 . . . 950]; [984 . . . 1015]; [1016 . . . 1048]; [1081 . . . 1113]; [1049 . . . 1080]; [1114 . . . 1145]; [1146 . . . 1179]; [1212 . . . 1245]; [1180 . . . 1211]; [1246 . . . 1277]; [1278 . . . 1310]; [1343 . . . 1377]; [1311 . . . 1342]; [1378 . . . 1409]; [1410 . . . 1444]; [1477 . . . 1512]; [1445 . . . 1476]; [1513 . . . 1544]; [1545 . . . 1577]; [1610 . . . 1644]; [1578 . . . 1609]; [1645 . . . 1676]; [1677 . . . 1711]; [1744 . . . 1779] [1712 . . . 1743]; 232 600 1070 [51 . . . 82]; [117 . . . 148]; [185 . . . 216]; [83 . . . 116]; [149 . . . 184]; [217 . . . 251]; [252 . . . 283]; [318 . . . 349]; [284 . . . 317]; [350 . . . 385]; [418 . . . 450]; [386 . . . 417]; [451 . . . 482]; [483 . . . 514]; [547 . . . 579]; [612 . . . 644]; [515 . . . 546]; [580 . . . 611]; [677 . . . 711]; [744 . . . 777]; [645 . . . 676]; [712 . . . 743]; [810 . . . 843]; [876 . . . 908]; [778 . . . 809]; [844 . . . 875]; [941 . . . 975]; [1008 . . . 1042] [909 . . . 940]; [976 . . . 1007] 233 110 1072 [51 . . . 82]; [117 . . . 148]; [83 . . . 116]; [149 . . . 181]; [182 . . . 213]; [249 . . . 280]; [214 . . . 248]; [281 . . . 314]; [315 . . . 346]; [382 . . . 413]; [347 . . . 381]; [414 . . . 446]; [447 . . . 478];[513 . . . 544]; [479 . . . 512]; [545 . . . 579]; [580 . . . 611]; [647 . . . 678]; [612 . . . 646]; [679 . . . 711]; [712 . . . 743]; [780 . . . 811]; [744 . . . 779]; [812 . . . 846]; [847 . . . 878]; [914 . . . 945]; [879 . . . 913]; [946 . . . 978]; [979 . . . 1010]; [1044 . . . 1075]; [1011 . . . 1043]; [1076 . . . 1109]; [1110 . . . 1141] [1142 . . . 1175] 233 110 1073 [51 . . . 82]; [115 . . . 146]; [83 . . . 114]; [147 . . . 179]; [180 . . . 211]; [244 . . . 275]; [212 . . . 243]; [276 . . . 310]; [311 . . . 342]; [379 . . . 410]; [343 . . . 378]; [411 . . . 445]; [446 . . . 477] [478 . . . 511] 234 111 1074 [51 . . . 82]; [117 . . . 148]; [83 . . . 116]; [149 . . . 181]; [214 . . . 246]; [182 . . . 213]; [247 . . . 278]; [279 . . . 313]; [346 . . . 379]; [314 . . . 345]; [380 . . . 411]; [412 . . . 445]; [478 . . . 511]; [446 . . . 477]; [512 . . . 543]; [544 . . . 578]; [611 . . . 643] [579 . . . 610] 234 111 1075 [51 . . . 82]; [118 . . . 149] [83 . . . 117]; [150 . . . 184] 235 112 1076 [51 . . . 82]; [117 . . . 148]; [183 . . . 214]; [83 . . . 116]; [149 . . . 182]; [215 . . . 247]; [248 . . . 279]; [313 . . . 344]; [280 . . . 312]; [345 . . . 378]; [379 . . . 410]; [445 . . . 476]; [411 . . . 444];[477 . . . 512]; [513 . . . 544]; [578 . . . 609]; [545 . . . 577]; [610 . . . 643]; [644 . . . 675]; [710 . . . 741]; [676 . . . 709]; [742 . . . 774]; [775 . . . 806]; [841 . . . 872]; [807 . . . 840]; [873 . . . 905]; [906 . . . 937]; [972 . . . 1003]; [938 . . . 971]; [1004 . . . 1036]; [1037 . . . 1068]; [1102 . . . 1133]; [1069 . . . 1101]; [1134 . . . 1166]; [1167 . . . 1198] [1199 . . . 1232] 236 113 1077 [51 . . . 82]; [119 . . . 150]; [83 . . . 118]; [151 . . . 186]; [187 . . . 218]; [253 . . . 284]; [219 . . . 252]; [285 . . . 318]; [319 . . . 350]; [384 . . . 415]; [351 . . . 383]; [416 . . . 448]; [449 . . . 480]; [516 . . . 547] [481 . . . 515]; [548 . . . 581] 237 114 1078 [51 . . . 82]; [118 . . . 149]; [184 . . . 215]; [83 . . . 117]; [150 . . . 183]; [249 . . . 280]; [314 . . . 345]; [216 . . . 248]; [281 . . . 313]; [380 . . . 411]; [446 . . . 477]; [346 . . . 379]; [412 . . . 445]; [512 . . . 543]; [578 . . . 609]; [478 . . . 511]; [544 . . . 577]; [643 . . . 674]; [709 . . . 740]; [610 . . . 642]; [675 . . . 708]; [775 . . . 806]; [842 . . . 873] [741 . . . 774]; [807 . . . 841]; [874 . . . 908] 237 114 1079 [51 . . . 83]; [117 . . . 149] [84 . . . 116]; [150 . . . 183] 238 115 1081 [51 . . . 71]; [112 . . . 136] [72 . . . 111]; [137 . . . 176] 239 116 1082 [51 . . . 79]; [116 . . . 144]; [80 . . . 115]; [145 . . . 180]; [181 . . . 209]; [246 . . . 274] [210 . . . 245]; [275 . . . 309] 240 117 1083 [51 . . . 77]; [112 . . . 138]; [78 . . . 111]; [139 . . . 172]; [173 . . . 199] [200 . . . 233] 241 118 1084 [51 . . . 85]; [116 . . . 150]; [86 . . . 115]; [151 . . . 181]; [182 . . . 216]; [248 . . . 282]; [217 . . . 247]; [283 . . . 313]; [314 . . . 348]; [380 . . . 414]; [349 . . . 379]; [415 . . . 444]; [445 . . . 479] [480 . . . 510] 241 118 1085 [51 . . . 87]; [124 . . . 159]; [88 . . . 123]; [160 . . . 189]; [227 . . . 255]; [190 . . . 226]; [256 . . . 292]; [293 . . . 321]; [357 . . . 386]; [322 . . . 356]; [387 . . . 423]; [424 . . . 452]; [490 . . . 518]; [453 . . . 489]; [519 . . . 555]; [556 . . . 584]; [622 . . . 650]; [585 . . . 621]; [651 . . . 687]; [688 . . . 716]; [754 . . . 781]; [717 . . . 753]; [782 . . . 818]; [819 . . . 847]; [885 . . . 913] [848 . . . 884] 242 119 1088 [51 . . . 70]; [118 . . . 137]; [172 . . . 191]; [71 . . . 117]; [138 . . . 171]; [192 . . . 237]; [238 . . . 257]; [304 . . . 323]; [258 . . . 303]; [324 . . . 383]; [384 . . . 403]; [451 . . . 470] [404 . . . 450]; [471 . . . 515] 243 120 1089 [51 . . . 78]; [116 . . . 143]; [79 . . . 115]; [144 . . . 180]; [181 . . . 208] [209 . . . 244] 244 121 1090 [51 . . . 78]; [116 . . . 143]; [79 . . . 115]; [144 . . . 180]; [181 . . . 208] [209 . . . 244] 245 122 1091 [51 . . . 78]; [116 . . . 143]; [79 . . . 115]; [144 . . . 180]; [181 . . . 208]; [245 . . . 272]; [209 . . . 244]; [273 . . . 311]; [312 . . . 339]; [358 . . . 385] [340 . . . 357]; [386 . . . 398] 246 123 1092 [51 . . . 69]; [108 . . . 126] [70 . . . 107]; [127 . . . 173] 276 605 1093 [51 . . . 74]; [111 . . . 134]; [75 . . . 110]; [135 . . . 171]; [172 . . . 195]; [233 . . . 256] [196 . . . 232]; [257 . . . 293] 277 606 1094 [51 . . . 70]; [106 . . . 135]; [71 . . . 105]; [136 . . . 172]; [173 . . . 203] [204 . . . 238] 278 612 1100 [51 . . . 70]; [106 . . . 135]; [71 . . . 105]; [136 . . . 172]; [173 . . . 203] [204 . . . 238] 279 613 1101 [51 . . . 70]; [107 . . . 136]; [71 . . . 106]; [137 . . . 172]; [173 . . . 202] [203 . . . 239] 280 614 1102 [51 . . . 82]; [117 . . . 148]; [183 . . . 214]; [83 . . . 116]; [149 . . . 182]; [215 . . . 248]; [249 . . . 280]; [314 . . . 345]; [281 . . . 313]; [346 . . . 379]; [380 . . . 411]; [445 . . . 476] [412 . . . 444]; [477 . . . 509] 281 615 1103 [51 . . . 80]; [117 . . . 146]; [81 . . . 116]; [147 . . . 182]; [183 . . . 212]; [249 . . . 278] [213 . . . 248]; [279 . . . 315] 282 622 1110 [51 . . . 80]; [116 . . . 145]; [181 . . . 210]; [81 . . . 115]; [146 . . . 180]; [211 . . . 246]; [247 . . . 276]; [312 . . . 341] [277 . . . 311]; [342 . . . 376] 283 623 1111 [51 . . . 70]; [106 . . . 135]; [71 . . . 105]; [136 . . . 172]; [173 . . . 203] [204 . . . 238] 284 624 1112 [51 . . . 82]; [118 . . . 149]; [83 . . . 117]; [150 . . . 186]; [187 . . . 218]; [255 . . . 286]; [219 . . . 254]; [287 . . . 321]; [322 . . . 353]; [388 . . . 419]; [354 . . . 387]; [420 . . . 454]; [455 . . . 486]; [522 . . . 553]; [487 . . . 521]; [554 . . . 587]; [588 . . . 619]; [653 . . . 684]; [620 . . . 652]; [685 . . . 719]; [720 . . . 751]; [785 . . . 816]; [752 . . . 784]; [817 . . . 853]; [854 . . . 885]; [920 . . . 951]; [886 . . . 919]; [952 . . . 985]; [986 . . . 1017]; [1051 . . . 1082] [1018 . . . 1050]; [1083 . . . 1116] 285 625 1113 [51 . . . 82]; [117 . . . 148]; [182 . . . 213]; [83 . . . 116]; [149 . . . 181]; [249 . . . 280]; [317 . . . 348]; [214 . . . 248]; [281 . . . 316]; [383 . . . 414]; [448 . . . 479]; [349 . . . 382]; [415 . . . 447]; [514 . . . 545]; [580 . . . 611]; [480 . . . 513]; [546 . . . 579]; [647 . . . 678]; [713 . . . 744]; [612 . . . 646]; [679 . . . 712]; [779 . . . 810] [745 . . . 778]; [811 . . . 844] 286 626 1114 [51 . . . 82]; [115 . . . 146]; [83 . . . 114]; [147 . . . 179]; [180 . . . 211]; [248 . . . 279]; [212 . . . 247]; [280 . . . 316]; [317 . . . 348]; [381 . . . 412]; [349 . . . 380]; [413 . . . 444]; [445 . . . 476]; [511 . . . 542]; [477 . . . 510]; [543 . . . 576]; [577 . . . 608]; [643 . . .674]; [609 . . . 642]; [675 . . . 708]; [709 . . . 740]; [774 . . . 805] [741 . . . 773]; [806 . . . 839] 287 627 1115 [51 . . . 74]; [102 . . . 125]; [75 . . . 101]; [126 . . . 147]; [148 . . . 171]; [196 . . . 219]; [172 . . . 195]; [220 . . . 241]; [242 . . . 265]; [290 . . . 313]; [266 . . . 289]; [314 . . . 335]; [336 . . . 359]; [384 . . . 407] [360 . . . 383]; [408 . . . 434] Prediction of PAM Motifs and Guide RNAs for the Transposases

The curated spacer sequences listed in Table 9 were used in blast searches against datasets of phage and viral genomic sequences. The viral genome dataset was downloaded from ENA (European Nucleotide Archive). The phage genome datasets were downloaded from ENA, NCBI (National Center for Biotechnology Information), and Actinobacteriophage (web page at phagesdb.org) databases. Hits that were 100% identical over 20 bp either from the 5′ start or from the 3′ end of the query spacer sequence were selected and aligned with the spacer sequence using clustalw. As an example, the spacer sequences associated with the cluster 1 proteins (spacer 1, SEQ ID NO: 2004; spacer 2, SEQ ID NO: 2005, spacer 3, SEQ ID NO: 2006) were searched and aligned with the phage sequence matches (KJ920400_1, SEQ ID NO: 2007; HE614281_1 SEQ ID NO: 2009; KJ024807_1, SEQ ID NO: 2010; NC 029008.1_1, SEQ ID NO: 2011), as shown in FIG. 2. This alignment suggested a PAM motif of nucleotide triplet 5′-TCA-3′ is present at the 5′ end of the spacer. Additionally, a PAM motif of nucleotide triplet 5′-TTA-3′ is likely an alternative 5′ PAM for cluster 1 proteins; a PAM motif of nucleotide triplet 5′-CCT-3′ is predicted to be a 5′ PAM for cluster 3 proteins, and the a PAM motif of nucleotide triplet 5′-CCA-3′, or 5′-CCT-3′, or 5′-ACA-3′ is predicted to be a 5′ PAM for cluster-11.

For at least one curated repeat sequence associated with each transposase, an analysis was done to predict secondary structure. All predicted structures showed a stem loop structure with differences in the length of the stem, with most of the repeats having a stem length ≥5 bp. As an example, FIG. 3 shows the predicted secondary structures for the first and second repeats (SEQ ID NOs: 2012 and 2013) associated with a transposase (PRT: SEQ ID NO: 136; DNA: SEQ ID NO: 304). The predicted secondary structure of the CRISPR repeat sequence illustrates that the repeat sequence is capable of forming a hairpin loop structure suggesting that the repeat sequence alone is sufficient to form an effective guide RNA.

The guide-RNA sequences for a transposase can be designed to comprise at least one of the associated repeat sequences (R) and at least one of the associated spacer sequences (S), including but not limited to the combinations and orientations such as R+S, antisense sequence of R+S, S+R, and antisense sequence of S+R. For example in Table 10, a pair of the repeat and spacer sequences is selected as a representative for each transposase and the potential guide-RNA sequences are constructed and listed. A guide-RNA sequence can also be generated based on the fragment of the repeat sequence and the spacer sequence. A guide-RNA sequence may be designed to comprise at least 20 nucleotides from a spacer sequence. One skilled in the art would be able to design various guide-RNAs using the CRISPR repeats and spacers identified for the transposases disclosed herein.

TABLE 10 Predicted guide-RNA sequences for the transposases. R + S DNA R + S Antisense S + R S + R PRT SEQ CRISPR Repeat Repeat Spacer Spacer SEQ SEQ SEQ Antisense SEQ ID SEQ ID Within SEQ Within SEQ ID ID ID SEQ ID NO NO CRISPR ID NO CRISPR ID NO NO NO NO ID NO 124 1 628 [197 . . . 226] 1116 [227 . . . 262] 1264 1412 1560 1708 1856 125 2 629 [197 . . . 226] 1117 [227 . . . 262] 1265 1413 1561 1709 1857 126 3 630 [107 . . . 138] 1118 [139 . . . 172] 1266 1414 1562 1710 1858 127 4 631 [174 . . . 203] 1119 [204 . . . 238] 1267 1415 1563 1711 1859 128 5 636 [174 . . . 203] 1120 [204 . . . 238] 1268 1416 1564 1712 1860 129 6 637 [174 . . . 203] 1121 [204 . . . 238] 1269 1417 1565 1713 1861 129 6 637 [303 . . . 332] 1122 [333 . . . 367] 1270 1418 1566 1714 1862 130 7 641 [174 . . . 203] 1123 [204 . . . 238] 1271 1419 1567 1715 1863 131 8 646 [51 . . . 80] 1124  [81 . . . 115] 1272 1420 1568 1716 1864 132 9 647 [239 . . . 268] 1125 [269 . . . 302] 1273 1421 1569 1717 1865 133 10 652 [239 . . . 268] 1126 [269 . . . 302] 1274 1422 1570 1718 1866 134 11 653 [304 . . . 333] 1127 [334 . . . 368] 1275 1423 1571 1719 1867 135 12 655 [172 . . . 201] 1128 [202 . . . 238] 1276 1424 1572 1720 1868 136 304 662 [107 . . . 136] 1129 [137 . . . 173] 1277 1425 1573 1721 1869 137 14 677 [241 . . . 270] 1130 [271 . . . 305] 1278 1426 1574 1722 1870 138 15 678 [240 . . . 269] 1131 [270 . . . 303] 1279 1427 1575 1723 1871 139 16 679 [240 . . . 269] 1132 [270 . . . 303] 1280 1428 1576 1724 1872 140 17 680 [51 . . . 80] 1133  [81 . . . 115] 1281 1429 1577 1725 1873 141 18 686 [51 . . . 80] 1134  [81 . . . 115] 1282 1430 1578 1726 1874 142 19 689 [171 . . . 200] 1135 [201 . . . 234] 1283 1431 1579 1727 1875 143 20 690 [174 . . . 203] 1136 [204 . . . 238] 1284 1432 1580 1728 1876 144 21 695 [51 . . . 80] 1137  [81 . . . 115] 1285 1433 1581 1729 1877 145 22 810 [174 . . . 203] 1138 [204 . . . 240] 1286 1434 1582 1730 1878 146 23 811 [248 . . . 277] 1139 [278 . . . 313] 1287 1435 1583 1731 1879 147 24 812 [109 . . . 138] 1140 [139 . . . 173] 1288 1436 1584 1732 1880 148 25 813 [51 . . . 80] 1141  [81 . . . 115] 1289 1437 1585 1733 1881 149 26 814 [172 . . . 201] 1142 [202 . . . 236] 1290 1438 1586 1734 1882 150 27 816 [58 . . . 87] 1143  [88 . . . 123] 1291 1439 1587 1735 1883 151 28 817 [239 . . . 268] 1144 [269 . . . 302] 1292 1440 1588 1736 1884 152 29 820 [306 . . . 335] 1145 [336 . . . 370] 1293 1441 1589 1737 1885 153 30 821 [51 . . . 80] 1146  [81 . . . 116] 1294 1442 1590 1738 1886 154 31 822 [237 . . . 266] 1147 [267 . . . 302] 1295 1443 1591 1739 1887 155 32 824 [173 . . . 202] 1148 [203 . . . 237] 1296 1444 1592 1740 1888 156 33 825 [108 . . . 137] 1149 [138 . . . 172] 1297 1445 1593 1741 1889 157 34 827 [51 . . . 80] 1150  [81 . . . 115] 1298 1446 1594 1742 1890 158 35 829 [109 . . . 138] 1151 [139 . . . 173] 1299 1447 1595 1743 1891 159 36 830 [171 . . . 200] 1152 [201 . . . 234] 1300 1448 1596 1744 1892 160 37 831 [177 . . . 206] 1153 [207 . . . 243] 1301 1449 1597 1745 1893 161 38 837 [51 . . . 80] 1154  [81 . . . 114] 1302 1450 1598 1746 1894 162 39 838 [174 . . . 203] 1155 [204 . . . 238] 1303 1451 1599 1747 1895 163 40 839 [115 . . . 144] 1156 [145 . . . 178] 1304 1452 1600 1748 1896 164 41 840 [115 . . . 144] 1157 [145 . . . 178] 1305 1453 1601 1749 1897 165 42 841 [51 . . . 81] 1158  [82 . . . 114] 1306 1454 1602 1750 1898 166 43 843 [51 . . . 80] 1159  [81 . . . 115] 1307 1455 1603 1751 1899 167 44 844 [51 . . . 80] 1160  [81 . . . 114] 1308 1456 1604 1752 1900 168 45 845 [174 . . . 203] 1161 [204 . . . 237] 1309 1457 1605 1753 1901 169 46 846 [237 . . . 266] 1162 [267 . . . 302] 1310 1458 1606 1754 1902 170 47 847 [174 . . . 203] 1163 [204 . . . 240] 1311 1459 1607 1755 1903 171 461 849 [174 . . . 203] 1164 [204 . . . 238] 1312 1460 1608 1756 1904 172 49 856 [173 . . . 202] 1165 [203 . . . 237] 1313 1461 1609 1757 1905 173 50 857 [107 . . . 136] 1166 [137 . . . 173] 1314 1462 1610 1758 1906 174 51 859 [173 . . . 202] 1167 [203 . . . 237] 1315 1463 1611 1759 1907 175 52 862 [107 . . . 136] 1168 [137 . . . 173] 1316 1464 1612 1760 1908 176 53 866 [174 . . . 203] 1169 [204 . . . 240] 1317 1465 1613 1761 1909 177 54 875 [177 . . . 206] 1170 [207 . . . 243] 1318 1466 1614 1762 1910 178 55 876 [177 . . . 206] 1171 [207 . . . 243] 1319 1467 1615 1763 1911 179 56 879 [177 . . . 206] 1172 [207 . . . 243] 1320 1468 1616 1764 1912 180 57 901 [177 . . . 206] 1173 [207 . . . 243] 1321 1469 1617 1765 1913 181 58 902 [51 . . . 80] 1174  [81 . . . 116] 1322 1470 1618 1766 1914 182 59 903 [109 . . . 138] 1175 [139 . . . 173] 1323 1471 1619 1767 1915 183 60 904 [177 . . . 206] 1176 [207 . . . 243] 1324 1472 1620 1768 1916 184 61 905 [175 . . . 204] 1177 [205 . . . 241] 1325 1473 1621 1769 1917 185 62 906 [180 . . . 209] 1178 [210 . . . 246] 1326 1474 1622 1770 1918 186 63 907 [109 . . . 146] 1179 [147 . . . 174] 1327 1475 1623 1771 1919 187 64 909 [51 . . . 80] 1180  [81 . . . 116] 1328 1476 1624 1772 1920 188 65 910 [51 . . . 80] 1181  [81 . . . 116] 1329 1477 1625 1773 1921 189 66 923 [107 . . . 136] 1182 [137 . . . 172] 1330 1478 1626 1774 1922 190 67 924 [51 . . . 81] 1183  [82 . . . 115] 1331 1479 1627 1775 1923 191 68 925 [109 . . . 139] 1184 [140 . . . 172] 1332 1480 1628 1776 1924 191 68 926 [105 . . . 134] 1185 [135 . . . 169] 1333 1481 1629 1777 1925 192 69 927 [51 . . . 81] 1186  [82 . . . 115] 1334 1482 1630 1778 1926 193 519 929 [51 . . . 80] 1187  [81 . . . 115] 1335 1483 1631 1779 1927 194 71 934 [182 . . . 212] 1188 [213 . . . 246] 1336 1484 1632 1780 1928 195 72 945 [51 . . . 80] 1189  [81 . . . 117] 1337 1485 1633 1781 1929 196 73 946 [51 . . . 81] 1190  [82 . . . 116] 1338 1486 1634 1782 1930 196 73 947 [170 . . . 199] 1191 [200 . . . 236] 1339 1487 1635 1783 1931 197 532 949 [51 . . . 80] 1192  [81 . . . 117] 1340 1488 1636 1784 1932 197 532 950 [51 . . . 80] 1193  [81 . . . 114] 1341 1489 1637 1785 1933 198 547 971 [51 . . . 81] 1194  [82 . . . 116] 1342 1490 1638 1786 1934 199 76 983 [110 . . . 139] 1195 [140 . . . 173] 1343 1491 1639 1787 1935 200 77 984 [51 . . . 80] 1196  [81 . . . 117] 1344 1492 1640 1788 1936 201 78 985 [115 . . . 144] 1197 [145 . . . 180] 1345 1493 1641 1789 1937 201 78 986 [51 . . . 80] 1198  [81 . . . 116] 1346 1494 1642 1790 1938 202 79 993 [51 . . . 80] 1199  [81 . . . 117] 1347 1495 1643 1791 1939 202 79 994 [51 . . . 80] 1200  [81 . . . 116] 1348 1496 1644 1792 1940 203 80 995 [51 . . . 80] 1201  [81 . . . 116] 1349 1497 1645 1793 1941 204 81 996 [106 . . . 135] 1202 [136 . . . 172] 1350 1498 1646 1794 1942 205 82 997 [105 . . . 136] 1203 [137 . . . 169] 1351 1499 1647 1795 1943 206 83 999 [106 . . . 135] 1204 [136 . . . 172] 1352 1500 1648 1796 1944 207 84 1000 [181 . . . 209] 1205 [210 . . . 246] 1353 1501 1649 1797 1945 208 85 1001 [180 . . . 209] 1206 [210 . . . 246] 1354 1502 1650 1798 1946 209 86 1002 [180 . . . 209] 1207 [210 . . . 246] 1355 1503 1651 1799 1947 210 87 1005 [106 . . . 135] 1208 [136 . . . 172] 1356 1504 1652 1800 1948 211 88 1025 [172 . . . 201] 1209 [202 . . . 238] 1357 1505 1653 1801 1949 212 89 1027 [183 . . . 212] 1210 [213 . . . 247] 1358 1506 1654 1802 1950 212 89 1028 [110 . . . 139] 1211 [140 . . . 175] 1359 1507 1655 1803 1951 213 90 1029 [118 . . . 147] 1212 [148 . . . 182] 1360 1508 1656 1804 1952 213 90 1030 [51 . . . 80] 1213  [81 . . . 116] 1361 1509 1657 1805 1953 214 91 1040 [182 . . . 212] 1214 [213 . . . 246] 1362 1510 1658 1806 1954 214 91 1041 [51 . . . 80] 1215  [81 . . . 116] 1363 1511 1659 1807 1955 215 92 1042 [51 . . . 80] 1216  [81 . . . 117] 1364 1512 1660 1808 1956 216 93 1043 [118 . . . 147] 1217 [148 . . . 182] 1365 1513 1661 1809 1957 217 94 1051 [117 . . . 146] 1218 [147 . . . 182] 1366 1514 1662 1810 1958 218 95 1052 [51 . . . 80] 1219  [81 . . . 117] 1367 1515 1663 1811 1959 218 95 1053 [116 . . . 146] 1220 [147 . . . 179] 1368 1516 1664 1812 1960 219 96 1054 [106 . . . 135] 1221 [136 . . . 171] 1369 1517 1665 1813 1961 220 97 1055 [51 . . . 81] 1222  [82 . . . 117] 1370 1518 1666 1814 1962 221 98 679 [240 . . . 269] 1132 [270 . . . 303] 1280 1428 1576 1724 1872 222 99 647 [239 . . . 268] 1125 [269 . . . 302] 1273 1421 1569 1717 1865 223 595 653 [304 . . . 333] 1127 [334 . . . 368] 1275 1423 1571 1719 1867 224 101 1057 [118 . . . 150] 1223 [151 . . . 184] 1371 1519 1667 1815 1963 225 598 1058 [116 . . . 144] 1224 [145 . . . 180] 1372 1520 1668 1816 1964 226 103 1060 [247 . . . 275] 1225 [276 . . . 310] 1373 1521 1669 1817 1965 227 104 1061 [247 . . . 275] 1226 [276 . . . 310] 1374 1522 1670 1818 1966 228 105 1062 [195 . . . 226] 1227 [227 . . . 261] 1375 1523 1671 1819 1967 229 106 1063 [120 . . . 151] 1228 [152 . . . 186] 1376 1524 1672 1820 1968 230 107 1064 [60 . . . 91] 1229  [92 . . . 125] 1377 1525 1673 1821 1969 230 107 1065 [120 . . . 151] 1230 [152 . . . 189] 1378 1526 1674 1822 1970 231 108 1066 [118 . . . 149] 1231 [150 . . . 183] 1379 1527 1675 1823 1971 231 108 1067 [118 . . . 149] 1232 [150 . . . 182] 1380 1528 1676 1824 1972 232 600 1070 [117 . . . 148] 1233 [149 . . . 184] 1381 1529 1677 1825 1973 233 110 1072 [117 . . . 148] 1234 [149 . . . 181] 1382 1530 1678 1826 1974 233 110 1073 [115 . . . 146] 1235 [147 . . . 179] 1383 1531 1679 1827 1975 234 111 1074 [117 . . . 148] 1236 [149 . . . 181] 1384 1532 1680 1828 1976 234 111 1075 [51 . . . 82] 1237  [83 . . . 117] 1385 1533 1681 1829 1977 235 112 1076 [117 . . . 148] 1238 [149 . . . 182] 1386 1534 1682 1830 1978 236 113 1077 [187 . . . 218] 1239 [219 . . . 252] 1387 1535 1683 1831 1979 237 114 1078 [118 . . . 149] 1240 [150 . . . 183] 1388 1536 1684 1832 1980 237 114 1079 [51 . . . 83] 1241  [84 . . . 116] 1389 1537 1685 1833 1981 238 115 1081 [112 . . . 136] 1242 [137 . . . 176] 1390 1538 1686 1834 1982 239 116 1082 [51 . . . 79] 1243  [80 . . . 115] 1391 1539 1687 1835 1983 240 117 1083 [51 . . . 77] 1244  [78 . . . 111] 1392 1540 1688 1836 1984 241 118 1084 [116 . . . 150] 1245 [151 . . . 181] 1393 1541 1689 1837 1985 241 118 1085 [190 . . . 226] 1246 [227 . . . 255] 1394 1542 1690 1838 1986 242 119 1088 [172 . . . 191] 1247 [192 . . . 237] 1395 1543 1691 1839 1987 243 120 1089 [51 . . . 78] 1248  [79 . . . 115] 1396 1544 1692 1840 1988 244 121 1090 [51 . . . 78] 1249  [79 . . . 115] 1397 1545 1693 1841 1989 245 122 1091 [51 . . . 78] 1250  [79 . . . 115] 1398 1546 1694 1842 1990 246 123 1092 [51 . . . 69] 1251  [70 . . . 107] 1399 1547 1695 1843 1991 276 605 1093 [111 . . . 134] 1252 [135 . . . 171] 1400 1548 1696 1844 1992 277 606 1094 [106 . . . 135] 1253 [136 . . . 172] 1401 1549 1697 1845 1993 278 612 1100 [106 . . . 135] 1254 [136 . . . 172] 1402 1550 1698 1846 1994 279 613 1101 [107 . . . 136] 1255 [137 . . . 172] 1403 1551 1699 1847 1995 280 614 1102 [51 . . . 82] 1256  [83 . . . 116] 1404 1552 1700 1848 1996 281 615 1103 [51 . . . 80] 1257  [81 . . . 116] 1405 1553 1701 1849 1997 282 622 1110 [51 . . . 80] 1258  [81 . . . 115] 1406 1554 1702 1850 1998 283 623 1111 [106 . . . 135] 1259 [136 . . . 172] 1407 1555 1703 1851 1999 284 624 1112 [118 . . . 149] 1260 [150 . . . 186] 1408 1556 1704 1852 2000 285 625 1113 [51 . . . 82] 1261  [83 . . . 116] 1409 1557 1705 1853 2001 286 626 1114 [115 . . . 146] 1262 [147 . . . 179] 1410 1558 1706 1854 2002 287 627 1115 [148 . . . 171] 1263 [172 . . . 195] 1411 1559 1707 1855 2003 Protein Domain Analysis

The cluster 1 members (104 unique proteins), including the CRISPR-associated transposase of SEQ ID NO: 136 (DNA: SEQ ID NO: 304), all have a central OrfB_IS605 (Insertion Element 605) and a C-terminal OrfB_Zn_ribbon domain. In addition, most members (102 unique proteins) also comprise Puf domains. The Insertion Element (IS) 605 or TnpB contains a split RuvC endonuclease domain and is considered a progenitor of Cpf1 and C2C1 proteins (Kapitonov, 2016). The RuvC domain provides the endonuclease activity of these enzymes. Proteins containing Zn-ribbon domains are thought to bind DNA. The CRISPR-associated transposases were analyzed for the presence of RuvC catalytic domains based on sequence alignment with split RuvC regions described in literature. Using the CRISPR-associated transposase of SEQ ID NO: 136 (DNA: SEQ ID NO: 304) as an example, a RuvC I and RuvC III regions with conserved catalytic “D” amino acids (position 233 and 408) and the RuvC II region with a conserved ‘E” amino acid (position 354) were identified, and these three conserved residues are indicated in FIG. 4.

Puf domains (Pumilio-family RNA binding repeat) have been reported in eukaryotic RNA binding proteins. They usually, but not always, occur in tandem repeats of 8 and bind to a sequence specific 8 bp RNA binding motif. Each Puf domain forms a helical hairpin with a short helix preceding it (Yin, 2013). Each domain binds to one of the 8 nucleotides in the consensus binding site—5′-UGUANAUA-3′ (Zhang and Muench, 2015). In addition to Pfam analysis, the protein structure prediction software, PSIPRED, was used to predict helical structures and identify additional Puf domains. For the CRISPR-associated transposase of SEQ ID NO: 136 (DNA: SEQ ID NO: 304), seven putative Puf domains were identified and their domain structures are outlined in FIG. 4, relative to the OrfB_IS605 and OrfB_Zn_ribbon domains, and the RuvC active sites. The domain annotations and sequences are further described for this CRISPR-associated transposase in FIG. 5 where each Puf domain sequence is underlined and the two Pfam domains—IS605 and Zn ribbon are enclosed by brackets [ ] and double brackets [[ ]], respectively.

Since Puf domains are known to bind the highly conserved consensus RNA sequence (5′-UGUANAUA-3′), the CRISPR repeats associated with the transposases (SEQ ID NOs: 124-246, 275-287) were searched for the presence of the consensus Puf binding motif. As depicted in FIG. 6 for the CRISPR-associated transposase of SEQ ID NO: 136 (DNA: SEQ ID NO: 304), the sequence alignment across the associated CRISPR repeats shows a highly conserved motif that is similar to Puf binding motifs. The observed consensus Puf motif in the CRISPR-associated transposase of SEQ ID NO: 136 (DNA: SEQ ID NO: 304) is also highly conserved across repeat sequences from other members in cluster 1. The identified protein domain structure and the putative Puf binding motif suggests that the CRISPR-associated transposase not SEQ ID NO: 136 (DNA: SEQ ID NO: 304) is a nuclease with RNA and DNA binding activity.

Example 3

A high through-put assay is conducted to determine if the identified CRISPR-associated transposases (a) have RNA-guided DNA nuclease activity, and (b) to identify the associated PAM motifs. This assay is generally applicable to RNA-Guided EndoNuclease (RGEN) proteins, which refer to DNA modifying enzyme that (1) includes endonucleolytic activity, and (2) are associated with a non-coding RNA species that is capable of guiding the RGENs to specific DNA target sites for enzymatic activity. Many of these enzymes may have, beyond endonuclease activity, other functions, which include, but are not limited to transposases, topoisomerases, recombinases, and resolvases.

A bacterial genomic region of interest (ROI) including a DNA sequence encoding a CRISPR-associated transposase represented by SEQ ID NOs: 124-246, 275-287 and the associated RNA species in its native genomic environment was cloned into a bacterial expression plasmid. Another LacZ reporter plasmid was also built for each RGEN system, which included one or more of the spacer sequences identified in the CRISPR array associated with the individual transposase. The spacer(s) sequence in each LacZ reporter plasmid was flanked at both ends by 12 nucleotides of randomized sequence. The LacZ reporter plasmids contain a low-copy replication origin and a selectable marker that is different from that of the plasmids encoding the CRISPR-associated transposases to allow selection for co-transformants.

The ROI expression plasmid and the LacZ reporter plasmid were co-transformed into E. coli. Upon expression of the ROI elements (CRISPR-associated transposase and associated guide-RNA), and when the variable region of the LacZ reporter plasmid includes a functional PAM 5′ or 3′ to the spacer for the CRISPR-associated transposase, the DNA nuclease activity will introduce double-strand breaks (DSBs) in the reporter plasmids, resulting in a reduction of the LacZ reporter plasmid copy number within the cells. Reduction of reporter plasmids is detected by phenotypic changes of the resulting bacterial colony. Specifically, in normal colonies without nuclease activity, the colonies are dark blue and large. In contrast, in colonies with activity of the CRISPR-associated transposase on the reporter plasmid, the colonies are small and light blue or white in color. This assay design is illustrated in FIG. 7. This assay identifies CRISPR-associated transposase systems where the initial endonuclease cleavage is not followed by subsequent re-ligation of the broken ends and thus the linearized reporter plasmids are eliminated by bacterial endogenous nucleases. For RNA-guided nucleases (RGENs) that have additional functions, such as transposase activity, additional mutations may be introduced before the reporter plasmid is re-ligated, and thus the selectable marker and reporter genes may not be affected. In these latter cases, high-throughout sequencing of the reporter plasmids recovered from the surviving colonies would reveal additional mutations.

Broken plasmid DNAs are eliminated by host-derived endogenous nucleases in E. coli, which facilitates the blue-white selection described above, and illustrated in FIG. 7A. However, another group of prokaryotes, namely Mycobacterium spp. carries a different DNA repair mechanism, called non-homologous end-joining, which would heal the cut plasmid in an error-prone fashion (FIG. 8). This mechanism could be utilized to identify efficacious CRISPR-associated transposase systems by detecting either integration of a short oligonucleotide or point mutations at the target site by PCR amplification and/or sequencing of recovered reporter plasmids of surviving Mycobacterium colonies which are co-transformed with the expression and reporter plasmids. This assay is used as an alternative of the blue-white selection assay.

Example 4

A eukaryotic cell is transformed with an expression vector comprising a heterologous promoter operably linked to a sequence encoding one of the CRISPR-associated transposases selected from SEQ ID NOs: 124-246, 275-287, and a sequence encoding a RNA guide comprising a sequence targeting an endogenous genomic sequence of the eukaryotic cell. The CRISPR-associated transposase complexed with the guide RNA cleaves the genomic DNA at the target site and indel mutations are created by improper repair. Mutations are detected by sequencing.

Example 5

A eukaryotic cell is transformed with an expression vector comprising a heterologous promoter operably linked to a sequence encoding a CRISPR-associated transposase selected from SEQ ID NOs: 124-246, 275-287, and a sequence encoding an RNA guide comprising a sequence targeting an endogenous sequence of the cell. A donor polynucleotide comprising an exogenous transgene or a sequence for templated editing is further provided to the cell. The CRISPR-associated transposase complexed with the guide RNA cleaves the genomic DNA at the target site and the donor polynucleotide is incorporated by non-homologous end-joining or homologous recombination. Integrations are detected by sequencing amplicons spanning the chromosome-oligo junctions (e.g., FIG. 10).

Example 6: In Vitro Cutting Assay

A sequence encoding one of the CRISPR-associated transposase proteins encoded by SEQ ID NOs: 124-246 and 275-287 is cloned into a bacterial expression plasmid, the expression plasmid is transformed into E. coli, the bacteria are harvested, a bacterial lysate is prepared, and the enzyme is purified from the bacterial lysate. The corresponding genomic region of interest (ROI) including CRISPR components associated with the transposase are cloned into a high-copy plasmid, which is transformed into E. coli, and RNA components associated with the transposase of interest encoded on the ROI construct are identified by RNA-seq of the bacterial lysate. These RNA components are synthesized, and the transposase protein and synthetic RNA components are combined in vitro, the resulting transposase/RNA complexes are added to synthetic DNA fragments carrying the spacer sequences as shown in FIG. 9. The DNA fragments are collected for sequencing to determine cutting.

Example 7: Determination and Validation of PAM Motif of a RNA-Guided DNA Nuclease

A bacterial genomic region of interest (ROI) including one of the DNA sequences encoding a CRISPR-associated transposase represented by SEQ ID NOs: 124-246 and 275-287, and the associated CRISPR RNA components associated with the transposase of interest in its native genomic environment is cloned into a first bacterial expression plasmid which comprises a first antibiotic resistance gene, such as kanamycin resistance (Kan). A second bacterial plasmid comprising a second antibiotic resistance gene, for example tetracycline or chloramphenicol, is constructed such that the plasmid contains a spacer flanked both 5′ and 3′ by 12 bp of randomly selected nucleotides (Ns). The two plasmids are transformed into E. coli and plated on two plates: (1) containing media with a single antibiotic for selection of the first plasmid; and (2) containing antibiotics for selection against both the first and second plasmid. Plasmid DNA is prepared from bacteria grown on both sets of plates, PCR amplification of the spacer with flanking N sequence is conducted, and the PCR amplions are deep sequenced to identify sequences which are depleted from the library. These sequences corresponding to the depleted sequence correspond to the PAM motif recognized by the respective CRISPR-associated transposase which was co-transformed.

Alternatively, the PAM preferences for a CRISPR-associated transposase can be empirically examined and determined by using a method relying on the in vitro cleavage of plasmid libraries containing a randomized PAM (3′ PAM or 5′ PAM library) as a function of Nuclease-guide RNA complex (Karvelis, 2015; Shmakov, 2015). Randomized PAM plasmid libraries are constructed using synthesized oligonucleotides (ssDNA) consisting of seven randomized nucleotides either upstream or downstream of a spacer target. The randomized ssDNA oligos are made double stranded (dsDNA) by annealing to a short primer and synthesizing the second strand in vitro, for example, by providing a Klenow enzyme to the in vitro synthesis reaction. The dsDNA product is assembled into a linearized pUC19 plasmid using any standard molecular biology cloning method. E. coli are transformed with the cloned products, several bacterial colonies are collected and pooled. Plasmid DNA is harvested using a QIAGEN® plasmid Maxi kit. The pooled library is co-transformed into E. coli with a CRISPR-associated transposase locus. After transformation, cells are plated and selected with antibiotic. After 16 hr of growth, >4×10⁶ cells are harvested and plasmid DNA is extracted using a QIAGEN® Maxi kit. The target PAM region is amplified and sequenced using an Illumina MiSeq® with single-end 150 cycles. Sequences corresponding to both PAMs and non-PAMs are cloned into pUC19 vectors. Competent E. coli with either the plasmid comprising the CRISPR-associated transposase locus or a pACYC184 control plasmid are transformed with PAM plasmid and plated on LB agar plates supplemented with ampicillin and chloramphenicol. After 18 hr, colonies were counted with OpenCFU (Geissmann, 2013).

Example 8: Validation of RNA-Guided DNA Nuclease Activity for CRISPR-Associated Transposases Using Blue-White Selection

A phenotypic assay is conducted to determine if CRISPR-associated transposases identified herein have RNA-guided DNA nuclease activity. The design of this assay is essentially as detailed in Example 3. A bacterial genomic region of interest (ROI) (SEQ ID NO: 2019) comprising the DNA sequence (SEQ ID NO: 304) encoding the CRISPR-associated transposase of SEQ ID NO: 136 and the associated CRISPR RNA species in its native genomic environment was cloned into a plasmid. Another ‘reporter’ plasmid comprising two of the spacer sequences (SEQ ID NOs: 2017 and 2018) identified in the CRISPR array (SEQ ID NO: 662) were also built. The spacer(s) were flanked by 12 variable nucleotides at both ends (depicted as ‘NNN’ in FIG. 11). The reporter construct had a low-copy replication origin (pAcyc 184) and a selectable marker (chloramphenicol resistance) that is different from that of the plasmids comprising the CRISPR-associated transposase (kanamycin resistance) to allow selection for co-transformants. The reporter plasmid also carried a LacZ cassette that provided blue-white selection. The ROI and reporter plasmids were co-transformed into E. coli. DNA nuclease activity of the CRISPR-associated transposase results in a double-strand break (DSBs) leading to linearized reporter plasmid. The linearized reporter plasmid is completely degraded in the E. coli, which was thought to be the only possible outcome of DNA repair. However, molecular evidence for existence of alternative DNA repair mechanisms that lead to re-circularization of linearized plasmids is accumulating. Not to be bound by a particular theory, these rearrangements may occur by recombination between short tracks of homologies as demonstrated by Wang (2015). Alternatively, short homologies between a linear plasmid and a circular one can also lead to recombination resulting in chimeric plasmids. Some of these new variants deriving from targeted cleavage of the reporter construct would eliminate the reporter gene (LacZ), while retaining the chloramphenicol resistance gene, which would produce rare chloramphenicol resistant white colonies in a ‘sea’ of blue colonies. Two negative controls were built as depicted in FIG. 11, where either the ROI (Control RGEN (−)) or the reporter region (Control Reporter (−)) were absent from their vector backbones. Co-transformation of the two plasmids resulted in 21 white colonies among 750 blue colonies, while no white colonies were found in either of the negative controls lacking either the ROI comprising the CRISPR-associated transposase or the reporter region as shown in Table 11. These results suggest that the CRISPR-associated transposase of SEQ ID NO: 136 either eliminated or mutated the reporter plasmids. For molecular analysis, plasmids were isolated from ten white colonies. A region of the reporter plasmid including the two spacers and their flanking variable regions was amplified (569 bp) in (1) the pool of reporter plasmids that did not go through transformation, (2) in plasmids isolated from two blue colonies that were apparently unaffected by the transposase, and (3) in the plasmids isolated from the ten white colonies. While strong bands of expected size were obtained from the negative controls (plasmid sources 1 and 2 listed above), only faint bands were detected in nine of ten white colonies. This suggested targeted degradation of the reporter plasmids in white colonies. The amplicon from one of ten white colonies—colony #6 was comparable to the control in intensity, which suggested that the corresponding plasmid was repaired by an alternative mechanism that preserved the reporter region. Sequencing of the amplicons revealed no mutations in the negative controls. Sequencing was also attempted in all ten white colonies, but was successful only in colony #6, which retained a significant amount of the reporter plasmid. Point mutations were identified in both spacers of this plasmid in colony #6, which may have originated from imperfect DNA repair. No such mutations were found in either the reporter plasmid pools when sequenced prior to transformation, or in randomly selected blue colonies, which went through transformation, but were apparently unaffected by the transposase possibly due to incompatibility in the variable PAM region.

TABLE 11 CRISPR-associated transposase of SEQ ID NO: 136 tested for blue-white selection assay. # of white colonies among 750 blue colonies Control PRT ROI Spacer-1 Spacer-2 Control Trans- SEQ ID SEQ ID SEQ ID SEQ ID Reporter posase NO NO NO NO (—) (—) Test 136 2018 2016 2017 0 0 21

Example 9: Validation of RNA-Guided Endonuclease Activity Using a 2-Plasmid or 3-Plasmid Selection System

A bacterial selection system was previously developed to study properties of homing endonucleases by linking DNA cleavage events with cell survival (Chen and Zhao, 2005). The 2-plasmid system of Chen and Zhao consists of a ‘reporter plasmid’ (p11-LacY-wtx1), and an inducible protein expression vector (pTrc-I-SceI). This system has been used to increase the in vivo cutting efficiency and specificity of a FokI nuclease domain (Guo, 2010). It has also been used to alter the PAM specificity of Cas9, an RNA-guided endonuclease (Kleinstiver, 2015). The assay may be modified into a highly sensitive selection system that couples RNA-guided endonuclease DNA cleavage with the survival of host cells. Three plasmids-pNuc-I-SceI, pCut-I-SceI, and pGuide are built to enable either a 2-plasmid (pNuc and pCut) selection system, or a more flexible 3-plasmid selection system. The protein expression vector, pNuc-I-SceI, uses a strong P-tac promoter. Another improvement is incorporation of the lad gene (lac repressor) in the pNuc-I-SceI backbone, such that the plasmid can work well in non-lacI^(q) hosts. pNuc-I-SceI is derived from the pACYC-Duet1 plasmid (Novagen), and has the P15a-ori and Chloramphenicol (Cm) resistance gene. pNuc appeared to express the I-SceI meganuclease at a low, non-toxic level in E. coli, in quantities sufficient to cut plasmids with an I-SceI restriction site. pNuc-I-SceI has unique NdeI and NotI sites that allow the easy replacement of the I-SceI coding region with other genes or operons. Cutting the plasmid with BamHI and NotI allows for cloning 1-9 kb genomic regions containing multiple ORFs, CRISPR loci or other sequences, where protein expression from ORFs will be originating from the native promoters, etc.

The reporter plasmid, pCut-I-SceI contains the highly toxic ccdB gene behind a well-regulated P-ara expression unit that expresses ccdB levels at such low levels in its uninduced state that cells containing pCut are healthy. The pCut-I-SceI contains a cassette conferring carbenicillin resistance. Addition of 0.2% arabinose to the growth medium, induces the expression of ccdB to levels that cause a 3-4 log-kill of cells bearing the plasmid. pCut-I-SceI also contains a ‘cut site’ immediately downstream of the ccdB gene. In pCut-I-SceI, the ‘cut site’ is a ˜50 bp sequence containing the 18 bp recognition sequence of the I-SceI meganuclease. The region flanking the cut site contains unique restriction sites that allow the sequence to be replaced by other desired sequences, such as a cut site library of sequences, containing degenerate nucleotides (i.e. N=A or C or G or T). Expression of an endonuclease that cuts pCut in its ‘cut site’ relieves the sensitivity to growth on arabinose is due to the rapid in vivo degradation of pCut and the loss of the arabinose-inducible ccdB gene. The system can be fine tuned for selecting recognition sequence variants of endonucleases, ‘kinetic variants’ (Guo, 2010), or studying the in vivo temperature optimum for DNA cleavage.

When competent BW25141 E. coli containing pCut-I-SceI are made and transformed with pNuc-I-SceI, and side-by-side with (empty) pACYC-Duet1, and allowed to recover for approx. 2.5 hrs, without antibiotics, with or without the addition of IPTG (to further induce I-SceI expression from the P-tac promoter), aliquots of the cells can be plated on LB+ 25 ug/ml Chloramphenicol (Cm) agar plates (to determine transformation efficiency of the pNuc construct), alongside LB+25 ug/ml Cm+0.2% arabinose plates. Depending on dilutions and competency of the E. coli, E. coli transformed with (empty) pACYC-Duet1 yield 0-1 colony-forming units (cfus) on LB+25 ug/ml Cm+0.2% arabinose plates as compared to >1000 cfus on LB+25 ug/ml Cm plates. In contrast, E. coli transformed with pNuc-I-SceI yield 30 to >100 cfu's on LB+Cm+arabinose plates as compared to >500 cfu's on LB+Cm plates. Plasmids similar to pNuc have been used by others to co-express RNA-guided endonucleases along with their guide RNA(s) or a CRISPR locus (Zetsche, 2015). A modification of this system that uses a separate third plasmid, pGuide, to co-express guide RNA increases the flexibility of the selection system. The pCDF-Duet1 backbone (Novagen) containing the CDF-ori and Spectinomycin-r genes is chosen and a synthetic DNA J23119 (a synthetic constitutive E. coli promoter used by Zetsche 2015.) is inserted in the ˜2.2 kB pCDF backbone to create the pGuide plasmid. The guide RNA associated with a CRISPR-associated transposase of interest, for example the CRISPR-associated transposase of SEQ ID NO: 136 (DNA: SEQ ID NO: 304), is inserted in the pCDF backbone to create the pGuide-transposase plasmid.

The 2-plasmid and 3-plasmid systems are used to determine RNA-guided nuclease activities for the CRISPR-associated transposase proteins selected from SEQ ID NOs: 124-246 and 275-287. Using the CRISPR-associated transposase of SEQ ID NO: 136 as an example, the transposase coding region (SEQ ID NO: 304) is cloned into the pNuc-I-SceI plasmid replacing the I-SceI component to create the pNuc-RGEN PRT: SEQ ID NO: 136 (DNA: SEQ ID NO: 304) plasmid. A, RGEN PRT: SEQ ID NO: 136 (DNA: SEQ ID NO: 304) ‘cut site’ (two spacers SEQ ID NOs: 2017 and 2018 flanked by 8 variable nucleotides at both ends) is cloned into the pCut-I-SceI plasmid replacing the I-SceI cut site to create the pCut-RGEN PRT: SEQ ID NO: 136 (DNA: SEQ ID NO: 304) plasmid. A pCut-control plasmid is generated by incorporating a non-RGEN PRT: SEQ ID NO: 136 (DNA: SEQ ID NO: 304) ‘cut site’ (e.g. Cas9 cut site) into the pCut-I-SceI plasmid.

The pNuc-RGEN PRT: SEQ ID NO: 136 (DNA: SEQ ID NO: 304) plasmids are tested with the pCut-RGEN PRT: SEQ ID NO: 136 (DNA: SEQ ID NO: 304) plasmid in the above described 2-plasmid assay to determine the minimal genomic fragment required for the RNA-guided nuclease activity. The pNUC-RGEN PRT: SEQ ID NO: 136 (DNA: SEQ ID NO: 304) plasmids can be further tested with the pCut-RGEN PRT: SEQ ID NO: 136 (DNA: SEQ ID NO: 304) plasmid and the pGuide plasmid to determine if the associated CRISPR locus is required for the nuclease activity of the CRISPR-associated transposase. The pCut-control plasmid is used to demonstrate specificity of the CRISPR-associated transposase mediated cleavage.

Example 10: Fragment Length Assay

This example describes an in vitro assay for high-throughput detection of targeted endonuclease activities for CRISPR-associated transposase proteins selected from SEQ ID NOs: 124-246 and 275-287. E. coli cells carrying expression vectors for CRISPR-associated transposases with or without guide RNAs (or an entire CRISPR locus) are lysed to prepare whole cell lysates, essentially as described in Example 6. Fluorescent end-labeled PCR amplicons carrying the predicted target site of the CRISPR-associated transposase are added to the lysates, and after incubation, the CRISPR-associated transposase present in the lysates cleaves the fluorescent end-labeled PCR amplicons. The fluorescent fragments can be detected and sized by high-throughput DNA length analysis (for example, on an ABI3700 instrument, Life technologies) to determine the extent of DNA cutting and the position of the cut site in the DNA fragments.

Example 11: RNA Binding Assay

This example describes the assay for assessing whether a transposase protein selected from SEQ ID NOs: 124-246 and 275-287 associates with a guide RNA sequence derived from its associated CRISPR array. The technology employed in this assay is the Alpha Screen (Perkin Elmer). This assay system uses a donor and acceptor bead that when brought into close proximity emits a detectable fluorescent signal. In this assay, several guide RNAs are made using in vitro transcription. These guide RNA sequences are linked to the flank sequences (Flank1: SEQ ID NO: 3380; Flank2: SEQ ID NO: 3381) via a linker sequence (SEQ ID NO: 3382) (FIG. 10). The nucleotide sequence (Flank2) binds to an oligo with an Alpha Streptavidin donor bead attached. An CRISPR-associated transposase is expressed in E. coli with a His-tag which serves as the binding site for the Alpha acceptor bead. As an example illustrated in FIG. 12, when a CRISPR-associated transposase of SEQ ID NO: 136 (with acceptor bead) binds to its predicted guide RNA (with donor bead) a detectable fluorescent signal is produced. For this experiment a CRISPR-associated transposase of SEQ ID NO: 136 (DNA: SEQ ID NO: 304) is expressed in an IPTG-inducible E. coli strain and the lysate is applied to the assay to look for signal. To first validate this assay a purified His-Cas9 is mixed with its gRNA (SEQ ID NO: 3383). If the assay functions under these conditions then it is further tested with a bacterial lysate containing expressed His-Cas9 to more closely mimic the conditions of the RGEN CRISPR-associated transposase experiment. If a detectable signal is measured from the Cas9 lysate then the assay is applied to a CRISPR-associated transposase lysate against its corresponding guide RNA. A number of putative guide RNA sequences (SEQ ID NOs: 3384-3402) are designed to be tested in the binding assay for the CRISPR-associated transposase of SEQ ID NO: 136, using the CRISPR repeats and spacers disclosed in Table 8 for SEQ ID NO: 136. Among these guide RNAs, two sequences (SEQ ID NOs: 3401 and 3402) are designed to be negative controls by introducing mutations into the native CRISPR repeat and spacer sequences comprised in these two guide RNAs.

Example 12: Use of CRISPR-Associated Transposases for Genome Editing in Plants

The CRISPR-associated transposases represented by SEQ ID NOs: 124-246 and 275-287 are tested for site-specific cleavage of genomic DNA in plants. To demonstrate this activity, vectors are created to express the transposase proteins and the associated guide RNAs. For example, vectors are created to express the CRISPR-associated transposase protein of SEQ ID NO: 136 and its associated guide-RNA. Codon-optimized open reading frames of the CRISPR-associated transposases represented by SEQ ID NOs: 124-246 and 275-287 for corn and soy are listed in Table 12. A promoter, such as maize Ubiquitin2 promoter, is used to drive the expression of CRISPR-associated transposases in plants. A nuclear localization signal (e.g. monopartite SV40) is added to the N terminus of a CRISPR-associated transposase and a bipartite nucleoplasmin nuclear localization signal (BiNLS) is included at the C terminus to facilitate nuclear localization. To validate the effectiveness of nuclear localization signal used, maize protoplasts are transformed with an transposase-GFP fusion protein construct and nuclear localized fluorescence is observed. A maize U6 snRNA promoter can be used for the generation of sgRNA in maize (WO2015131101 incorporated by reference herein; Zhu, 2016). The PAM sequences are identified for the CRISPR-associated transposases as described in Example 7, and the protospacer sequences recognized by CRISPR-associated transposases can be used to identify sgRNA-specific target sites within the maize genome with minimal off-target cuts, using the approach described by Zhu (2016). Target sites located in the first two exons are good candidates for the purpose of targeted gene disruption in maize, since mutations occurred at the beginning of the coding sequence are more likely to disrupt the function of the proteins.

To test the activity of CRISPR-associated transposases for maize endogenous gene editing, a protoplast transient assay is conducted to detect the function of the engineered CRISPR-transposase system. To increase the transformation efficiency, binary plasmids with both sgRNA and transposase expression cassettes are generated and then transformed into maize protoplasts. Genomic DNA is extracted from transformed protoplasts cultured for 24 h and amplicons encompassing target sites are prepared for sequencing (for example, Illumina deep sequencing) and targeted genome edits can be observed.

TABLE 12 The codon-optimized open reading frames for CRISPR- associated transposases for corn and soy. PRT Corn codon- Soy codon- SEQ ID optimized optimized NO Organism SEQ ID NO SEQ ID NO 124 Bacillus sp. multi 2020-2024 2700-2704 125 Bacillus sp. multi 2025-2029 2705-2709 126 Bacillus sp. multi 2030-2034 2710-2714 127 Bacillus sp. multi 2035-2039 2715-2719 128 Bacillus sp. multi 2040-2044 2720-2724 129 Bacillus sp. multi 2045-2049 2725-2729 130 Bacillus sp. multi 2050-2054 2730-2734 131 Bacillus sp. multi 2055-2059 2735-2739 132 Bacillus sp. multi 2060-2064 2740-2744 133 Bacillus sp. multi 2065-2069 2745-2749 134 Bacillus thuringiensis 2070-2074 2750-2754 135 Bacillus sp. multi 2075-2079 2755-2759 136 Bacillus sp. Multi 2080-2084 2760-2764 137 Bacillus sp. multi 2085-2089 2765-2769 138 Bacillus sp. multi 2090-2094 2770-2774 139 Bacillus sp. multi 2095-2099 2775-2779 140 Bacillus sp. multi 2100-2104 2780-2784 141 Bacillus sp. multi 2105-2109 2785-2789 142 Bacillus sp. multi 2110-2114 2790-2794 143 Bacillus sp. multi 2115-2119 2795-2799 144 Bacillus sp. multi 2120-2124 2800-2804 145 Bacillus sp. multi 2125-2129 2805-2809 146 Bacillus sp. multi 2130-2134 2810-2814 147 Bacillus sp. multi 2135-2139 2815-2819 148 Bacillus sp. multi 2140-2144 2820-2824 149 Bacillus sp. multi 2145-2149 2825-2829 150 Bacillus sp. multi 2150-2154 2830-2834 151 Bacillus sp. multi 2155-2159 2835-2839 152 Bacillus sp. multi 2160-2164 2840-2844 153 Bacillus sp. multi 2165-2169 2845-2849 154 Bacillus sp. multi 2170-2174 2850-2854 155 Bacillus sp. multi 2175-2179 2855-2859 156 Bacillus sp. multi 2180-2184 2860-2864 157 Bacillus sp. multi 2185-2189 2865-2869 158 Bacillus sp. multi 2190-2194 2870-2874 159 Bacillus sp. multi 2195-2199 2875-2879 160 Bacillus sp. multi 2200-2204 2880-2884 161 Bacillus sp. multi 2205-2209 2885-2889 162 Bacillus sp. multi 2210-2214 2890-2894 163 Bacillus sp. multi 2215-2219 2895-2899 164 Bacillus sp. multi 2220-2224 2900-2904 165 Bacillus sp. multi 2225-2229 2905-2909 166 Bacillus sp. multi 2230-2234 2910-2914 167 Bacillus sp. multi 2235-2239 2915-2919 168 Bacillus sp. multi 2240-2244 2920-2924 169 Bacillus sp. multi 2245-2249 2925-2929 170 Bacillus sp. multi 2250-2254 2930-2934 171 Bacillus sp. multi 2255-2259 2935-2939 172 Bacillus sp. multi 2260-2264 2940-2944 173 Bacillus sp. multi 2265-2269 2945-2949 174 Bacillus sp. multi 2270-2274 2950-2954 175 Bacillus sp. multi 2275-2279 2955-2959 176 Paenibacillus sp. novel 2280-2284 2960-2964 177 Bacillus thuringiensis 2285-2289 2965-2969 178 Bacillus sp. multi 2290-2294 2970-2974 179 Bacillus sp. multi 2295-2299 2975-2979 180 Bacillus sp. multi 2300-2304 2980-2984 181 Bacillus sp. multi 2305-2309 2985-2989 182 Bacillus sp. multi 2310-2314 2990-2994 183 Bacillus sp. multi 2315-2319 2995-2999 184 Bacillus sp. multi 2320-2324 3000-3004 185 Bacillus sp. multi 2325-2329 3005-3009 186 Bacillus sp. multi 2330-2334 3010-3014 187 Bacillus sp. multi 2335-2339 3015-3019 188 Bacillus sp. multi 2340-2344 3020-3024 189 Bacillus sp. multi 2345-2349 3025-3029 190 Bacillus sp. multi 2350-2354 3030-3034 191 Bacillus sp. multi 2355-2359 3035-3039 192 Bacillus sp. multi 2360-2364 3040-3044 193 Bacillus sp. multi 2365-2369 3045-3049 194 Bacillus sp. multi 2370-2374 3050-3054 195 Bacillus thuringiensis 2375-2379 3055-3059 196 Bacillus sp. multi 2380-2384 3060-3064 197 Bacillus sp. multi 2385-2389 3065-3069 198 Bacillus sp. multi 2390-2394 3070-3074 199 Bacillus sp. multi 2395-2399 3075-3079 200 Bacillus sp. multi 2400-2404 3080-3084 201 Bacillus sp. multi 2405-2409 3085-3089 202 Bacillus sp. multi 2410-2414 3090-3094 203 Bacillus sp. multi 2415-2419 3095-3099 204 Bacillus sp. multi 2420-2424 3100-3104 205 Bacillus sp. multi 2425-2429 3105-3109 206 Bacillus sp. multi 2430-2434 3110-3114 207 Bacillus sp. multi 2435-2439 3115-3119 208 Bacillus sp. multi 2440-2444 3120-3124 209 Bacillus sp. multi 2445-2449 3125-3129 210 Bacillus sp. multi 2450-2454 3130-3134 211 Bacillus sp. multi 2455-2459 3135-3139 212 Bacillus sp. multi 2460-2464 3140-3144 213 Bacillus sp. multi 2465-2469 3145-3149 214 Bacillus sp. multi 2470-2474 3150-3154 215 Bacillus sp. multi 2475-2479 3155-3159 216 Bacillus sp. multi 2480-2484 3160-3164 217 Bacillus sp. multi 2485-2489 3165-3169 218 Bacillus sp. multi 2490-2494 3170-3174 219 Bacillus sp. multi 2495-2499 3175-3179 220 Bacillus sp. multi 2500-2504 3180-3184 221 Bacillus sp. multi 2505-2509 3185-3189 222 Bacillus sp. multi 2510-2514 3190-3194 223 Bacillus thuringiensis 2515-2519 3195-3199 224 Bacillus megaterium 2520-2524 3200-3204 225 Bacillus sp. multi 2525-2529 3205-3209 226 Bacillus sp. multi 2530-2534 3210-3214 227 Bacillus sp. multi 2535-2539 3215-3219 228 Paenibacillus 2540-2544 3220-3224 thiaminolyticus (multi) 229 Paenibacillus 2545-2549 3225-3229 thiaminolyticus (multi) 230 Paenibacillus sp. multi 2550-2554 3230-3234 231 Paenibacillus lentimorbus 2555-2559 3235-3239 (multi) 232 Paenibacillus 2560-2564 3240-3244 thiaminolyticus (multi) 233 Paenibacillus 2565-2569 3245-3249 thiaminolyticus (multi) 234 Paenibacillus 2570-2574 3250-3254 thiaminolyticus (multi) 235 Paenibacillus terrae 2575-2579 3255-3259 236 Paenibacillus 2580-2584 3260-3264 thiaminolyticus (multi) 237 Paenibacillus 2585-2589 3265-3269 thiaminolyticus (multi) 238 Bacillus sp. multi 2590-2594 3270-3274 239 Bacillus sp. multi 2595-2599 3275-3279 240 Streptomyces sp. multi 2600-2604 3280-3284 241 Bacillus sp. multi 2605-2609 3285-3289 242 Bacillus sp. multi 2610-2614 3290-3294 243 Bacillus sp. multi 2615-2619 3295-3299 244 Bacillus sp. multi 2620-2624 3300-3304 245 Bacillus sp. multi 2625-2629 3305-3309 246 Lysinibacillus sp. multi 2630-2634 3310-3314 275 Bacillus sp. multi 2635-2639 3315-3319 276 Streptomyces sp. multi 2640-2644 3320-3324 277 Bacillus sp. multi 2645-2649 3325-3329 278 Bacillus sp. multi 2650-2654 3330-3334 279 Bacillus sp. multi 2655-2659 3335-3339 280 Bacillus sp. multi 2660-2664 3340-3344 281 Bacillus sp. multi 2665-2669 3345-3349 282 Bacillus sp. multi 2670-2674 3350-3354 283 Bacillus sp. multi 2675-2679 3355-3359 284 Paenibacillus 2680-2684 3360-3364 thiaminolyticus (multi) 285 Paenibacillus lentimorbus 2685-2689 3365-3369 (multi) 286 Paenibacillus 2690-2694 3370-3374 thiaminolyticus (multi) 287 Stenotrophomonas sp. 2695-2699 3375-3379 multi

To test the mutation efficiency of CRISPR-associated transposases in stable expression lines, a target site verified in the maize transient assay is chosen. Construct(s) with sgRNA and the selected target site, and the transposase is then transformed into maize immature embryos via Agrobacterium tumefaciens. T₀ transgenic lines are analyzed and the transposase positive lines are identified based on immunoblot analysis. SURVEYOR assays can be used to determine whether edits are introduced in the target site (Zhu, 2016). For detailed analysis of editing efficiency and mutation type introduced by CRISPR-associated transposases, the PCR amplicons encompassing the target site can be deep-sequenced for the transposase positive T₀ generation plants. The experimental designs and assays as described above in this example can also be adapted to program and test the CRISPR-associated transposases for genome editing in soy, wheat, canola, cotton, tomato, or other plants and vegetables. 

What is claimed is:
 1. A recombinant nucleic acid, comprising a heterologous promoter operably linked to a polynucleotide encoding a CRISPR-associated transposase with an amino acid sequence selected from the group consisting of SEQ ID NOs: 124-133, 135-246 and 275-287.
 2. The recombinant nucleic acid of claim 1, wherein the CRISPR-associated transposase: a. is from a bacterium selected from the group consisting of Lysinibacillus sp., Brevibacillus sp., Sphingobium sp., Undibacterium sp., Bacillus sp., Chryseobacterium sp., Sphingomonas sp., Labrys sp., Paenibacillus sp., Streptomyces sp., and Stenotrophomonas sp.; b. is from a bacterium selected from the group consisting of Brevibacillus brevis, Brevibacillus laterosporus, Brevibacillus parabrevis, Bacillus megaterium, Bacillus thuringiensis, Bacillus weihenstephanensis, Enterococcus faecalis, Undibacterium pigrum, Novosphingobium rosa, Labrys methylaminiphilus, Paenibacillus thiaminolyticus, Paenibacillus lentimorbus, and Paenibacillus terrae; c. is associated in the bacterial genome with a CRISPR locus; d. is located in the same operon as a CRISPR locus; e. is located within 2.5 kilobases of a CRISPR locus; f. is encoded by a nucleotide sequence having at least 90% identity to a sequence selected from the group consisting of SEQ ID NOs: 1-123, 604-627 and 2020-3379; or g. any combination of (a), (b), (c), (d), (e), and (f).
 3. The recombinant nucleic acid of claim 1, further comprising at least one polynucleotide encoding a guide RNA capable of hybridizing with a target sequence, wherein the guide RNA forms a complex with the CRISPR-associated transposase.
 4. The recombinant nucleic acid of claim 1, further comprising at least one polynucleotide encoding a donor polynucleotide.
 5. The recombinant nucleic acid of claim 1, wherein the polynucleotide encoding the CRISPR-associated transposase further encodes at least one nuclear localization signal (NLS).
 6. A vector comprising the recombinant nucleic acid of claim
 1. 7. A eukaryotic cell comprising the recombinant nucleic acid of claim
 1. 8. A non-naturally occurring system for sequence-specific modification of a target nucleic acid sequence, comprising (a) one or more guide RNAs or a DNA molecule encoding the one or more guide RNAs, wherein the one or more guide RNAs are capable of hybridizing with the target nucleic acid sequence, and (b) a CRISPR-associated transposase having an amino acid sequence selected from the group consisting of SEQ ID NO: 124-133, 135-246 and 275-287 or polynucleotide encoding the CRISPR-associated transposase, wherein the one or more guide RNAs and the CRISPR-associated transposase do not naturally occur together.
 9. The system of claim 8, (a) wherein the target nucleic acid sequence comprises a coding nucleic acid sequence, a non-coding nucleic acid sequence, or a combination of a coding and a non-coding nucleic acid sequence; or (b) wherein the target nucleic acid sequence comprises an endogenous gene or a transgene; or (c) any combination of (a) and (b).
 10. The system of claim 8, wherein the system comprises a divalent cation.
 11. The system of claim 8, further comprising a donor polynucleotide.
 12. A method for sequence-specific modification of a target nucleic acid sequence in a cell, comprising providing the system of claim 8 to a cell that comprises the target nucleic acid sequence.
 13. A method for sequence-specific modification of a target nucleic acid sequence in a cell, comprising providing to the cell a CRISPR-associated transposase comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 124-133, 135-246 and 275-287, whereby the target nucleic acid sequence is modified.
 14. The method of claim 13, further comprising a guide RNA capable of associating with the CRISPR-associated transposase and hybridizing with the target nucleic acid sequence.
 15. The method of claim 14, wherein: (a) the guide RNA is provided by expressing in the cell a recombinant DNA molecule encoding the guide RNA; (b) the CRISPR-associated transposase is provided by expressing in the cell a recombinant DNA molecule encoding the CRISPR-associated transposase; or (c) both (a) and (b).
 16. The method of claim 14, wherein: (a) the guide RNA is provided by contacting the cell with a composition comprising the guide RNA or a recombinant DNA molecule encoding the guide RNA; (b) the CRISPR-associated transposase is provided by contacting the cell with a composition comprising the CRISPR-associated transposase or a recombinant DNA molecule encoding the CRISPR-associated transposase; or (c) the CRISPR-associated transposase is complexed with the guide RNA and is provided to the cell as a particle.
 17. The method of claim 13, further comprising providing a donor polynucleotide to the cell.
 18. A eukaryotic cell containing the non-naturally occurring system of claim
 8. 